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ABSTRACT 
 
Chemotactic axon guidance has an essential role in development and is important for re-
innervation of target tissues after neuronal injury. The aim of the work described in this thesis 
was to determine whether the low density lipoprotein receptor-related protein 1 (LRP1) and 
LRP2 receptors mediate neurite chemoattraction, and to assess their therapeutic potential in a 
model of peripheral neuropathy. I found that LRP1 and LRP2 were expressed on growth 
cones at the leading edge and on filopodia, suggesting that they are part of the environment-
sensing machinery.  I used the growth cone turning assay to test whether a range of LRP 
ligands were chemotactic to growth cones in vitro. The ligands tested included 
metallothionein II (MTII), apolipoproteinE3, tissue plasminogen activator (tPA), alpha-2-
macroglobulin (α2M), vitamin D and transthyretin. E16-18 embryonic rat sensory neuron 
growth cones grew towards a microgradient of MTII (+11.6°±2.1°, p<0.0001, cf. control -
1.8°±1.1°), and turned away from a microgradient of MTIII (-13.8°±1.9, P<0.0001), α2M (-
11.9°±3.4, P<0.01) and tPA (-11.1°±2.1 P<0.001). I used siRNA knock down and 
pharmacological inhibition to demonstrate that LRP1 and LRP2 were both required for 
growth cone responses to MTII and MTIII.  Growth cone turning towards a gradient of MTII 
or MTIII was abolished by LRP-receptor inhibition with receptor associated protein and 
siRNA knockdown of LRP1 or LRP2.  In addition, pharmacological inhibition of TrkA 
receptors significantly augmented the turning response. These data demonstrate that both 
LRP1 and LRP2 are necessary for MTII and MTIII-mediated chemotactic signal 
transduction, and potentially form part of a signalling hub, recruiting other co-receptors such 
as TrkA. MTII and MTIII-mediated chemotaxis was found to be dependent on calcium ion 
concentration: when neurons were depleted of extracellular calcium, the turning response 
underwent a complete switch in direction. Furthermore, pharmacological inhibition of 
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calcium/calmodulin-dependent kinase II suggested that LRP1 and LRP2 signal via 
established downstream effectors.  I then asked whether LRP-mediated chemotaxis could be 
exploited to guide axon regeneration in vivo.  I used a model of small-fibre neuropathy in 
rats. Ten age-matched rats had topical 8% capsaicin cream and placebo cream applied to 
contralateral areas on the lumbar dorsum.  Treated areas were given 3x weekly intradermal 
injections of MTII or saline. Punch and epidermal roof biopsies were harvested weekly to 
monitor regeneration. At 14 days, regeneration was observed in saline treated capsaicin 
regions, compared to contralateral control skin, however MTII treated rats had complete 
regeneration by 7 days.  LRP-mediated chemotaxis represents a novel, non-classical axon 
guidance signalling system.  MTII has therapeutic potential as a disease-modifying agent for 
the injured nervous system. 
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CHAPTER 1:  INTRODUCTION 
1.1 NEURONAL NETWORKS 
1.1.1 The nervous system is interconnected 
As a staggeringly complex network of cell connections throughout the body, the nervous 
system governs virtually all body activity; from conscious movement and thought, to the 
completely unconscious action potential or ebb and flux of hormones and ions involved in 
homeostasis of the body’s internal environment.  There are trillions of synapses which allow 
for chemical and electrical continuity between neurons.  Disruption or disconnection of these 
neuronal networks can occur commonly in trauma, neurodegenerative diseases, surgical 
procedures, systemic illnesses, and as a side effect of drug toxicity.  Such damage may result 
in cognitive decline, in the loss of motor function and/or sensation, or the development of 
pain syndromes (Singer, 1986). 
During development, neurons send out an axonal process which uses a range of guidance 
cues to navigate the embryonic environment, establishing the early framework of the 
neuronal circuitry.  The existence of hundreds of billions of cells in the developing embryo 
means that finding the correct target with which to synapse is no small feat.   Growth cones 
are exquisitely sensitive structures present at the distal end of axons that facilitate the growth 
of axon to target (Caudy and Bentley, 1986).  The mechanism by which the direction of 
growth cones can be manipulated in development has been the topic of investigation for 
many decades, not only for an intrinsic understanding of development, but for its application 
in regenerative processes.  This thesis focusses on growth cone pathfinding through novel 
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mechanisms in a developmental in vitro model, and its translation into an in vivo model of 
nerve injury, to promote regeneration.  Specifically, the hypothesis that underpins this thesis 
is that members of the multifunctional low-density lipoprotein (LDL) receptor family posess 
novel roles in growth cone pathfinding.  The first experimental chapters within this thesis 
investigate the chemotactic abilities of LDL receptor ligands on neuronal growth cones, and 
include an investigation into their mechanism of action. Elucidating these LDL receptor 
mediated growth cone guidance pathways is important for developing new mechanisms for 
promoting and enhancing neuronal regeneration after injury. Therefore, the later chapters 
describe the initial outcomes of the translation of this in vitro work into models of nerve 
injury. 
This introductory chapter will review the process of growth cone guidance by chemotactic 
factors, and outline evidence relating to the potential involvement of the LDL receptor family 
in this activity.  An examination of the application of chemotactic factors in neuropathy will 
follow, with specific emphasis on diabetic neuropathy, the most common form of neuropathy. 
1.1.2 Axon pathfinding in development 
Our understanding of axon pathfinding has blossomed since Ramón y Cajal first described 
growth cones as “battering rams” that are “endowed with amoeboid movements” which force 
their way between cells to direct these axons to their targets (Cajal, 1952, Landmesser, 1986).  
Structure and function studies have since demonstrated the exquisite complexity of growth 
cones and their role in sensing and responding to the internal environment, in axon turning, 
extension and in initiating bifurcation (Sato et al., 1994, Hollyday and Morgan-Carr, 1995).  
The growth cone mediates axonal pathfinding: a complex process that is essential for the 
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development of the nervous system and for its maintenance following neuronal injury or 
turnover. In early development, neuronal growth cones respond to soluble and substrate-
bound chemotactic guidance cues spatially and temporally, to allow the axon to navigate the 
internal milieu and make appropriate connections (Sperry, 1963).  There is consensus that a 
similar process is involved in the adaptive capacity of mature neurons: that is, in synaptic 
plasticity and regeneration of the nervous system (Kolodkin, 1996).  
During axon pathfinding in development, neurons extend an axonal process ending in a 
growth cone, which navigates through the extracellular matrix, extending to meet the target 
cell with which it synapses (Caudy and Bentley, 1986). A growth cone comprises a 
membranous, receptor-rich, fan-shaped structure (lamellipodia) which extends between long 
finger-like projections (filopodia) (Fig 1.1).  Its cytoskeleton, comprised of filamentous actin 
(F-actin), closely interacts with the axonal microtubule core (Lewis and Bridgman, 1992, 
Bentley and O'Connor, 1994, Suter and Forscher, 2000) (Fig 1.1).  F-actin forms bundles in 
filopodia, and an irregular cross-linked arrangement along the leading edge, which also gives 
structure to the lamellipodia (Lewis and Bridgman, 1992, Korey and Van Vactor, 2000, Suter 
and Forscher, 2000) (Fig 1.1). Microtubules are arranged as parallel bundles along the neurite 
and splay outwards within the growth cone (Bridgman and Dailey, 1989).  Microtubules 
interact and cooperate with F-actin in order to adhere to the matrix, sense and respond to 
growth cues in the extracellular milieu, and allow extension to the target (or repulsion from 
an inhibitory cue). These principles are the basis for the development of “the growth cone 
turning assay” developed by M.M. Poo that detects the response of growth cones to stimuli 
(Lohof et al., 1992). Thus, the growth cone provides a powerful model for studying the 
interaction of neurons with their extracellular environment, and also for the receptor  
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Figure 1.1 Structure of the neuronal growth cone 
A growth cone comprises a membranous, receptor-rich, fan-shaped structure (lamellipodia) 
which extends between long finger-like projections (filopodia).  Its cytoskeleton, comprised 
of filamentous actin (F-actin), and microtubules, closely interact (Lewis and Bridgman, 1992, 
Bentley and O'Connor, 1994, Suter and Forscher, 2000).   
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signalling pathways which transduce this information into directional changes in axonal 
growth.  Such signalling pathways could be critically important for promoting regeneration 
after neuronal damage. 
 
1.1.3 Axon pathfinding is necessary for formation and regeneration of the central 
nervous system (CNS) and peripheral nervous system (PNS) 
Subtle errors in axon pathfinding during development contribute to a range of disorders of the 
nervous system such as schizophrenia, epilepsy, and mental retardation (Marco et al., 1997, 
Mason et al., 2001).  The failure of regeneration in the adult CNS can be evidenced by 
several pathologies of the nervous system, including neurodegenerative diseases such as 
Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis, which involve the 
loss of neurons and their synaptic connections (Van Uden et al., 1999, Mason et al., 2001, 
Puttaparthi et al., 2002, Hoglund and Salter, 2013).  In addition, failure of regeneration may 
result in neuropathies, developed as sequelae of systemic diseases such as diabetes, as a 
consequence of chemotherapeutic drug use, or during traumatic injury, where sensation 
and/or movement may be permanently lost distal to the injury (Mar et al., 2014). Although 
axon guidance is primarily involved in development of the nervous system, it also has an 
essential role in peripheral nerve regeneration and re-innervation of target tissues after 
neuronal injury.  The processes encompassing neuronal re-sprouting after injury closely 
recapitulate those that occur during axon pathfinding in development, making the study of 
developmental processes particularly relevant in the context of neuronal injury (Hoffman and 
Cleveland, 1988). 
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Neuronal injury activates a series of pathological processes, including inflammation, scar 
formation, necrosis and apoptosis (Fitch and Silver, 2008, Huebner and Strittmatter, 2009). 
Damage to neural tissue in the adult CNS is virtually always irreparable, due to a 
combination of inhibitory factors and glial scar formation, the incapacity to re-express 
developmental molecules associated with guidance and growth, and inherent inability of the 
neuron to form functional regenerative sprouts (Buffo et al., 2009). In the peripheral nervous 
system (PNS), however, nerves are sometimes able to regenerate and re-innervate post injury, 
although this process is very slow and often inaccurate, and may result in aberrant function 
and pain syndromes (Aguayo et al., 1981).   Hence, there is a need for therapeutic 
intervention to improve the outcome in neuronal injury of the CNS and PNS. 
1.1.4 Axon pathfinding in regeneration 
The development of an approach to enhance axonal regrowth after injury or neuropathy has 
been a goal for researchers for many centuries.  In 1830, Theodor Schwann reported the 
phenomena of nerve regeneration in rabbits. Almost a century later, Santiago Ramon y Cajal 
first postulated that nerve regeneration required chemotactic signals; however this was not 
demonstrated until 1963 by Sperry (Sperry, 1963). The discovery of the first of many 
neuronal chemotactic factors arose from the identification of a substance in a mouse sarcoma 
which was found to enhance nerve growth.   The substance Rita Levi-Montalcini and 
collaborators identified was nerve growth factor (Cohen et al., 1954).  The use of chemotactic 
factors in animal models of nerve damage has had great success and promise (Levi-
Montalcini and Angeletti, 1963, Varon et al., 1979).  However, in humans, most trials using 
chemotactic factors to promote regeneration have had poor functional outcomes (Calcutt et 
al., 2008).  Poor outcomes have been largely resultant of differences in therapeutic dose, and 
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low tolerance resulting from inappropriate (often systemic) administration of trophic factors 
whose expression is usually spatially restricted (Apfel, 2002). 
1.2 THE MECHANICS OF AXON PATHFINDING 
1.2.1 Guidance cues and chemotactic factors 
In the process of axon pathfinding, growth cones must respond to a multitude of diffusible 
and substrate-bound chemotactic factors and guidance cues in the extracellular environment, 
and integrate this information into a directional response (Tessier-Lavigne and Goodman, 
1996).  Growth cones are fitted with an elaborate suite of receptors that allow for the 
simultaneous integration of a multitude of chemotactic cues (Tessier-Lavigne and Goodman, 
1996).  The presence of chemotactic factors is detected by their specific receptors located on 
the growth cone membrane, inducing an intracellular signalling cascade.  This cascade 
manipulates the cytoskeletal elements, and dictates whether the response of the growth cone 
culminates in turning, extension, stasis or retraction, collapse or bifurcation (Suter and 
Forscher, 2000). This diverse range of responses produces a highly specific set of movements 
and allows the axon to be directed to an individual target.  By necessity, studies in growth 
cone guidance and axon pathfinding have looked at the relative involvement of individual 
chemotactic cues; although in the human body, microenvironments may contain numerous 
chemotactic cues and their simultaneous integration is not only necessary for directional 
responses, but also the adaptation to changing cues in different intermediate targets (Tessier-
Lavigne et al., 1988, Shirasaki et al., 1998, Tojima, 2012).  Whilst growth cues generally 
produce a characteristic growth cone turning response (eg. inducing attraction); this response 
can be altered or switched depending on the developmental stage of the neuron, the type of 
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neuron, the extracellular environment,  the status of intracellular second messengers, or 
differential receptor expression (Song and Poo, 1999, Gallo and Letourneau, 2002, Dontchev 
and Letourneau, 2003). Therefore, the targeting of a growth cone to its correct cellular target 
is the product of multiple signalling events, both intracellular and extracellular. 
1.2.2 Intracellular signalling in growth cone navigation 
The intracellular signalling pathways that mediate growth cone chemotaxis are varied and yet 
to be fully elucidated.  It is well established that calcium ions (Ca
2+
)
 
are an early second 
messenger of most chemotactic signalling cascades that influence the direction of the 
developing neuron (Song and Poo, 1999). Ca
2+
 is able to mediate both attractive and 
repulsive responses in growth cones (Song and Poo, 1999). The ability for Ca
2+
 to mediate 
repulsion or attraction is principally modulated by to two factors: 1) the spatial and temporal 
localisation of the Ca
2+
 signal, and; 2) the activation of differentially sensitive calcium-
dependent signalling molecules (Song and Poo, 1999, Wen et al., 2004, Tojima et al., 2009).  
The source of Ca
2+
 is important in mediating a directive signal: attraction towards a 
chemotactic cue results when there is a large change in intracellular Ca
2+ 
levels, whereas 
repulsion occurs when the influx is modest (Berridge et al., 2000). A large change in 
intracellular Ca
2+
 can be achieved by an influx of extracellular Ca
2+
, combined with release 
from intracellular stores within the endoplasmic reticulum, in a process called calcium-
induced calcium-release (CICR) or inositol 1,4,5 trisphosphate-induced calcium-release 
(IP3ICR) (Ooashi et al., 2005). When an influx of Ca
2+
 occurs in the absence of CICR or 
IP3ICR, (ie. solely from the extracellular milieu, through Ca
2+ 
channels), the resulting change 
in Ca
2+
 is modest and repulsion occurs  (Ooashi et al., 2005). In light of this finding, it has 
recently been proposed that changes in calcium-dependent regulation of neurite outgrowth 
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tends to follow the IP3ICR pathway early in development, but the voltage dependent calcium 
channel (VDCC) or ryanodine receptor (RyR) pathways in later stages of development (Arie 
et al., 2009).  Secondary to the Ca
2+
 signal are the downstream effectors of growth cone 
turning – with the role of differentially sensitive calcium-dependent signalling molecules 
having major importance. Calcineurin phosphatase (CaN) is highly sensitive to Ca
2+ 
and 
mediates growth cone repulsion. If the influx of Ca
2+
 in response to a trophic cue is modest, 
CaN is preferentially activated, and the growth cone will be repelled (Wen et al., 2004).  
Calmodulin dependent kinase II (CaMKII), which is abundant in growth cones, has a lower 
affinity for Ca
2+
, and therefore larger influxes of Ca
2+
 are required to activate CaMKII (Wen 
et al., 2004).  A higher abundance of activated CaMKII over CaN in the growth cone will 
therefore initiate growth cone attraction (Fig 1.2).  Regardless of whether the cue is attractive 
or repulsive, relatively higher concentrations of Ca
2+
 are observed on the side of the growth 
cone where the concentration of soluble chemotactic cue is highest, in turn facilitating an 
asymmetric rearrangement of cytoskeletal elements and growth cone turning (Tojima, 2012). 
Cyclic nucleotides (cAMP and cGMP) are also important downstream effectors of growth 
cone turning, with crosstalk occurring between cyclic nucleotides and local Ca
2+ 
levels 
(Nishiyama et al., 2003, Forbes et al., 2012).  Cyclic nucleotide signalling operates within an 
optimal concentration range, and levels are dependent on the rate of conversion of adenosine 
triphosphate and guanosine triphosphate to cAMP and cGMP, respectively (Song et al., 1998, 
Song and Poo, 1999, Nishiyama et al., 2003).  Importantly, Nishiyama and colleagues (2003) 
determined that when a guidance cue induces a high ratio of cAMP:cGMP, the directional 
response of growth cones is modulated, such that neurons are attracted; however when the 
ratio is low, growth cones can instead be repulsed (Nishiyama et al., 2003).   One of the ways 
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that cAMP is able to promote attraction of growth cones is by inhibition of CaN, the Ca
2+ 
dependent effector of growth cone repulsion, shifting the balance towards attraction (Wen et 
al., 2004). Taken together, the magnitude of Ca
2+
 influx, in conjunction with its temporal and 
spatial localisation, together are able to elicit both attractive and repulsive responses in 
growth cones. 
1.2.3 The growth cone cytoskeleton 
As a growth cone advances, actin filaments are continuously transported away from the 
peripheral domain to the transitional zone by a myosin-motor driven process known as 
retrograde F-actin flow (Bentley and O'Connor, 1994). When the growth cone is subjected to 
a gradient of the guidance cue, the side of the growth cone facing the higher concentration 
will have a larger influx of Ca
2+ 
ions, allowing a directional response to be propagated.  
Microtubules and F-actin polymerise on the side of the growth cone where the concentration 
of Ca
2+
 is highest, meanwhile they will be destabilised on the side with the lower 
concentration, facilitating a directional response (Fan and Raper, 1995, Gallo et al., 2002).  In 
response to a chemorepulsive cue, the change in i[Ca
2+
] is moderate, leading to the activation 
of CaN, which culminates in the re-assembly of cytoskeletal elements, and ultimately, to 
neurite repulsion.  Repulsive cues activate actin destabilising proteins, and promote F-actin 
retrograde flow.  Microtubules and actin are destabilised on the side of the growth cone 
where the concentration of the repulsive cue is highest, meanwhile stabilisation instead is 
favoured on the opposite side of the growth cone, allowing the growth cone to turn away  
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Figure 1.2 The cytoskeletal events that underlie growth cone navigation 
 
Inside the growth cone, the initiation of turning is usually elicited by a change in i[Ca
2+
] 
(shown by graded colour bar). As a growth cone advances, actin filaments are continuously 
transported away from the peripheral domain to the transitional zone (Bentley and O'Connor, 
1994). When the growth cone is subjected to a gradient of chemoattractant, the side of the 
growth cone facing the higher concentration will have a larger influx of Ca
2+ 
ions, resulting in 
stabilisation and polymerisation of microtubules and F-actin. Microtubules and F-actin are 
destabilised on the side with the lower concentration of attractive cue (Gallo et al., 2002). In 
response to a chemorepulsive cue, the change in i[Ca
2+
] is moderate, leading to the activation 
of CaN, and microtubules and F-actin are destabilisation and disassembly.  Stabilisation 
instead is favoured on the opposite side of the growth cone, allowing the growth cone to turn 
away from the gradient (Gallo and Letourneau, 2002). Original figure. 
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from the gradient (Gallo and Letourneau, 2002).  If, however, the cue is chemoattractive, 
CICR or IP3ICR is activated, the resultant change in i[Ca
2+
] is high, CaMKII is activated, 
which also inhibits CaN. Attractive cues inhibit F-actin retrograde flow, and activate actin 
stabilising proteins and promote the anterograde assembly of actin at the peripheral domain 
(Bhide and Frost, 1991, Dontchev and Letourneau, 2003). Microtubule monomers are 
destabilised and disassembled on the side with the lowest concentration of chemoattractant; 
the monomers are subsequently targeted to the side with the highest concentration of 
chemoattractive cue by stabilising proteins (Gallo and Letourneau, 2002).  Coupling of actin 
and microtubule assembly is imperative for growth cone motility. The exact mechanism by 
which Ca
2+
 regulates the cytoskeleton remains elusive.  These data are summarised in Fig 
1.2. 
1.2.3 Receptors implicated in growth cone guidance 
Signal transduction mechanisms initiated during growth cone guidance are necessarily highly 
complex, in order to navigate through many different tissues within the body.  Many 
receptors will function in concert to produce a distinct turning response of a growth cone in 
the body and deliver it to its target.  Well defined receptors for chemotactic signals include 
the family of tyrosine related kinase (Trk) receptors, the low-affinity p75 neurotrophin 
receptor, the receptor tyrosine kinase RET, Nogo-66 receptor, neuropilin, ephrins, 
roundabout (Robo) and deleted in colorectal cancer (DCC) (Dickson, 2002). Recent studies 
allude to the potential role of another receptor family:  low-density lipoprotein (LDL) 
receptors.  All LDL receptors are expressed in the nervous system and knockout studies 
suggest an indispensable role in neurodevelopment of higher-order organisms (Beffert et al., 
2004).  The hypothesis that underpins this thesis is that receptors of the LDL family are 
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involved in growth cone guidance. Hence, this review will now focus on the LDL receptor 
family and their known roles in the nervous system, and the evidence pertaining to a possible 
role in growth cone guidance. 
1.3 THE MULTIFUNCTIONAL LDL RECEPTOR GENE FAMILY  
The LDL receptor family comprises a large group of multi-ligand receptors with a diverse 
range of functions. The family includes core members: LDL receptor, the LDL receptor-
related protein (LRP1, also known as CD91 and α-2-macroglobulin receptor) (Herz et al., 
1988), LRP1b (Liu et al., 2000a), LRP2 (LRP2, also known as GP330 or megalin) 
(Raychowdhury et al., 1989), the VLDL receptor (VLDLR) (Takahashi et al., 1992), 
Apolipoprotein receptor-2 (ApoER2, also known as LRP8) (Kim et al., 1996), LRP5 (Hey et 
al., 1998), LRP6 (Brown et al., 1998), and sorLA-1 (also known as LR11) (Yamazaki et al., 
1996) (See Fig 1.3). Owing to their ability to interact with other cell-surface receptors, ion 
channels and adhesion molecules, the LDL receptor family is able to initiate a diverse range 
of physiological processes. The LDL receptor family is characterised by its ability to 
endocytose ligands and nutrients, carrying them to acidic endosomes where release of the 
ligand can occur, while the receptor is cycled back to the cell surface (Brown et al., 1997).  
The LDL receptor family is traditionally described for its endocytic roles in lipid metabolism, 
cellular entry of viruses and toxins and vitamin uptake; cell signalling; and activation of 
various proteases and enzymes (Li et al., 2001a).  
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Figure 1.3 The core members of the LDL receptor family. 
The common structural motifs are highlighted, demonstrating similarity between the family 
members. (Adapted from May et al. 2004) 
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1.4  LDL RECEPTOR FAMILY IN NEURONAL FUNCTION  
1.4.1 Overview of LDL receptor function in neurons  
The LDL receptor family have been implicated in numerous functions of the nervous system.  
These processes include neuronal outgrowth (Handelmann et al., 1992), synaptogenesis 
(Mauch et al., 2001, Pfrieger, 2003b, Mulder et al., 2004), synaptic transmission (May et al., 
2004, Martin et al., 2008), neuromuscular junction formation (Weatherbee et al., 2006), long-
term potentiation (Weeber et al., 2002), neuronal migration and neuronal patterning 
(Trommsdorff et al., 1999, Spoelgen et al., 2005). The LDL receptor family has an integral 
role in cholesterol metabolism. Cholesterol is a principal component of cell membranes and 
myelin sheaths, and stabilises membrane lipid rafts (Pfrieger, 2003a).  Therefore, LDL 
receptors have a pivotal role in the developing nervous system, and in maintenance of the 
adult brain. Cholesterol uptake is regulated by receptor mediated endocytosis of ApoE- 
flagged chylomicron, with ApoE a ligand of most LDL family receptors. In vitro, the addition 
of cholesterol to neurons enhances the number and efficacy of synapses (Mauch et al., 2001). 
Some of the most pertinent evidence of LDL receptor function in neurons can be ascertained 
from receptor knockout studies.   LDLR deficient mice have deficits in learning and memory, 
likely due to reduced synaptic density (Mulder et al., 2004).  LRP5 and LRP6 form 
morphogenic signalling domains with the canonical Wnt/Frz complex involved in 
development; not surprising is the finding that either LRP5 or LRP6 knockout mice have 
gross malformations in neuronal patterning. LRP5 and LRP6 double knockout mice are 
embryonic lethal (Tamai et al., 2000, Kato et al., 2002, Kelly et al., 2004).  ApoER2 and 
VLDL double knockout mice have abnormalities in the layering of the brain, including 
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ectopic placement of neurons (Trommsdorff et al., 1999, Weeber et al., 2002). LRP1 and 
LRP2 are the largest and most promiscuous members of the receptor family.  Individual 
knockout studies involving LRP1 of LRP2 in mice have shown that these knockouts are both 
almost exclusively embryonic lethal and associated with malformations of the brain (Willnow 
et al., 1996a, Lillis et al., 2008).  All LDL family receptors are expressed in the central 
nervous system and the knockout studies mentioned above suggest an indispensable role in 
neurodevelopment.  Some of the roles of LDL receptors in neurodevelopment have been the 
subject of intense investigation and are described in detail below. 
1.4.2 VLDL and ApoER2 receptors 
Knockout mice lacking both VLDL and ApoER2 exhibit migration defects resulting in 
malformations of the cortex, cerebellum and spinal cord, as well as failed retino-geniculate 
connectivity (Trommsdorff et al., 1999, Su et al., 2013). These defects are phenotypically 
identical to the very distinct and unique disordered lamination displayed in knockout mice 
lacking extracellular signalling ligand Reelin or its downstream intracellular adapter molecule 
disabled-1 (Dab-1) (Trommsdorff et al., 1999). In subsets of neurons, Reelin stimulates 
dendrite outgrowth and polarisation, as well as adhesion and stabilisation of these dendritic 
processes, culminating in migration of neurons (Niu et al., 2004, Nichols and Olson, 2010, 
Sekine et al., 2012).  This led to the discovery that ApoER2 and VLDL are high affinity 
receptors of Reelin (D'Arcangelo et al., 1999, Hiesberger et al., 1999). ApoER2/VLDL are 
also necessary for migration of neuroblasts in the forebrain, in a process independent of 
Reelin (Andrade et al., 2007).  Single ApoER2 or VLDL knockout mice have a milder 
phenotype, in part due to redundancy in function of the two receptors. More recently, it has 
been demonstrated that there are temporal differences in the expression of these receptors 
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during critical stages of development which may also lead to differences in phenotype 
observed between single ApoEr2 or VLDL knockout mice (Cheng et al., 2011).  Humans 
with mutations of the VLDL receptor gene are at increased risk of schizophrenia, which is 
thought to be due to subtle migration defects of neurons within the brain (Deutsch et al., 
2010). 
The Reelin-ApoER2/VLDLR signalling system is also implicated in dendritic spine 
development and synaptic transmission and plasticity in the hippocampus (Weeber et al., 
2002, Beffert et al., 2005, D'Arcangelo, 2005, Niu et al., 2008). Modulation of synaptic 
transmission occurs through controlling Ca
2+
 entry through NMDA receptors. ApoER2 is 
able to phosphorylate NMDA receptors by tyrosine phosphorylation of its cytoplasmic tail, 
and VLDL is able to interact with NMDA receptors physically, although the exact molecular 
mechanisms underpinning this interaction are yet to be fully elucidated (Chen et al., 2005, 
Herz, 2009). Hippocampal plasticity, in the form of long-term potentiation (LTP) or long 
term depression (LTD) is essential for learning and memory, as well as general cognition 
(Grover and Teyler, 1990, Norris et al., 1996, Norris et al., 1998). Plasticity occurs when 
tetanic stimulation of the dendrite increases (LTP) or decreases (LTD) excitatory 
postsynaptic potentials (EPSPs). Perfusing hippocampal slices with Reelin increases 
miniature EPSPs (Qiu et al., 2006).  Supporting these observations, infusion of Reelin into 
the ventricles of wild type mouse brains increased dendritic spine density, hippocampal LTP, 
and improved performance in various associative and spatial learning and memory tasks 
(Rogers and Weeber, 2008), thereby demonstrating the involvement of 
Reelin/VLDL/ApoER2 signalling in cognitive processes. 
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1.4.3 LRP5 and LRP6 receptors 
LRP5 and LRP6 are closely related to each other in structure and amino acid sequences, and 
are widely co-expressed in neurons (Houston and Wylie, 2002).  Together LRP5 and LRP6 
(LRP5/6) are implicated in neuronal migration by virtue of their involvement in Wnt 
signalling pathways (Pinson et al., 2000, Wehrli et al., 2000, Houston and Wylie, 2002). Wnt 
proteins are extracellular signalling molecules with important signalling functions during 
development of the central nervous system, particularly in establishing cell polarity, cell type, 
axon guidance and synapse formation (Wodarz and Nusse, 1998, Strutt, 2003). LRP5/6 
knockout mice have gross developmental malformations of the nervous system which result 
from disruptions in Wnt signalling (Pinson et al., 2000, Kelly et al., 2004).  LRP5 and LRP6 
form a signalling complex Frizzled (Fz) receptors, and through this complex interact with 
Wnt-1, Wnt-3a, Wnt-3 or Wnt-7a (Yang-Snyder et al., 1996, Pinson et al., 2000, Tamai et al., 
2000).  When Wnts are bound to the LRP5/6/ Fz complex, the Wnt-β-catenin canonical 
pathway, is activated causing an accumulation of β-catenin in the cytoplasm and its eventual 
translocation into the nucleus, where it is able to regulate gene transcription pathways 
essential for neuronal development (Pinson et al., 2000, Wehrli et al., 2000, He et al., 2004, 
Tamai et al., 2004).  Furthermore, Wnts have a direct role in axon guidance through their 
function as chemotactic factors, and have pivotal roles in anterior-posterior axon guidance, 
particularly for commissural axons in mice (Lyuksyutova et al., 2003, Domanitskaya et al., 
2010).  Taken together, LRP5/6 and Wnts have crucial roles in axon pathfinding and 
development of the nervous system.  
  
 
27  |     Chapter 1 
 
1.4.4 LR11 (SorLA) receptor 
SorLA is a receptor that is highly conserved, and robustly expressed in the brain, having 
features of both LDL receptors and the sortilin family of receptors, which are known for 
sorting proteins through secretory and endocytic pathways (Jacobsen et al., 2001). SorLA is 
involved in the control of neurotrophic activity through regulating the secretion and cellular 
uptake of glial cell line-derived neurotrophic factor (GDNF) (Saarma and Sariola, 1999, 
Geng et al., 2011).  SorLA and GDNF knockout mice exhibit the same phenotype, which 
includes severe disruption of nigrostriatal connectivity in the CNS (Glerup et al., 2013).  
GDNF plays a critical role in neuronal survival, differentiation and function (particularly for 
dopaminergic neurons in the CNS, and various subsets of sympathetic, parasympathetic, 
sensory and enteric neurons of the PNS), as well as modulating cell migration, neurite 
outgrowth and synapse formation (Saarma and Sariola, 1999, Ibanez, 2010, Bespalov et al., 
2011).  In addition, recycling of the GDNF co-receptor, GFR-α1, is mediated by SorLA 
(Glerup et al., 2013). SorLA is a negative regulator of amyloid precursor protein (APP), thus 
indirectly modulates the neuritogenic effects of soluble APP, and as such SorLA is a major 
risk factor of Alzheimer’s disease (Andersen 2005, Rohe 2008).  SorLA has been 
demonstrated to interact with the highly multifunctional family member LRP1 (Gliemann et 
al., 2004, Spoelgen et al., 2009).  Head activator peptide, a ligand of the SorLA orthologue 
found in hydra, is responsible for regeneration of the organism’s head (Hampe et al., 1999).  
This intriguing role in regeneration may be of relevance to humans, but has not been 
investigated in detail. 
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1.4.5 LRP1 receptor 
LRP1 is a 600kDa cell surface receptor with established roles in the kidney and the brain.  
LRP1 is highly expressed in neurons, particularly in the entorhinal cortex, hippocampus and 
cerebellum, and is also present in Schwann cells, activated astrocytes and microglia (Wolf et 
al., 1992, Bu et al., 1994, Rebeck, 2009, Marzolo and Farfan, 2011).  Within neurons, LRP1 
is predominantly localised to the postsynaptic region where it interacts with NMDA receptors 
via intracellular scaffold postsynaptic density protein 95 (PSD-95) (Trommsdorff et al., 1998, 
Gotthardt et al., 2000). LRP1 is able to influence the activity of NMDA receptors and 
regulate their distribution and internalisation (May et al., 2004, Maier et al., 2013, Nakajima 
et al., 2013). LRP1 is also able to modulate the NMDA-induced internalisation of AMPA 
receptor subunit GluR1 (Nakajima et al., 2013). The very nature of this LRP1/NMDA 
receptor relationship suggests LRP1 plays an integral role in neurotransmitter-induced 
calcium signalling, particularly in synaptic plasticity and thus learning and memory (Maier et 
al., 2013, Nakajima et al., 2013).  This relationship has been demonstrated by neuron-specific 
cre-lox deletion of LRP1 in mice. These mice exhibit severe tremor and dystonia, behavioural 
abnormalities, hyperactivity, age-dependent dendritic spine degeneration, synapse loss, 
neuroinflammation, memory loss, eventual neurodegeneration and premature death (May et 
al., 2004, Liu et al., 2010), clearly demonstrating that LRP1 is crucial to neuronal function. 
LRP1 contains multiple signalling domains. During post-translational modification, LRP1 is 
cleaved into two subunits by furin, which subsequently re-join in a non-covalent manner 
(Willnow et al., 1996b). LRP1 comprises a 515kD subunit and an 85kD transmembrane 
subunit (Willnow et al., 1996b).  The soluble extracellular domain of LRP1 (sLRP1) can be 
cleaved by enzymes including BACE1 (von Arnim et al., 2005) and metalloproteinase 
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(Selvais et al., 2011), and can be detected in the blood and CSF (Liu et al., 2009, Zlokovic, 
2011). sLRP1 contains the α-chain and a 55kDa fragment of the β-chain (Quinn et al., 1999). 
The physiological function of sLRP1 is poorly understood, but as it can bind most LRP1 
ligands, one function may be as a mechanism to terminate cell signalling events, and quench 
excess ligands (Gaultier et al., 2008).  sLRP1 administered prior to sciatic nerve constriction 
injury in mice was found to decrease expression of proinflammatory mediators Tissue 
necrosis factor-α (TNF-α) and IL-1α local to the contusion site (Gaultier et al., 2008). 
Furthermore, sLRP1 also inhibited p38 MAPK activation (Gaultier et al., 2008) which is 
induced during cellular stress, such as during apoptosis and inflammation (Chang and Karin, 
2001).  sLRP1 administration significantly decreased measures of neuropathic pain, 
concomitant with a decrease in inflammatory cytokine expression in the spinal dorsal horn, 
where neuropathic pain processing occurs (Gaultier et al., 2008). 
1.4.6 LRP2 receptor 
LRP2 (also known as megalin) is a 600kDa endocytic receptor with key roles in protein 
reabsorption in the kidney (Nykjaer et al., 1999). In the CNS, LRP2 is highly expressed in the 
forebrain, optic stalk and optic vesicle.  It is also present early in development on the apical 
surface of the neural tube. In adult mice, expression of LRP2 in the nervous system is 
predominantly in the choroid plexus (Chun et al., 1999), ependymal cells (Gajera et al., 2010) 
and spinal cord (Wicher et al., 2005).  LRP2 KO mice (on a 129SvEv x C57BL/6 hybrid 
background) have a series of midline defects that include cleft palate, arhinencephaly (lack of 
olfactory bulb formation) and holoprosencephaly (a syndrome in which the forebrain 
hemispheres are fused and only one ventricle forms), and most die perinatally (Willnow et 
al., 1996a).  Holoprosencephaly results from altered activation of LRP2 ligand, bone 
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morphogenetic protein 4 (BMP4), and the decreased expression of LRP2 ligand sonic 
hedgehog (Shh) (McCarthy et al., 2002, Spoelgen et al., 2005, Christ et al., 2012). BMP4 and 
Shh have competing effects on neuronal stem cell proliferation (Spoelgen et al., 2005, 
Balordi and Fishell, 2007). LRP2 promotes neurogenesis in the adult mammalian brain by 
down-regulating BMP4-mediated anti-proliferative signals (Gajera et al., 2010). However, 
this function of LRP2 in the morphogen signalling pathways of neuronal development must 
be an evolutionarily recent adaptation in higher order vertebrates, as loss of LRP2 in 
zebrafish does not alter forebrain development (Kur et al., 2011).  LRP2 also promotes 
neuronal migration through Shh-signalling pathways by sequestering Shh so that it can bind 
its other receptor, Patched-1 (Christ et al., 2012).  The few mice that survive LRP2 KO have 
severe Vitamin D3 deficiency, as Vitamin D and its carrier protein Vitamin D binding protein 
(VDBP), normally reabsorbed by LRP2 in the kidney proximal tubule, are instead excreted in 
the urine (Willnow et al., 1996a, Nykjaer et al., 1999). Vitamin D has been implicated in 
cognition and depressive symptoms (Wilkins et al., 2006, Przybelski and Binkley, 2007, 
Shaffer et al., 2014), suggesting a further role in neuronal function which remains to be fully 
elucidated.   LRP2 mutation in humans results in Donnai-Barrow syndrome (DBS), or facio-
oculo-acoustico-renal syndrome. DBS is an autosomal recessive disorder that in its 
presentation includes disrupted brain formation, including agenesis of the corpus callosum, 
and is associated with developmental delay (Kantarci et al., 2007).  
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1.5  LRP1 AND LRP2 EXTRACELLULAR LIGANDS HAVE IMPORTANT FUNCTIONS 
IN NEURONS  
LRP1 and LRP2 serve uniquely important functions roles as suggested by their expression 
throughout development and adulthood, and conservation among eukaryotes (Nimpf et al., 
1994, Christensen and Birn, 2002).  LRP1 and LRP2 share structural similarities, overlapping 
ligands and a remarkable array of functions (Spuch et al., 2012), setting them apart from the 
rest of the LRP receptors, and as such will form the focus of this thesis.   
Recently, the role of LRP1 and LRP2 receptors in mediating regenerative growth of injured 
neurons has been a topic of investigation (Fitzgerald et al., 2007, Ambjorn et al., 2008, 
Chung et al., 2008, Fleming et al., 2009a, Leung et al., 2012 ).  Following binding by the 
ligand metallothionein, an endogenous protein released by astrocytes following injury, LRP1 
and LRP2 receptors have been shown to promote post-injury neurite sprouting in the CNS 
(Chung et al., 2008).  LRP1 and LRP2 also promote regenerative axonal growth of peripheral 
DRG neurons (Leung et al., 2012).  Each receptor also binds other ligands that are known to 
have important functions in neurons. LRP1 binds a number of distinct ligands, such as 
apolipoprotein E (ApoE) (Herz and Bock, 2002), tissue-type plasminogen activator (tPA) (Bu 
et al., 1993, Grobmyer et al., 1993), transthyretin (TTR) (Sousa et al., 2000), α-
macroglobulin (α2M) (Hanover et al., 1983, Marynen et al., 1984),  ß amyloid (Krieger and 
Herz, 1994), neuronal prion protein (Lauren et al., 2009) and metallothionein (Klassen et al., 
2004).  LRP2 binds some overlapping ligands including ApoE (Herz and Bock, 2002) and 
metallothionein (Klassen et al., 2004), as well as other proteins with putative roles in 
neuronal function, such as Vitamin D/VDBP complexes (Nykjaer et al., 1999). 
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Owing to their numerous ligand-binding complement-type repeat domains, LRP1 and LRP2 
are able to bind more ligands than any other LDLR family member. LRP1 and LRP2 are able 
to bind at least 40 different ligands extracellularly, many of which are structurally unrelated 
(Spuch et al., 2012).   As such, LRP1 and 2 are able to be involved in diverse biological 
processes, including synaptic function, neurite outgrowth, neuronal protection, cell migration 
and cell growth.  The ligands discussed herein have pertinent roles in nervous system 
function, and as candidates for involvement in axon guidance, many will form the basis of the 
investigation of LRP1 and LRP2 function in growth cone guidance within this thesis. 
1.5.1 α2-macroglobulin (α2M) 
Activated human α2M is a 720KDa glycoprotein that is a ligand of LRP1 and ApoER2 
(Sottrup-Jensen et al., 1985, Ashcom et al., 1990, Strickland et al., 1990, Stockinger et al., 
1998), though most of the described effects in neurons are mediated through LRP1 signalling.  
α2M is a serum pan-proteinase inhibitor, structurally related to complement proteins, that is 
able to direct proteinase clearance when endocytosed by LRP1  (Sottrup-Jensen et al., 1985, 
Sottrup-Jensen, 1989).  α2M is synthesised by numerous cell types, including neurons, where 
it is able to modulate migration, neuroprotection and neurite outgrowth (Mori et al., 1990, 
Moestrup et al., 1992, Higuchi et al., 1994, Narita et al., 1997, Du et al., 1998, Yamamoto et 
al., 1998). Because of the ability of α2M to bind a large number of neurotrophins, cytokines 
and growth factors, it has been ascribed roles in innate immunity, regulation of inflammation, 
and cell signalling, particularly in response to neuronal injury (Crookston et al., 1994, Gonias 
et al., 1994, Skornicka et al., 2002).  When activated in PNS injury, α2M binds a number of 
inflammation-associated cytokines including interleukins (IL-6 and IL-8) and TNF-α. 
Consistent with an immunomodulatory role, α2M is structurally related to complement 
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components C4 and C3 (Armstrong and Quigley, 1999, Samonte et al., 2002).  The ability of 
α2M to bind brain-derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), 
neurotrophin-4 (NT-4) and nerve growth factor-β is thought to regulate their neurotrophic 
activity (Wolf 1994).  Intracranial infusion of α2M decreases dopamine production in vivo 
(Hu et al., 1994), and as such, deregulation of α2M may have roles in neurodegenerative 
disorders such as Parkinson’s disease.  Activated α2M is able to modulate Ca2+ influx 
through NMDA receptors in an LRP1-dependent mechanism (Bacskai et al., 2000, Qiu et al., 
2002a).  Accordingly, exposure of hippocampal neurons to α2M reduces the basal Ca2+ levels 
within the neuron in vitro, and was found to inhibit long-term-potentiation in hippocampal 
slices (Cavus et al., 1996, Qiu et al., 2002a).  NMDA channels are essential in development, 
synaptic plasticity and in generation of long term potentiation, and the disruption of these 
channels can lead to numerous neurological disorders (Qiu et al., 2002b).   
1.5.2 Tissue-type plasminogen activator (tPA) 
LRP1 ligand tissue-type plasminogen activator is a serine protease that has a pivotal role in 
fibrin clot degradation and haemostasis via the well-established tPA/plasminogen cascade 
and blood-brain barrier permeability (Medcalf, 2007).  The expression of tPA is very high in 
neurons and microglia in regions of the brain associated with learning and memory 
(hippocampus), motor learning (cerebellum), fear and anxiety (amygdala), and autonomic 
and endocrine functions (hypothalamus) (Qian et al., 1993, Seeds et al., 1995, Seeds et al., 
1999, Salles and Strickland, 2002, Pawlak et al., 2003, Seeds et al., 2003, Teesalu et al., 
2004). Activity-dependent glutamatergic transmission through N-methyl-D-aspartate 
(NMDA) receptors is modulated by tPA.  tPA increases the permeability of NMDA to Ca
2+
 
(Nicole et al., 2001, Samson et al., 2008).  Depolarisation of dendritic spines and axon 
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terminals in the hippocampus (particularly in response to LTP) induces release of tPA, and 
through its proteolytic activity plays a role in modifying the extracellular matrix, allowing 
synaptic changes to occur during learning and memory (Qian et al., 1993, Lochner et al., 
2006). A similar role for tPA is found in synaptic remodelling associated with emotional 
learning and fear conditioning.  tPA is upregulated in the amygdala in response to restraint 
stress in mice, preceding anxiety-like behavioural changes (Pawlak et al., 2003). In addition, 
mice lacking tPA do not develop anxiety behaviour in response to restraint stress (Pawlak et 
al., 2003).  Although tPA knockout mice do not have any macroscopic phenotype (Carmeliet 
et al., 1995) they do exhibit marked impairment in the rate and extent of motor learning 
(Seeds et al., 2003).  The ability for tPA to modify the extracellular environment by 
proteolysis also has implications for axon pathfinding and cell migration.  tPA is secreted 
from the tip of growth cones, thus modulating the extracellular environment and facilitating 
axon pathfinding  (Krystosek and Seeds, 1981, 1984, 1986).  Mice lacking tPA exhibit 
retarded neuronal migration in the cerebellum, which is postulated to be due to the loss of 
tPA secretion (Seeds et al., 1999).  The role of tPA is has also been investigated in morphine 
and alcohol addiction pathways. Upregulation of tPA occurs in the nucleus accumbens and 
limbic system during morphine and ethanol addiction, respectively. In tPA knockout mice, 
however, in the absence of tPA the reward effect of alcohol and morphine is diminished 
(Nagai et al., 2004).  Taken together, these studies demonstrate the importance of tPA in both 
development of the nervous system and synaptic modulation.  
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1.5.3 Apolipoprotein E (ApoE) 
ApoE is a 34-kDa secreted glycoprotein that associates with LDL receptors and primarily 
functions in plasma to promote the endocytosis of cholesterol-rich chylomicron (Herz et al., 
2000).  There are three isoforms of ApoE resulting from single-nucleotide polymorphisms, 
most commonly ApoE3, followed by ApoE4 and ApoE2. ApoE has been implicated in 
development, synapse formation and neuronal plasticity (Masliah et al., 1995, Fagan et al., 
1996, Mauch et al., 2001, Ji et al., 2003, Hoe and Rebeck, 2005). Mice deficient in ApoE 
develop normally, but have an age-dependent decrease in spine density and arborisation in 
the hippocampus and frontal cortex, as well as dysregulation of microtubules in dendrites 
(Masliah et al., 1995). By 6 months of age, mice lacking ApoE demonstrated significant 
deterioration in working memory (Gordon et al., 1995). Consistent with a role in learning and 
memory formation, application of recombinant ApoE to hippocampal slices revealed that 
compared to controls, apoE4 exposure increased LTP, while apoE2 decreased LTP. ApoE3 
application had no effect on LTP (Korwek et al., 2009). ApoE3 is able to promote neurite 
extension in vitro, suggesting a role in trophic support to neurons (Holtzman et al., 1995, 
Hayashi et al., 2007), highlighting the importance of ApoE in maintenance of the nervous 
system. 
1.5.4 Transthyretin (TTR) 
LRP2 ligand, Transthyretin (TTR), is a plasma and cerebrospinal fluid protein chiefly known 
for its role in retinol and thyroxine transport (Sousa et al., 2000). Mutations of TTR are 
associated with increased aggregation and deposition in the PNS, triggering development of 
the peripheral neurodegenerative amyloidopathy known as familial amyloid polyneuropathy 
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(Saraiva, 2003). TTR knockout mice do not have any macroscopic phenotypes, however they 
have impaired performance in sensorimotor and cognitive tests (Sousa et al., 2004, Fleming 
et al., 2007, Sousa et al., 2007).  TTR knockout mice are also associated with decreased signs 
of depressive behaviour and anxiety, demonstrated by increased exploratory behaviour 
(Sousa et al., 2004).  The mechanism by which this occurs has not been fully elucidated, but 
evidence suggests involvement of noradrenergic neurons of the limbic region (Sousa et al., 
2004). TTR has been demonstrated to have roles in neuronal maintenance and regeneration, 
enhancing neurite outgrowth in vitro and promoting nerve regeneration following injury in 
vivo (Fleming et al., 2007, Fleming et al., 2009a). 
1.5.5 Vitamin D/vitamin D binding protein complex 
Neurons obtain Vitamin D when the vitamin D/vitamin D binding protein complex is 
internalised by neurons via LRP2 (Nykjaer et al., 1999). Vitamin D is able to elicit roles 
within cells by binding the vitamin D receptor in the nucleus, where it acts as a transcription 
factor principally upregulating expression of proteins involved in Ca
2+
 absorption (Chatterjee, 
2001).  However, the classic non-genomic function of vitamin D is through its metabolised 
form calcitriol, in regulation of serum calcium levels (Haussler et al., 2013). Vitamin D is 
reported to have a number of protective roles in various neurological disorders in humans, 
with much of our understanding of vitamin D amassing from investigations into one of its 
inactive precursors, 25(OH)D3 (vitamin D3), which is metabolised into its active form, 
1,25(OH)D3. Vitamin D3 has been observed to increase expression of neurotrophins nerve 
growth factor (NGF), neurotrophin-3 (NT-3), GDNF in vitro (Neveu et al., 1994, Naveilhan 
et al., 1996, Cornet et al., 1998) as well as in vivo (Wang et al., 2000). Therefore, perhaps not 
surprising was the finding that vitamin D3 supplementation improves myelination and 
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functional recovery after rat peroneal nerve transection (Chabas et al., 2013), and is 
neuroprotective in response to various toxic insults to the nervous system (Garcion et al., 
2002). Vitamin D3 deficiency is commonly reported in patients with multiple sclerosis (MS), 
and is associated with a poorer disease prognosis (van der Mei et al., 2007).  The 
immunomodulatory action of vitamin D3 likely plays an important role in the pathogenesis of 
MS (Hewer et al., 2013). A number of clinical trials using vitamin D3 supplementation in MS 
support the notion that vitamin D3 may improve the clinical outcome (Aivo et al., 2012, 
Stewart et al., 2012).  A similar observation has been made relating to low vitamin D3 and 
the risk of epilepsy (Harms et al., 2011). A recent study reporting that vitamin D3 
supplementation was found to reduce the incidence of seizures in epilepsy by 40% (Hollo et 
al., 2012).  Although the study was limited by a small sample size, the results did highlight 
the importance of vitamin D in normal brain function.   
Severe vitamin D3 deficiency has been linked to cognitive deficits, but the exact process by 
which vitamin D3 is involved remains enigmatic.  Seasonal affective disorder (SAD) is a 
common depressive disorder that has long has been associated with low vitamin D levels 
(Stumpf and Privette, 1989).  Maternal vitamin D3 deficiency during pregnancy results in 
altered neurodevelopment in rat offspring (Eyles et al., 2003).  Enlarged ventricles, thinner 
cortices and enhanced cell proliferation were observed, with concomitant reductions in NGF, 
GDNF, and p75 neurotrophin receptor (Brown et al., 2003, Eyles et al., 2003, Cui et al., 
2007, Eyles et al., 2009).  Even after these offspring were maintained on a normal diet, 
persistent changes in the adult brain were still observed (Feron et al., 2005). These included 
enlarged ventricles and reduced NGF expression, as well as reduced expression of 
neurofilament, MAP-2 and GABA-A (α4), which are important for neuronal structure and 
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transmission, respectively (Feron et al., 2005).  Vitamin D3 levels during pregnancy are also 
inversely correlated with autism (Cannell and Grant, 2013) and schizophrenia (McGrath et 
al., 2010) risk in offspring. Given the varied etiology of schizophrenia and autism-spectrum 
disorders, the mechanisms by which vitamin D3 may be implicated are likely diverse. 
Numerous mechanisms for this association have been proposed. For example, the ability for 
the active metabolite of vitamin D3 to upregulate DNA repair genes (Chatterjee, 2001) may 
promote repair of the de novo mutations contributing to the risk of autism (Sanders et al., 
2012) and schizophrenia (Xu et al., 2011).  Vitamin D has numerous immunomodulatory and 
anti-autoimmune actions; both schizophrenia and autism have also been linked to 
autoimmune dysfunction, with various brain-specific autoantibodies (Cabanlit et al., 2007, 
Ezeoke et al., 2013) appearing to influence the disease severity in a dose-dependent manner 
(Mostafa and Al-Ayadhi, 2011). Taken together, vitamin D/VDBP have roles in many 
aspects of neuronal function, both in the developing and adult nervous system. 
1.5.6 Myelin-associated glycoprotein (MAG) 
The strongest evidence to date, linking LRP1 to axon pathfinding, is the recent identification 
of LRP1 as a novel receptor for myelin-associated glycoprotein (MAG).  MAG is a sialic-
acid binding Ig-family lectin cell-membrane glycoprotein implicated in neurite outgrowth 
inhibition, growth cone collapse, and has important and well established roles in development 
and maintenance of the nervous system (Henley et al., 2004, Hines et al., 2010). MAG is able 
to bind LRP1 directly, independently of its lectin activity (Stiles et al., 2013), to form a 
complex with p75 neurotrophin receptor, activating RhoA (Mantuano et al., 2013).  RhoA is 
localised to developing axons and growth cones, where it is established as a potent mediator 
of growth cone collapse and neurite retraction (Wu et al., 2005).  Inhibition of growth is 
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equally as important as promotion of growth in nervous system development, as the balance 
between these two processes allows for target discrimination in axon pathfinding. 
1.5.7 Metallothionein 
Metallothioneins (MTs) are highly conserved, small (6-7 kDa), inducible heavy metal 
binding proteins.  By virtue of a high cysteine content (30% of amino acid sequence), MTs 
are also avid scavengers of reactive oxygen species (Thornalley and Vasak, 1985).  There are 
four isoforms of MT: MTI and MTII, which are widely expressed in the nervous system and 
body; MTIII, which is primarily a brain-specific isoform, and MTIV, which is found in some 
stratified squamous epithelia and has not been identified in nervous tissue (Kobayashi et al., 
1993, Quaife et al., 1994, reviewed in Coyle et al., 2002).  MTI and MTII only differ by a 
few amino acids, and to the best of our current understanding, are identical in function 
(Hidalgo et al., 2001), therefore are often referred to in the literature as MTI/II.  MTI/II and 
III encompass a surprisingly diverse range of functions, which importantly includes neuronal 
protection, cognition, neuronal outgrowth and regeneration (West et al., 2008).   MTI/II are 
ligands of LRP1 and LRP2 (Klassen et al., 2004, Ambjorn et al., 2008), although whether 
LRP1 and LRP2 are receptors for MTIII is yet to be determined. MTI/II are constitutively 
expressed, and are upregulated in response to neuronal injury, protecting neurons from 
apoptosis as well as promoting regrowth and repair in vivo (Giralt et al., 2002a, Chung et al., 
2003).   MTI/II knockout mice exhibit impaired cognition, are associated with a poorer 
outcome in response to CNS injury, and are more susceptible to toxicants and oxidative 
stressors (Lazo et al., 1995, Carrasco et al., 2000, Giralt et al., 2002b, Trendelenburg et al., 
2002, Levin et al., 2006).  The association of MT I/II with LRP1 and LRP2 receptors 
transiently activates Akt and ERK, which belong to the mitogen activated protein kinase 
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(MAPK) and the phosphoinositide-3 kinase/Akt (PI3K/Akt) intracellular signalling pathways 
(Asmussen et al., 2009a), which have established roles in neuronal differentiation and 
survival respectively (Brunet et al., 2001, Chang and Karin, 2001).  The sustained response of 
neurite outgrowth seen is due to MT initiated activation of the transcription factor, CREB, 
which alters gene transcription of proteins that are conducive to sustaining neuroprotection 
and neurite outgrowth (Ambjorn et al., 2008).   
1.6 LRP1 AND LRP2 AND THEIR DIVERSE CELL SIGNALLING PATHWAYS IN 
NEURONS  
Although LRP1 and LRP2 are able to endocytose many ligands and target them for lysosomal 
degradation, it has become increasingly evident that this describes only one of many 
functions (Herz et al., 2000). LRP1 and LRP2 have a complex extracellular domain and an 
intracellular domain that together allow for the propagation of diverse signalling pathways 
(Spuch et al., 2012).  The intracellular domains of both LRP1 and LRP2 have been shown to 
interact with numerous signalling and scaffold proteins in a phosphorylation-dependent 
manner, allowing for the formation of signalling hubs through the binding of co-receptors 
(Spuch et al., 2012).   
1.6.1 LRP1 INTRACELLULAR SIGNALLING MECHANISMS 
The intracellular domain (ICD) of LRP1 contains several motifs that regulate receptor 
endocytosis, cell signalling and binding to co-receptors. There are a number of co-receptors 
of LRP1 that have been identified, including platelet-derived growth factor receptor beta 
(PDGFR-β) (Boucher et al., 2002, Loukinova et al., 2002), tyrosine kinase receptor A (TrkA) 
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(Shi et al., 2009), TGFβR-I (Huang et al., 2003), Frizzled-1 (Pinson et al., 2000, Tamai et al., 
2000), amyloid precursor protein (APP) (Knauer et al., 1996) and insulin-like growth factor 1 
receptor (Woldt et al., 2011). These associations compound the number of intracellular 
pathways by which distinct LRP1 ligands may elicit their effects in neurons. LRP1 can be 
cleaved by ɣ-secretase to release the ICD allowing it to translocate to the nucleus, where it 
has been demonstrated to act as a transcription factor (Zurhove et al., 2008).  The role of the 
LRP1 ICD as a transcription factor highlights the diverse ways in which LRP1 can signal 
intracellularly. 
LRP1 ICD contains two di-leucine motifs, one YXXL motif and two NPXY motifs, which 
together are able to bind many cytosolic ligands in a phosphorylation dependent manner (Li 
et al. 2001). LRP1 can activate various processes via signalling through adaptor proteins.  For 
example, as a result of binding scaffold Dab1(Trommsdorff et al., 1998), LRP1  is able to 
activate tyrosine kinases involved in cytoskeletal remodelling and cell motility (Hiesberger et 
al., 1999). LRP1 is able to bind PSD-95 (Gotthardt et al., 2000) which is a scaffold that 
regulates the dynamic synaptic environment.  LRP1 is also able to bind JIP-1/JIP-2, 
(Gotthardt et al., 2000) which are involved in inhibition of the pro-apoptotic stress-activated 
protein kinase/c-Jun N-terminal kinase JNK/SAPK signalling pathway (Kyriakis et al., 1994).  
LRP1 can be phosphorylated by cAMP-dependent protein kinase A (PKA) (Li et al., 2001b).  
Src family kinases (SFKs) can mediate tyrosine phosphorylation of the second NPxY motif in 
the LRP1 ICD, which allows Shc to bind, allowing for the propagation of MAPK pathways 
(Barnes et al., 2001). MAPK pathways are important for neurite outgrowth, and cell survival 
signalling (Chang and Karin, 2001). In response to PDGFR-β receptor activation, or to α2M 
or tPA binding to LRP1, SFKs phosphorylate LRP1 (Boucher et al., 2002, Loukinova et al., 
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2002, Shi et al., 2009). LRP1 phosphorylation activates the downstream MAPK pathway 
(Boucher et al., 2002, Loukinova et al., 2002), and transactivates TrkA, which in turn 
activates downstream target Akt (Boucher et al., 2002, Loukinova et al., 2002, Shi et al., 
2009)Shi et al., 2009).  The many intracellular binding proteins of LRP1 highlight the diverse 
array of pathways that can be elicited in response to LRP1 receptor binding. 
1.6.2 LRP2 INTRACELLULAR SIGNALLING MECHANISMS 
Like LRP1, LRP2 can be proteolytically cleaved by ɣ-secretase to release an ICD that is able 
to regulate gene expression (Zou et al., 2004, Li et al., 2008).  There are a number of motifs 
that are present in the LRP2 ICD  that are likely involved in intracellular signalling processes, 
and they include: one dileucine motif, three NXPY motifs, two proline-rich sequences, one 
PDZ terminal motif, a Src-homology 3 binding motif, a Src-homology 2 binding motif, 
several putative protein kinase C and casein kinase II phosphorylation motifs as well as one 
PKA phosphorylation motif  (Hjalm et al., 1996).   However, the roles of many of these 
motifs, particularly in neurons, are not as well defined for LRP2 as they are for LRP1. Given 
the paucity of information about LRP2 intracellular signalling pathways, some evidence 
comes from the interaction of intracellular adapter molecules and their known roles in 
neuronal signalling.  Some possible signalling pathways in neurons, relevant to development, 
are discussed below.   
An adaptor site for casein kinase II (CKII) is present on the LRP2 ICD (Hjalm et al., 1996) 
CKII is able to regulate NMDA activity (Hu et al., 2014), and thus may be a link between 
LRP2 and Ca
2+
signalling. NMDA Ca
2+
signalling is important for synaptic function, and this 
relationship is cemented by the finding that LRP2 binds PSD-95 (Larsson et al., 2003). PSD-
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95 has well established roles in the postsynaptic density as a scaffold for glutamatergic 
receptors, and regulating their function and trafficking (Xu, 2011).    Ankyrin-repeat family A 
protein (ANKRA) interacts with the PXXPXXP within the proline rich region.  ANKRA 
binds the large-conductance Ca
2+
 activated K
+
 (BK) channel and positively regulates its 
activity (Lim and Park, 2005). The BK channel regulates excitability of neurons and 
neurotransmitter release in the CNS (Pedarzani et al., 2000) and neuropathic pain in the PNS 
(Chen et al., 2009).  Intriguingly, TRPV1, a cation channel also involved in nociception, has 
been found to cross talk and bind BK channels (Wu et al., 2013) raising the possibility that 
LRP2 can modulate complex Ca
2+
 signalling events in the CNS and PNS. 
An additional intracellular adapter that can bind the ICD of LRP2 is membrane-associated 
guanylate kinase with inverted orientation-1 (MAGI-1) (Patrie et al., 2001).  Little is known 
about the function of MAGI-1 but it is thought to act as a scaffold in cell adhesion. MAGI-1 
has been identified in growth cones (Ito et al., 2012) and has been shown to bind p75 
neurotrophin receptor (p75NTR) (Ito et al., 2013a), and as such, LRP2, via MAGI-1,  may be 
involved in the regulation of neurite outgrowth or guidance of peripheral neurons. 
The third NXPY motif of LRP2 binds cytosolic scaffold protein disabled protein-2 (Dab2) 
(Oleinikov et al., 2000, Gallagher et al., 2004).  As a scaffold protein, Dab2 has diverse roles 
within the cell and is implicated in cell proliferation and differentiation (Hocevar et al., 
2003).  One function of Dab2 is as a negative regulator of canonical Wnt signaling (which 
involves LRP5/6, discussed at 1.4.3) by stabilising the β-catenin destruction complex, thereby 
promoting degradation of β-catenin and terminating Wnt signalling (Hocevar et al., 2003).  
Dab2 is able to modulate RhoA, which as outlined earlier, is important for growth cone 
navigation (Huang et al., 2007).  Dab2 is also able to bind nonmuscle myosin heavy chain  
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Figure 1.4. Intracellular domain of LRP2 
Schematic of LRP2 structure. The PDZ domain facilitates binding to PSD-95 and MAGI-1. 
PXXPXXP binds ANKRA. The highly conserved PPPSP (red) motif is responsible for the 
interaction allowing LRP2 to be constitutively phosphorylated by GSK3 which has a role in 
negative-regulation of LRP2 recycling to endosomes (Yuseff et al., 2007). Figure from 
(Marzolo and Farfan, 2011). 
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IIA (NMHC-IIA); indeed LRP2, Dab2 and NMHC-IIA were able to be isolated as a 
functional complex in kidney cells along with beta actin (Hosaka et al., 2009). Class II 
myosins such as NMHC-IIA are thought to be important for cytoskeleton organization, which 
is important  for cell motility (Sellers, 2000). These associations support a potential role of 
LRP2 in neuronal growth and axon guidance. 
1.7 NERVE REGENERATION IN PERIPHERAL NEUROPATHY 
To date I have described a number of LRP1 and LRP2 ligands that have protective effects on 
neurons, and may be candidates for promoting axon pathfinding; as such, the properties of 
these ligands will be investigated within the experimental chapters to follow.  The 
overarching aim within this thesis is to identify a candidate chemotactic molecule that can be 
used therapeutically in peripheral neuropathy or denervation, to guide the regenerative 
growth of neurons in vivo and promote functional regeneration. As such, a discussion into 
chemotactic factors and peripheral neuropathy follows. 
Peripheral neuropathies are diseases of the nerves of varied etiology and complexity 
(Brannagan, 2012).  In the past two decades, the potential of growth factors as a means of 
directing neuronal repair and preventing apoptosis of damaged neurons in neuropathy has 
become increasingly apparent (Terenghi, 1999).  There is evidence that the expression of 
growth factors (particularly neurotrophins) and/or their receptors is altered in various forms 
of peripheral neuropathy (Leinninger et al., 2004).  Given that neurotrophins promote 
survival and maintenance of neurons, it has led to the therapeutic application of 
neurotrophins, both in vitro and in vivo, to promote neuronal regeneration in models of 
diabetic neuropathy (Leinninger et al., 2004). 
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1.8 SENSORY NERVES OF THE SKIN  
The principal neurons affected in peripheral neuropathies are sensory neurons (Lauria et al., 
2005). Sensory neurons are a heterogenous group that convey different kinds of information, 
and are classified broadly by diameter of the cell body: small (20um, called C-fibres), 
medium (21-40um, called A-δ) and large (>40um, called A-α and A-β) (Baron, 2006).  
Epidermal nerve fibres (ENFs) are the nerves that exist in the outermost layer of the skin, the 
epidermis. ENFs comprise of C-fibres and A-δ fibres (Baron, 2006).  Peripheral nerve 
terminals relay normal and abnormal sensory input, such as thermal, mechanical or chemical 
information, as electrical action potentials of varied intensity into the CNS (Julius and 
Basbaum, 2001).  Although research demonstrates there is increasing overlap between 
characteristics of the crudely delineated subtypes, there is some general consensus: C-fibres 
are unmyelinated and involved in nociception and heat; A-δ are lightly myelinated 
mechanoreceptive fibres; A-α and A-β are the heavily myelinated, fast conducting 
proprioceptive fibres (Julius and Basbaum, 2001). Heavily myelinated processes tend to enter 
the spinal cord medially, and terminate in deeper laminae of the dorsal horn, whereas smaller 
unmyelinated fibres enter laterally and terminate in superficial lamina, such as lamina I and II 
of the dorsal horn (Light et al., 1979). Although individual ENFs are initially myelinated, 
once they reach the basement membrane, they lose their Schwann cell ensheathment 
(Kennedy and Wendelschafer-Crabb, 1993).  Peripheral neuropathies are characterised based 
on the trigger and on the subtype of neuron affected. 
  
 
47  |     Chapter 1 
 
1.9 PERIPHERAL NEUROPATHY 
Peripheral neuropathies (PN) are an indication of many diseases, specifically affecting 
peripheral nerves (Martyn and Hughes, 1997), and are associated with a significantly 
decreased quality of life.  PN occurs through disparate etiologies, including: as a symptom of 
systemic illness such as diabetes, vitamin deficiency (such as vitamin B12), renal failure and 
as a side effect of medications such as some chemotherapeutic drugs (Martyn and Hughes, 
1997). 
Epidemiological studies tend to underestimate the prevalence of these conditions in the 
general population, due to neuropathy being present in some individuals without overt 
symptoms (and therefore requiring sensitive equipment for its detection), and in some cases a 
lack of consensus of the diagnostic criteria.  Although there is a scarcity of epidemiological 
studies of PN, the data that exists from early studies suggests a prevalence of between 2.4 and 
7% in the general population (Bharucha et al., 1991, Martyn and Hughes, 1997, Philip-
Ephraim et al., 2013, Remiche et al., 2013).   However, a systematic meta-analysis of studies 
examining  neuropathic pain (as symptom of some, but not all PNs) suggest that neuropathic 
pain has a prevalence of 6.9 to 10% in the general population (van Hecke et al., 2014), which 
would indicate that the earlier epidemiological studies on PN incidence are at best, an 
inadequate representation. Assessing the incidence of peripheral neuropathies as a whole 
allows us to emphasise the impact of disability and socioeconomic burden of PN related 
disease in the community, and requires further investigation. 
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1.10 DIABETIC NEUROPATHY 
1.10.1 Clinical presentation 
In the western world, diabetic neuropathy is the most prevalent form of peripheral 
neuropathy, with mild to severe forms of the disease affecting between 20-60% of people 
with diabetes (Ziegler et al., 1992, Dyck et al., 1993, Won et al., 2014). Diabetic neuropathy 
is the most common complication of diabetes mellitus (Candrilli et al., 2007). Diabetes 
mellitus is a group of diseases of heterogenous etiology, that are characterised by high blood 
sugar (Zimmet et al., 2001).  The pathophysiology of diabetic neuropathies can be just as 
diverse as the etiology of the underlying disease.   The neuropathy may affect sensory, motor 
and autonomic nerve fibres, and is associated with axonal atrophy, demyelination, attenuated 
regenerative potential, inflammation and progressive loss of peripheral nerve fibres 
(Sinnreich et al., 2005).  The disease often affects the longest nerves first, such that nerves in 
the feet are initially affected, followed by the hands, progressing from distal to proximal sites, 
forming a characteristic stocking/glove distribution (Sinnreich et al., 2005).  The clinical 
manifestation of the most common form of the disease (diabetic peripheral neuropathy) 
includes symptoms such as development of mechanical allodynia (pain that results in 
response to stimulus that would not normally cause pain), hyperalgesia (increased sensitivity 
to painful stimuli), muscle weakness and sensory loss (Sinnreich et al., 2005).  Sensory loss 
(loss of light touch and pain) predisposes individuals to lesions on the feet and ulcerations, 
which when untreated and unrecognised, can result in limb amputation secondary to gangrene 
(Sorensen et al., 2006b).  Neuropathic pain is a common and poorly tolerated symptom that is 
resistant to most therapeutic interventions (Zimmermann 2001).  Frequently, the neuropathy 
will decrease the quality of life more than the underlying disease itself and as such poses a 
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significant socioeconomic burden (Ziegler and Luft, 2002).   Underlying these symptoms is 
the pathology of the neuropathy itself, which not only includes loss and degeneration of 
neurons, but the associated Schwann cells as well (Dey et al., 2013).  
In diabetic peripheral neuropathy, there is withdrawal of nerve fibres from the epidermis, and 
their improper termination instead occurs in the dermis (Fig 1.5).  The improper termination 
of these fibres contribute to pain syndromes.  Loss of ENFs can occur early in diabetes even 
before the onset of overt symptoms or slowed nerve conduction, although is more severe in 
patients experiencing neuropathic pain (Sorensen et al., 2006a, Loseth et al., 2008).  
Furthermore, there is increasing evidence that neuropathy can develop during impaired 
glucose tolerance, prior to the onset of diabetes (Novella et al., 2001, Singleton et al., 2001, 
Sumner et al., 2003).  C-fibres are among the most commonly affected in diabetic neuropathy 
(Polydefkis et al., 2003). The extent of ENF loss is a function of the duration of diabetes 
(Shun et al., 2004, Lauria, 2007). 
1.10.2 Current therapeutics for diabetic neuropathy 
There is currently no curative treatment for diabetic neuropathy, other than restoration and 
maintenance of normoglycaemia, although complete reversal of severe neuropathy is unlikely 
in humans. The use of insulin to restore normoglycaemia in some animal models of diabetic 
neuropathy reversed the neuropathic phenotype (conduction slowing and restored sensory 
axon calibre) however such favourable results are rarely seen in humans (Zochodne et al., 
2004). Existing therapies only address the underlying disease (diabetes mellitus) or the 
symptom of pain, (although for many this is inadequate or poorly tolerated), and do not treat 
the nerve fibre dysfunction itself or promote nerve regeneration.  
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1.10.3 Pathophysiology of diabetic neuropathy 
Understanding the pathologic basis of diabetic neuropathy is important for devising effective 
therapeutics. Despite intense investigations over the decades, the definitive pathogenesis of 
diabetic neuropathy has remained controversial and for the most part unclear (Vincent et al., 
2011).  The pathophysiological triggers for DN can be diverse, as is evidenced by the many 
types of nerve fibre affected (Sinnreich et al., 2005).  Furthermore, the course of disease may 
be influenced by a number of modalities, for example, the type of diabetes (Vincent et al., 
2011). The development of diabetic neuropathy is propelled by hyperglycemia and is also 
affected by insulin deficiency and dyslipidemia (Vincent et al., 2011). Mechanisms 
implicated in the disease include microangiopathy with ischemia, deficiency in neurotrophic 
factors and/or their receptors, excessive formation of advanced-glycation end-products, 
oxidative stress, mitochondrial dysfunction, genetic susceptibility and polyol flux (Vincent et 
al., 2011). Polyol accumulation in diabetic neuropathy leads to a number of downstream 
deregulations within the cell.  Polyol accumulation occurs in cells that do not require insulin 
to take up glucose (such as neurons), and as such are subject to the large fluctuations in blood 
glucose (Greene and Lattimer, 1985).  In a hyperglycaemic state, aldose reductase becomes 
flooded with glucose and metabolises some to sorbitol (Clements, 1986). Sorbitol (the polyol 
implicated in this pathway) cannot cross cell membranes and thus accumulates, causing an 
osmotic imbalance, disrupting ion channels, impairing transport of cytoskeletal proteins, and 
culminating in slowed conduction speeds (Naziroglu et al., 2012).  In advanced diabetes 
where vascular insufficiencies exist and exacerbate the course of neuropathy, one argument 
may be that the vascular insufficiency is due to a loss in growth factors. Nerves and blood 
vessels arborise in an orderly pattern throughout the body, often together, and recent studies  
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Figure 1.5 Innervation of the epidermis in the distal leg of humans 
Sensory neurons stained in black. Arrows indicate ENFs within (A) Normal skin. Fibres have 
a straight course and slight varicosities. (B) Diabetic skin. Fibres terminate improperly and 
ENFs are short and tortuous.   Scale bar 50µm. (Lauria, 2007) 
 
A 
B 
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have revealed that guidance cues involved in the development of the nervous system also 
help blood vessels navigate to their targets (Carmeliet and Tessier-Lavigne, 2005).  Neurons 
in diabetic neuropathy demonstrate a diminished regenerative potential (Bisby, 1980, 
Ekstrom and Tomlinson, 1989, Kennedy and Zochodne, 2005, Zochodne et al., 2007). In 
diabetic peripheral neuropathy, there is a significant decrease in the neurotrophins NGF, 
BDNF, NT-3 and GDNF (Anand, 2004). These neurotrophins have well established roles in 
sensory neuron survival (Maisonpierre et al., 1990, Davies, 1994). The nerves affected in 
diabetic neuropathy are in a diseased state, and may be particularly vulnerable to further 
insult.  A decrease in survival signals from neurotrophic factors thus likely contributes to the 
course of disease.  Regardless of the underlying pathogenesis of diabetic neuropathy, two 
things remain clear: in order to treat diabetic neuropathy, firstly nerve degeneration must be 
prevented, and secondly, nerve regeneration must be promoted.   
1.10.4 Experimental models of diabetic neuropathy 
Experimental models are a means by which therapeutics for diabetic neuropathies can be 
developed. While mouse models of diabetic neuropathy have been widely used, there remains 
a lack of consensus of the most appropriate animal models for diabetic neuropathy, due to the 
differences in disease markers, and inconsistencies between symptoms measured in human 
disease pathogenesis and that of the murine model (Bierhaus and Nawroth, 2012).  Rat 
models are less widely used despite their closer symptomatic profile to humans, and 
possession of very similar skin architecture (Islam, 2013). This discrepancy between use of 
rat and mouse models is likely due to housing requirements and cost factors.  Obese Zucker 
rats, which have a deletion in the leptin receptor, are a very popular model of type II diabetes 
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(Islam, 2013).  However, the emergent role of leptin as an important neuroprotective factor 
deems this model inappropriate for the study of diabetic neuropathy (Folch et al., 2012).   
Although many models of diabetes are raised through genetic manipulation, diabetes can also 
be induced artificially through use of the drug streptozotocin, which has specific toxicity for 
insulin producing β-cells in the pancreas (Like et al., 1978).  Extensive review of the 
literature suggests that the best rodent model of diabetic neuropathy is the high-fat diet low-
streptozotocin-treated rat, first described in 2000 by Reed and colleagues (Reed et al., 2000). 
This model of type 2 diabetes has been used for preclinical screening of drugs, however, like 
most diabetic models, neural function has been insufficiently categorised and profiled.  The 
accepted best-practice protocol for high-fat low-streptozotocin induced diabetes involves 
introduction of a high-fat diet (22% fat by weight) at least two weeks prior to injection of 
streptozotocin (30-50mg/kg) (Reed et al., 2000, Srinivasan et al., 2005). Although rats solely 
fed a high fat diet do not become hyperglycemic, streptozotocin damages insulin producing 
β-cells such that hyperglycaemia develops (Reed et al., 2000). Rats treated with 
streptozotocin combined with a high fat diet results in the development of mechanical 
allodynia, and exhibit a substantial loss of ENF secondary to characteristic insulin resistance, 
hyperglycemia and dislipidemia (Reed et al., 2000).  In humans, type 2 diabetes develops 
when hyperglycaemia occurs secondary to a decrease in insulin production and insulin 
resistance, and is usually associated with a nutritionally poor high fat diet; indicating that the 
high-fat low-streptozotocin model is representative of the disease. 
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1.10.5 Neurotrophic factors as experimental therapeutics in diabetic neuropathy 
In the past two decades the potential of neurotrophic factors and growth factors as candidate 
therapeutics in neuropathy has become evident, because they are able to direct neuronal 
regrowth, promote sprouting, survival and phenotypic maintenance, and protect neurons from 
mechanical, oxidative or ischemic damage (Siegel and Chauhan, 2000).  Indeed, several 
neurotrophins have been tested in rodent models of diabetic neuropathy, with encouraging 
results (Akkina et al., 2001, Pradat et al., 2001, Schmidt et al., 2001, Christianson et al., 
2007).  However, many experimental therapies have had poor translation into human 
therapeutics (Apfel, 1999).  Further understanding in the area of diabetic neuropathies 
continues to suggest a beneficial role of neurotrophins.  More rigorous considerations of the 
dosage and delivery system are needed for future success of neurotrophins as a therapeutic in 
neuropathy (Apfel, 2002). Understanding the mechanisms by which these factors elicit these 
effects on cells offers an opportunity into the development of unique therapeutics. 
JUSTIFICATION FOR PROJECT 
The loss of neuronal connections as a result of disease contributes to the pathogenesis of 
neuropathies such as diabetic neuropathy.  The ‘connection’ of neurons is the product of 
individual growth cones responding to a myriad of chemotrophic growth cues.  There would 
be great therapeutic benefit if it was possible to harness the properties of chemotactic cues 
and use them to guide and accelerate neuronal repair after connections have been damaged or 
lost, thereby having implications in the treatment of some neurological diseases, or in re-
innervating tissues that have lost their neuronal connections as a result of disease or traumatic 
injury.  The primary challenge encountered when promoting regeneration of nerves is the 
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ability to reintegrate into neural circuitry and form functional connections.  It is therefore 
important to understand the mechanisms by which chemotactic factors function, to provide 
additional avenues for enhancing directed neurite regrowth and connectivity in neuropathy. 
Although some surgical strategies exist for enhancing regeneration in gross nerve lesions of 
the PNS, the intricate network of nerves in the skin region is not amenable to surgical repair. 
Conceptually, a repair strategy could be based on the topical application of chemotactic 
factors, which attracts the regrowth of ENFs back to their correct locations into the epidermis 
(Fig 1.6). 
It is well established that LRP receptors are capable of forming complex signalling domains 
by recruiting co-receptors.  Given the emerging role of LRP1 and LRP2 in modulation of 
neuronal growth, especially during injury, I ask whether ligands of LRP1 or LRP2 could 
guide neuronal growth, and promote regeneration in animal models of neuropathy.  Such a 
system would represent a novel, non-classical axon guidance system. Furthermore, 
understanding the mechanisms by which these factors elicit these effects on neurons presents 
an opportunity into the development of unique therapeutic analogues. 
To address this hypothesis, this thesis explores two overarching aims: 
1. To examine the ability of LRP1 and LRP2 ligands (with known roles in neuronal 
function), to promote growth cone guidance in vitro and determine the mechanism of 
action 
2. To examine the effect of candidate LRP1 and LRP2 ligand/s to guide regenerative 
growth and promote reinnervation after peripheral nerve damage in vivo. 
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Fig 1.6. Visual representation underlying the hypothesis of a topical repair strategy 
utilising chemotactic factors as a therapeutic for diabetic neuropathy 
In the instance of diabetic neuropathy, where specific regrowth of nerves back into the 
epidermis is the goal, the concentration gradient of a chemoattractive factor would 
necessarily be highest in the epidermis and gradually diffuse downwards into the underlying 
dermis in order to deliver a directional signal.  It was hypothesised that a topical application 
would most likely produce such a gradient. Original figure.   
  
 
57  |     Chapter 2 
 
 
 
 
 
 
CHAPTER 2 
Establishing the chemotactic responses of 
growth cones to LRP1 and LRP2 ligands  
in vitro 
 
  
 
58  |     Chapter 2 
 
CHAPTER 2 
ESTABLISHING THE CHEMOTACTIC RESPONSES OF GROWTH CONES TO LRP1 
AND LRP2 LIGANDS IN VITRO  
2.1 INTRODUCTION 
During axon pathfinding, neuronal growth cones respond to substrate-bound and soluble 
chemotactic guidance cues both spatially and temporally, to allow the axon to navigate the 
internal milieu and make appropriate connections (Tessier-Lavigne and Goodman, 1996).  
The poor ability of neurons to recover from insult has led researchers to hunt for chemotactic 
factors that may enhance axonal regrowth and restore connections lost after injury or 
neuropathy (Gordon, 2009).   
The low-density lipoprotein (LDL) receptor family has more recently been implicated in 
neuronal regeneration and correct wiring of the nervous system (Willnow et al., 1996a, Herz 
and Bock, 2002, May et al., 2004). LRP1 and LRP2 are the largest and most complex 
members of the LDL receptor family which have been ascribed a number of functions in the 
nervous system (Herz and Bock, 2002, Lillis et al., 2008, Spuch et al., 2012).  Global gene 
knockout models of both LRP1 and LRP2 reveal a critical, but largely undefined role in 
development and neuronal migration (Herz et al., 1992, Lillis et al., 2008, Christ et al., 2012). 
Given the emerging role of LRPs in modulation of neuronal growth, especially during injury 
(Yoon et al., 2013), this chapter addresses whether LRP1 or LRP2 were able to regulate 
neuronal growth cone motility.  To the best of our knowledge, there has been no investigation 
into ligands of LRP1 and LRP2 and their ability to promote growth cone guidance.  Such a 
system would represent a novel, non-classical axon guidance system.   
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While there are many LRP1 and 2 ligands, I focused on a selection from those implicated in 
neuronal function: namely, Apolipoprotein E (ApoE), α-2 macroglobulin (α2M), transthyretin 
(TTR), vitamin D/vitamin D binding protein complex (vitamin D/VDBP), tissue plasminogen 
activator (tPA), metallothionein II (MTII) and LRP receptor associated protein, RAP.  ApoE, 
a promiscuous ligand of both LRP1 and LRP2, has been implicated in neuronal development 
and cognition, and is known to promote neurite extension in sensory neurons in vitro 
(Postuma et al., 1998).  MTII, a ligand of both LRP1 and LRP2, is a metal binding protein 
that has roles in neuroprotection, neurite outgrowth and nerve regeneration in vivo (West et 
al., 2008). Vitamin D/VDBP is an LRP2 ligand, and has been linked to cognitive function 
(Dean et al., 2011). Vitamin D promotes neurite outgrowth in hippocampal neurons in vitro 
(Brown et al., 2003). α2M is a ligand of LRP1 and has been implicated in neuronal signal 
transduction, and has been shown to both enhance and repress neurite outgrowth and 
migration (Mori et al., 1990, Cavus et al., 1996, Yamauchi et al., 2013).  Transthyretin 
mediates neuroprotection and neurite extension via LRP2 (Fleming et al., 2009b). tPA is an 
LRP1 ligand that is involved in axon pathfinding and neuronal migration, and through 
regulation of NMDA receptor activity has roles in learning and memory (Krystosek and 
Seeds, 1981, Hu et al., 2006).  RAP is a chaperone of the LRP-receptor family, and is an 
established pan-LRP receptor inhibitor (Strickland et al., 1990, Williams et al., 1992, Medved 
et al., 1999).   
The specific focus of the present chapter was to screen LRP1 and LRP2 receptor ligands for 
the ability to regulate growth cone chemotaxis. Sensory neurons from the dorsal root 
ganglion (DRG) of  E16-18 rat embryos were used in the growth cone turning assay (Lohof et 
al., 1992, Gasperini et al., 2009), to determine whether LRP1 and LRP2 ligands function in 
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axon guidance.  The turning assay is a well-characterised in vitro assay that can be used to 
screen for novel axon guidance cues and deduce their signalling pathways (Lohof et al., 1992, 
Gasperini et al., 2009). I also determined whether the chemotactic effects of LRP ligands 
required signalling via LRP1 or LRP2, using the pan-LRP inhibitor RAP and siRNA. 
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2.2 EXPERIMENTAL PROCEDURES & MATERIALS 
2.2.1 Disclosure 
All animal experimentation was performed in accordance with the guidelines and protocols of 
the Animal Ethics Committee, University of Tasmania (Ethics number A0012322), and are 
compliant with the Australian NHMRC Code of Practice for the Care and Use of Animals for 
Scientific Purposes.   
2.2.2 Primary DRG neuron culture 
Primary culture of  embryonic day 16-18 dorsal root ganglia (DRG) from Sprague Dawley 
rats was performed as described previously (Gasperini et al., 2009).  Briefly, thoracolumbar 
DRGs were dissected and placed in sensory neuron media (SNM). SNM comprises: 
Dulbecco’s Modified Eagle’s F-12 Medium (Gibco Biosciences, CA, USA), 1:1 Penicillin G 
(100U/mL) and streptomycin (100µg/mL; Gibco Biosciences, CA, USA), nerve growth 
factor (50ng/mL; Sigma-Aldrich, MO, USA), foetal calf serum (5% v/v; Bovogen 
Biologicals, VIC, Australia) and N2 neural medium supplement (1x; Gibco Biosciences, CA, 
USA).  The DRGs were mechanically dissociated by trituration.  The cell suspension was 
then plated at low density, onto laminin (50µg/mL; Invitrogen, CA, USA) and poly-L-
ornithine (1mg/ml; Sigma-Aldrich, MO, USA) coated coverslips, embedded in 35mm petri 
dishes (Iwaki, Tokyo, Japan). Unless otherwise stated, cultures were allowed to grow for a 
minimum of 2 hours prior to imaging, at 37°C, 5% CO2.   
  
 
62  |     Chapter 2 
 
2.2.3 siRNA knockdown of LRP1 and LRP2 
We used siRNA to reduce LRP protein in DRG neurons, using a previously published 
technique (Gasperini et al., 2011). Four LRP1 siRNA were trialled: 
GGGCAUUUGUGCUGGACGA, GGACAGACGUGACGACCCA, 
UCAAUAAGCAGACGGGAGA and UGGACAAGAUCGAACGUAU. Four LRP2 siRNA 
were trialled: CCUCAGUUGACGACGAAUA, GAGGGAAAUCAGCGUGUUA, 
GGAACAUCUUCAAACGAAA and GGAUGGUAGCAAUCGGAA. There was no cross 
reactivity between LRP1 and LRP2 sequences. All specific and negative control siRNA were 
obtained from Thermo Fisher Scientific, MA, USA.  Individual siRNA (50µM) were loaded 
into neurons by trituration with the DRGs, prior to plating, as per section 2.2.2.  Cultures 
were allowed to grow for a minimum of 6 hours prior to imaging.  Reduction of LRP1 and 
LRP2 protein expression was quantified by immunofluorescence and western blot.  LRP1 
expression with LRP2 siRNA and vice versa was evaluated quantitatively by 
immunofluorescence and no crossreactivity was noted (Pavez, 2013). 
2.2.4 In vitro growth cone turning assay 
The growth cone turning assay was performed as described previously (Lohof et al., 1992, 
Gasperini et al., 2009). A molecular microgradient was generated by the pulsatile ejection of 
various guidance cues or LRP ligands via a micropipette pulled from glass into a live cell 
imaging dish.  Primary DRG neuron culture was performed as per section 2.2.2. DRG 
cultures were placed on an inverted microscope (Eclipse TiE, Nikon Instruments) and images 
were captured using a EMCCD digital camera (Evolve, Photometrics) and using a 40x Fluor-
S oil-immersion objective (Nikon).  Isolated growth cones were positioned at a 45° angle and 
90µM from the micropipette, such that the concentration of guidance cues and ligands at the 
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growth cone were 10
-3
 less than that within the pipette (Lohof et al., 1992, Gasperini et al., 
2009).  
Reagents used to generate the microgradient were: LRP ligands [MTII (HPLC purified 
human MTIIA, 300µg/mL, Zn7 form, Bestenbalt LCC, Tallinn, Estonia), apolipoprotein E3 
(ApoE, 1.8mg/mL R+D systems, Minneapolis, MN, USA), LRP receptor-associated protein 
RAP (1mg/mL, in Tris-buffered saline; a kind gift from David Small, Tasmania, Australia), 
alpha-2-macroglobulin (α2m, from human plasma, 2.25mg/mL, Sigma, MO, USA), wild-type 
transthyretin (8mg/mL, a gift from David Small, Tasmania, Australia), vitamin D 
(100umol/L, Sigma, MO, USA) combined with 1:1 molecular ratio of vitamin D binding 
protein (Abcam, Cambridge, UK), tissue-type plasminogen activator (tPA, 3.3mg/mL, 
Abcam, Cambridge, UK), EmtinA (1mg/mL, Schafer N, Copenhagen, Denmark,), EmtinB 
(1mg/mL, Schafer N, Copenhagen, Denmark)]; putative LRP ligand MTIII (1mg/mL, Zn7 
form, Bestenbalt LCC, Tallin, Estonia); control solutions [Netrin-1 (5µg/mL, R&D Systems, 
MN, USA), BDNF (10µg/mL, R&D Systems, MN, USA), zinc sulphate (50mM; Sigma, MO, 
USA)]; saline to assess for any effects of mechanical disturbance attributed to the pulsatile 
ejection technique (Phosphate buffered saline, pH 7.4, comprising 10mM Na2HPO4, 1.8mM 
KH2PO4, 137mM NaCl and 2.7mM KCl, all from Sigma, MO, USA. see Appendix 1, 
Solution protocols). Bath applied pharmacological agents added to the culture media were: 
RAP (25µg/mL) and Tris-buffered saline control (25µl/mL; comprising 50mM Tris and 
150mM NaCl, both from Sigma, MO, USA). These were added to the culture media 20 
minutes prior to imaging.   
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2.2.5 Video acquisition in growth cone turning assay 
Time lapse images of growth cones in the growth cone turning assay (section 2.2.4) were 
acquired by Matlab & Stimulink V7.1.0.124 (The Mathworks, MA, USA). Images were 
captured every 7 seconds for 30 minutes. After 30 minutes of imaging, axonal trajectories 
were measured using ImageJ (NIH, MD, USA).  Axons that extended less than 10µm were 
excluded from analysis. Statistical analysis was conducted in GraphPad Prism V4.03 
(Software Mackiev, CA, USA).  Attraction and repulsion was defined as a positive or 
negative turning angle, respectively, that was significantly different from the PBS control. All 
significance values are the product of a Mann-Whitney t-test (Lohof et al., 1992). 
2.2.6 Immunocytochemistry 
DRG cultures, grown on cover slips for 2-8 hours, were fixed in situ in 4% paraformaldehyde 
(Sigma-Aldrich, MO, USA) in PBS pH 7.4 at 4°C overnight, followed by blocking in 5% 
goat serum (Sigma-Aldrich, MO, USA), 0.04% Triton X-100 (Sigma-Aldrich, MO, USA) in 
PBS for 30 minutes.  
Antibodies used: Anti LRP1 antibody (L2170, 1:1000; Sigma, MO, USA) was raised in 
rabbits against a synthetic peptide corresponding to amino acids in the intracellular C-
terminus of human LRP1.  Anti-LRP2 primary antibody used was raised in rabbits against the 
intracellular C-terminal fragment of human LRP2 (sc-H245, 1:1000; Santa Cruz 
Biotechnology, CA, USA). Fixed cells were incubated overnight at 4°C with the primary 
antibody, diluted in PBS with 5% goat serum. Controls for immunolabelling were performed 
by omitting the primary antibody (zero primary control). After washing, the cells were 
incubated with the secondary antibody, fluorescent goat anti rabbit Alexa 594-conjugated 
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(1:1000, Molecular probes, OR, USA), in the dark, overnight at 4°C, or at room temperature 
for 4 hours. The actin component of the cytoskeleton was labeled with phalliodin-Alexa 488 
(5U/mL, 20 mins; Molecular Probes, OR, USA). Cultures were mounted with DPX 
fluorescent mounting media (Koch-Light Laboratories, England, UK). 
Images were acquired using an Olympus BX50 microscope, equipped with a UP-lanSApo 
60x-1.35 water immersion lens (Olympus, Tokyo, Japan), and captured with MagnaFire 
V2.1c (Optronics, CA, USA), with a cooled CCD camera (Optronics, CA, USA).  During 
image capture the exposure time was set so that cells would not be over exposed and the 
pixels not saturated. Exposure was kept constant throughout the imaging session.  Images 
were processed using Image J (NIH, MD, USA), JASC Paint Shop Pro V 9.0 (JASC Software 
Inc., MN, USA). 
2.2.7 Western Blot 
To determine LRP1 and LRP2 knockdown with siRNA, protein levels were quantified using 
western blot and analysis of pixel intensity, as previously described (Gasperini et al., 2011).  
Briefly, DRG neurons were loaded with either no siRNA, control siRNA or one of four LRP1 
or LRP2 siRNAs, in an identical protocol as per section 2.2.3.  Cells were grown with siRNA 
for 6 hours, then cells were harvested from the culture dish by scraping down into a small 
volume of RIPA buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM phenylmethylsulphonyl 
fluoride, 1 mM EDTA, 5 ug/ml aprotinin, 5 ug/ml leupeptin, 1% Triton X-100, 1% Na 
deoxycholate, 0.1% SDS, all from Sigma, MO, USA), and immediately frozen.  Sample 
protein concentration was measured using the Bio-Rad DC protein assay kit (Bio-Rad 
Laboratories Pty. Ltd., Gladesville, Australia) with bovine serum albumin as standard. 
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Samples with total protein of 15ug were separated on 8% SDS-PAGE and electroblotted onto 
0.2um PVDF membrane.  Membranes were blocked in 5% skim milk powder for 30 minutes.  
Membranes were incubated with antibodies for LRP1 (1:1000; Sigma-Aldrich, St Louis, MA 
USA), LRP2 (1:1000; Santa Cruz, CA USA), or β-actin (1:40,000; Sigma-Aldrich, St Louis, 
MO, USA) at room temperature for 2-4 hours, then rinsed thoroughly. Membranes were then 
incubated with goat anti-rabbit HRP secondary antibody (Dako, Glostrup, Denmark) for 2 
hours at room temperature, and rinsed thoroughly.  Blots were processed using ECL 
chemiluminescence reagent (Pierce, Rockford, IL, USA) and detected using a Chemi-Smart 
5000 gel documentation system (Viber Lourmat, Torcy, France). Images were captured, and 
signal intensity was quantified using Image J software (RSB; NIH, 
http://rsbweb.nih.gov/ij/index.html). The ratio of immunoreactivity for each protein relative 
to the respective β-actin loading control was calculated. 
2.2.8 Statistical analysis 
Means and standard error of the mean were calculated for each group using GraphPad Prism 
6.0. Mann Whitney t-test was used to calculate the statistical significance for growth cone 
turning assays. Students t-test was used for comparisons between control and knockdown 
protein levels in western blot. Western blots were repeated at least three times. 
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2.3 RESULTS 
2.3.1 LRP1 and LRP2 are present in the chemical sensing region of the growth cone 
In order to test the hypothesis that LRP1 and LRP2 are able to modulate growth cone turning, 
I first determined whether LRP1 and LRP2 were present in DRG sensory neurons in situ, and 
specifically within the highly specialized and motile growth cone in vitro.  Immunoreactivity 
for LRP1 (Figure 2.1.A-B) and LRP2 (Figure 2.1.C-D) were identified within the neuronal 
cell bodies and surrounding glial cells of thoracolumbar E17 DRG, and was consistent with 
the work of others (Postuma et al., 1998, Fleming et al., 2009b, Yamauchi et al., 2013).  In 
order to detect LRP2 and LRP1 expression within growth cones cultures were stained 
(Representative images shown in Figure 2.1 E-M).  Whilst it has been previously reported 
that LRP1 and LRP2 are present in DRG (Postuma et al., 1998, Fleming et al., 2009b, 
Yamauchi et al., 2013), their subcellular location has not been examined in detail.  For the 
first time we show the distribution of LRP1 and LRP2 immunoreactivity in DRG growth 
cones.   LRP1 staining was diffuse, and extended throughout the lamellipodia of the leading 
edge (Figure 2.1.J) and filopodia.  LRP2 positive immunoreactivity was identified on the 
leading edge and filopodia (Figure 2.1. M;). The leading edge and filipodia are the regions of 
the growth cone actively involved in chemical sensing of the environment; suggesting that 
LRP1 and LRP2 are distributed in regions involved in growth cone navigation.  LRP 
receptors, as endocytic receptors, are known to be recycled through endosomal compartments 
following endocytosis that occurs after the receptor binds a ligand.  Therefore, it is plausible 
that the large immunoreactive puncta located in the central zone are endocytic vesicles or 
endosomes with LRP inclusions.   However, it is important to mention  
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Figure 2.1  LRP1 and LRP2, are present in rat DRG in situ, and rat DRG growth cones in 
vitro. 
(A) LRP1 positive staining (red) and neuronal nuclear marker, NeuN (green) in E17 rat 
embryo DRG in situ. (B) Magnification of LRP1 and NeuN staining in DRG from panel A. 
(C) LRP2 positive staining (red) and neuronal nuclear marker, NeuN (green) in E17 rat 
embryo DRG in situ. (D) Magnification of LRP2 and NeuN staining in DRG from panel A. 
(E-K) Representative images of thoracolumbar DRG growth cones from E16-18 rat embryos 
cultured in vitro.  Growth cone morphology is highlighted with filamentous actin labelling 
(green).  (E-G) Zero primary control demonstrates the specificity of secondary antibody. (H-
J) LRP1 immunopositive puncta combined with diffuse immunoreactivity are located 
throughout the growth cone, including the leading edge and filopodia.  (K-L) 
Immunoreactivity of a growth cone for an antibody specific to LRP2 receptor (red).  Large 
LRP2 immunopositive puncta are distributed throughout the growth cone, including the 
leading edge, in a similar manner to LRP1.  A and C conform to the same scale bar.  E-K 
conform to the same scale bar. Images K-M in Figure 2.1 were assessed as part of my 
honours thesis, Landowski 2009. 
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that the cultures shown were not given additional permeabilisation as maintaining membrane 
integrity is important for LRP staining. As such, the immunoreactivity shown mostly reflects 
expression on the cell membrane. 
2.3.2 Determine whether LRP1 or LRP2 ligands have chemotropic effects on neuronal 
growth cones  
Given that LRP1 and LRP2 are present in growth cones, we sought to determine whether any 
of the well characterised ligands of these receptors had chemotactic effects on growth cones.  
To ascertain whether LRP1 and LRP2 were involved in growth cone chemotaxis, we used 
selected LRP ligands, and control solutions, in the well described growth cone turning assay 
(Lohof et al., 1992). The vehicle control was phosphate buffered saline (PBS), a balanced salt 
solution, which caused random growth (-1.8° ± 1.1,) with no net attraction or repulsion.  A 
concentration gradient of ApoE3, TTR, VD/VDBP and RAP (applied as a concentration 
gradient, not as an inhibitor in the culture bath), all resulted in random growth and not 
significantly different from the control (Fig 2.2).  α2M and tPA induced growth cone 
repulsion, compared to the control (-11.9° ± 3.4, p<0.01 and -11.1° ± 2.1 p<0.001, 
respectively; Fig 2.2).  The repulsion induced by gradients of α2M and tPA was found to be 
more robust than the repulsion in response to Semaphorin3a (-8.2° ± 1.9, p<0.02; Fig 2.2), an 
established chemorepulsive cue.   A gradient of MTII induced significant chemoattraction of 
growth cones towards its concentration gradient (11.6° ± 2.1, p<0.001), which was 
comparable to growth cone turning in response to the classic chemoattractant, BDNF (14.87° 
± 1.8 p<0.0001; Fig 2.2). Axon extension was also measured during the 30 minutes of 
imaging, to ensure that growth cones were healthy, were not involved in external interactions, 
and to assess whether additional effects were observed, for example growth cone collapse.    
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Figure 2.2 The LRP ligands, tPA, α2M and MTII induce chemotaxis in DRG growth 
cones. 
A chemical microgradient of LRP ligands and controls were applied to isolated growth cones 
in vitro.  (A) Quantification for average turning angles of neurites in response to vehicle 
control (1:1 phosphate buffered saline, pH 7.4), standard attractive cue, BDNF; standard 
repulsive cue, Sema3a; apoE3, transthyretin, tPa, α2M, vitamin D bound to Vitamin D 
binding protein,  MTII and  RAP. (B) Axon extension for the same growth cones were 
analysed, and with the exception of RAP did not differ significantly after 30 minutes of 
imaging. Error bars represent standard error of the mean.  ***p<0.0001, **p<0.002.  
Asterisks (*) directly above error bars indicate significance when compared to control. 
Numbers within parentheses indicate the number of growth cones that were analysed per 
treatment group and apply to both (A) & (B). Note that some of the growth cone turning data 
points included within the results for PBS, Sema3a, BDNF, MTII, and RAP in Figure 2.2 
were assessed as part of my honours thesis, Landowski 2009.  The remaining data is a result 
of PhD work. The control and MTII data points are used in Chapters 2 and 3. 
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Extension was uniform across all treatment groups except for RAP, which mitigated a 
significant enhancement of neurite outgrowth (p<0.03), which is in agreement with previous 
observations (Postuma et al., 1998). 
The observation of a turning effect of growth cones towards MTII was followed up with an 
investigation into the importance of protein structure for eliciting this effect (Figure 2.3). 
Structurally similar family members, MTIII and MTIV, were examined for chemotactic 
ability, as well as the truncated synthetic analogues of MTII, EmtinA and EmtinBn.  
Surprisingly, MTIII had a significant and opposing effect to MTII (-13.2 ± 1.9 p<0.0001).  
Furthermore, MTIII was significantly more repulsive than established repulsive guidance cue, 
Sema3a (p<0.04).  MTIV, EmtinA and EmtinBn had no significant chemotactic effect. 
Additionally, as MTs are metal-binding proteins used in their zinc bound form, it was 
important to assess whether a zinc solution (zinc sulphate, 50mM) alone exerted any 
directional influence.  It is known that zinc is able to transactivate neurotrophin receptor 
TrkB (Huang et al., 2008).  However, zinc solution did not have any chemotactic effect.  
Axon extension, which is also measured during the 30 minutes of imaging, was significantly 
enhanced in the EmtinA and zinc treatment group; these findings are consistent with previous 
studies that demonstrate enhanced neurite outgrowth (Nusetti et al., 2005, Asmussen et al., 
2009a).   
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Figure 2.3 MTs can be chemoattractive or chemorepulsive 
(A) A chemical gradient of MTII, MTIII, MTIV and synthetic metallothionein-mimetic 
peptides, EmtinA and EmtinB, were used in the growth cone turning assay. Only MTII and 
MTIII elicited a significant turning angle. (B) EmtinA, EmtinB and Zinc significantly 
increased axon outgrowth after 30 minutes of imaging. ****p<0.0001. **p<0.007.  Error bars 
represent SEM.  Asterisks (*) directly above error bars indicate significance when compared 
to control. Numbers within parentheses indicate the number of growth cones that were 
analysed per treatment group and apply to both (A) & (B). Note that some of the growth cone 
turning data points included within the results for MTIII in Figure 2.3 was assessed as part 
of my honours thesis, Landowski 2009.  The remaining data is a result of PhD work. The 
MTIII data points are used in Chapters 2 and 3. 
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2.3.3 Determine whether LRP receptors are required in MTII or MTIII induced growth 
cone chemoattraction 
In order to determine whether chemoattractive signalling is elicited by MTII interacting with 
LRP receptors, the chemotactic response of MTII was measured in the presence of an LRP 
receptor inhibitor. Receptor associated protein (RAP) is a 39kDa chaperone protein residing 
in the endoplasmic reticulum involved in the correct folding of LDL family receptors (Bu et 
al., 1995).  When applied exogenously, RAP can act as a competitive inhibitor of all LDL 
family receptors and this has been demonstrated both in vitro and in vivo (Willnow et al., 
1992). RAP binds LDL-receptors LRP1 and LRP2 with high affinity and  LDLR, VLDLR 
and apoER2 to a lesser degree (Herz et al., 1991).  On the premise that LRP1 and LRP2 
ligands elicit chemotaxis by signalling solely through receptors of the LRP family, we would 
expect that the addition of RAP or small interfering RNA (siRNA) would abolish the 
chemotactic response.  Pan-inhibitor of the LRP-family, receptor-associated protein (RAP), 
was added to the culture media 30 minutes prior to imaging, and growth cones were 
subsequently exposed to a concentration gradient of MTII or MTIII. The addition of RAP 
significantly abrogated the turning effect elicited by MTII and MTIII to control levels (-0.6°± 
1.2, p=0.0015 and 0.9°± 1.2, p=0.0002, respectively; control, -1.8°± 1.1; Fig 2.4A).  Axon 
extension was not affected (data not shown).  These findings suggest that LRP receptors are 
capable of mediating chemoattraction in response to MTII and MTIII, but it does not discern 
which of the MTII or MTIII receptors, LRP1 or LRP2, are implicitly involved. 
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2.3.4 Demonstrate reduced LRP1 and LRP2 expression in siRNA transfected DRG 
In order to determine which specific LRP receptor/s are responsible for mediating the growth 
cone chemoattractive response, I used siRNA to reduce endogenous expression of LRP1 and 
LRP2, the known receptors of MTII. The level of protein expression in DRG cultures were 
assayed with western blot and quantified relative to actin loading controls (Fig 2.4B-E).  For 
both LRP1 and LRP2, all 4 siRNAs yielded equally significant knock down of protein 
expression after 6 hours.  Compared to levels of LRP1 and LRP2 in control siRNA treated 
tissue, LRP1 siRNAs gave an average of 50% ± 3 reduction in LRP1 (p<0.03) and LRP2 
siRNAs gave an average of 71% ± 4 reduction, (p<0.0001) (Fig 2.4C and Fig 2.4E).   
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Figure 2.4  Perturbation of MT-mediated growth cone turning with Pan-inhibition of 
LRPs suggests that reduced expression of specific LRP receptors is required 
(A) Quantification of growth cone trajectories demonstrate that the addition of competitive 
inhibitor of LRP receptors, RAP, to the imaging media, prior to growth cone exposure to a 
concentration gradient of MTII and MTIII.  Error bars represent standard error of the mean.  
Numbers within parentheses indicate the number of growth cones that were analysed per 
treatment group. (B) Western blot and analysis of lysate from DRG culture treated with 
control siRNA or one of the four specific LRP1 siRNA demonstrates reduced LRP1 
expression after 6 hours of siRNA treatment. (C) Quantification of western blot shows an 
average of 50% decrease in immunoreactivity compared to the control, with all specific 
siRNA being equally effective (n=3). (D) Western blot and analysis of lysate from DRG 
culture treated with control siRNA or one of the four specific LRP2 siRNA demonstrates 
LRP2 knockdown after 6 hours of siRNA treatment. (E) Quantification of western blot shows 
an average of 71% decrease in immunoreactivity when compared to the control, with all 
specific siRNA being equally effective (n=3). Values are expressed as a percentage of the 
control and are obtained over 3 experiments.  Error bars represent SEM. *p<0.05, *** 
p<0.0001. Unpaired t-test.  Note that some of the growth cone turning data points included 
within the results for Figure 2.4A were assessed as part of my honours thesis, Landowski 
2009. 
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2.3.5 MTII and MTIII-mediated growth cone chemotaxis is LRP1 and LRP2 dependent 
The turning response of growth cones to MTII and MTIII were used in growth cones 
transfected with siRNA to knock down expression of LRP1 or LRP2 individually, or LRP1 + 
LRP2 simultaneously.  Knockdown of LRP1 or LRP2 abolished growth cone turning in 
response to MTII (3.5° ± 1.9, p=0.003 and 3.6° ± 2.6, p=0.03 respectively, compared to the 
turning response of growth cones to MTII in control siRNA culture, (12.9° ± 2.7; Figure 2.5). 
Furthermore, dual LRP1/LRP2 receptor knockdown also abolished the growth cone turning 
response to MTII (0.6° ± 1.5, p=0.002; Figure 2.5). 
To ensure that reduced LRP expression did not interfere with the turning machinery of 
growth cones, or abolished the turning response to guidance cues in a non-specific manner, I 
examined growth cone turning in response to netrin, a well-established chemoattractive 
guidance cue, after dual reduction of LRP1 and LRP2.  Netrin induces chemoattraction via 
DCC receptors (Ming et al., 1999). There was no difference in growth cone turning in 
response to netrin after dual reduction of LRP1 and LRP2 compared to cultures transfected 
with control siRNA (Fig 2.5). 
It is yet to be determined whether LRP1 and LRP2 are receptors for MTIII.  Surprisingly, 
reduced expression of LRP1 or LRP2 appeared to switch the turning effect in response to 
MTIII (5.8° ± 2.6, p=0.0005 and 10.0° ± 2.8, p<0.0001 respectively, compared to the turning 
response of MTIII in control siRNA culture, -13.9° ± 4.0; Fig 2.6). Furthermore, while 
reduced expression of LRP1 and LRP2 abolished the growth cone turning response to MTII 
(0.6° ± 1.5, p=0.002; Fig 2.6), MTIII reverted back to a repulsive response, albeit weakened, 
(-7.1° ± 2.8; Fig 2.6) suggesting complex receptor interplay. 
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Figure 2.5 Targeted LRP1 and LRP2 receptor knockdown with siRNA perturbed MTII-
induced growth cone chemoattraction 
 (A) A chemical gradient of MTII, in the presence of various LRP modulators, were used in 
the growth cone turning assay.  Quantification of average turning angles demonstrates that 
the incorporation of siRNA against LRP1, or LRP2, into DRG neurites abolishes the response 
of neurites to MTII.  Similarly, dual reduction of LRP1/LRP2 abolishes MTII-mediated 
attraction.  Netrin, a chemotactic guidance cue which does not signal through LRP receptors, 
is not significantly affected by the simultaneous addition of both LRP1 and LRP2 siRNA, 
compared to control siRNA.  (B) Axon extension did not differ significantly after 30 minutes 
of imaging.   Error bars represent standard error of the mean.  Numbers within parentheses 
indicate the number of growth cones that were analysed per treatment group and apply to 
both (A) & (B). *p<0.02, **p<0.002 and ***p<0.001 
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Figure 2.6 Targeted LRP1 and LRP2 receptor knockdown with siRNA perturbed 
MTIII-induced growth cone chemorepulsion 
 (A) A chemical gradient of MTIII, in the presence of various LRP modulators, were used in 
the growth cone turning assay.  LRP1 or LRP2 knockdown reversed the turning angle in 
response to MTIII. However, dual reduction of LRP1/LRP2 expression attenuated the turning 
response of growth cones to MTIII; the response was neither significantly different from the 
control nor to the normal response of growth cones to MTIII.   (B) Axons did not differ 
significantly after 30 minutes of imaging.   Error bars represent standard error of the mean.  
Numbers within parentheses indicate the number of growth cones that were analysed per 
treatment group and apply to both (A) & (B). *P<0.05 and ***P<0.0001.   
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2.3.5 Demonstration of LRP1 and LRP2 co-localisation in growth cones 
The finding that LRP1 and LRP2 both appear to be necessary for the chemoattractive effect 
of MTII raised the question whether these receptors may be signalling together in close 
proximity. Dual staining for LRP1 and LRP2 in growth cones undergoing random growth 
revealed significant colocalisation throughout the lamellipodia and filopodia in a punctate 
distribution (Fig 2.7, arrows), supporting the notion that LRP1 and LRP2 are signalling 
together, potentially in a complex signalling hub. 
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Figure 2.7  LRP1 and LRP2 colocalise in growth cones in vitro 
Representative images of immunoreactivity of growth cones with an antibody specific to 
LRP1 (green) and LRP2 (red).  Significant areas of colocalised immunopositive puncta are 
present, as demonstrated by yellow staining in the merged images (arrows). Colocalisation is 
located throughout the growth cone, including the leading edge.  Scale bar is 10µm and 
applies to all images. 
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2.4 DISCUSSION 
A new neuron specific role for LRP1 and LRP2 was identified in mediating growth cone 
chemotaxis.   LRP ligand MTII induced neurite chemoattraction, while α2M, tPA and MTIII 
were found to have chemorepulsive effects. I demonstrated that LRP1 and LRP2 signalling 
could mediate chemoattraction and chemorepulsion.  The remaining LRP ligands tested had 
no discernible chemotactic effect. LRP1 and LRP2 were present in growth cones in chemical 
sensing regions (leading edge and filopodia), and colocalisation of these receptors was also 
observed in vitro.  These data demonstrate that LRP receptors are able to direct axon 
guidance in vitro.   
The chemoattractive effects of MTII are not unique to neuronal growth cones, and have been 
described in other cell types, promoting keratinocyte and astrocyte migration in vitro after 
scratch injury (Carrasco et al., 2003, Morellini et al., 2008).  The MT genes are in close 
proximity to other chemokine genes, located on chromosome 16q13, and MT proteins share 
some amino acid motifs characteristic of cytokines (Yin et al., 2005).  Again, as with many 
cytokines it was found that leucocytes migrate towards a gradient of MTI/II, and this activity 
increased F-actin content, as occurs in growth cones (Yin et al., 2005). Metallothionein I/II 
knockout mice exhibit subtle neurocognitive deficits; although the underlying mechanism 
involved is currently unknown, these data support the notion that the LRP-MTII system has 
roles in neuronal function (Yoshida et al., 2005, Levin et al., 2006). 
α2M is expressed in the spinal cord and brain during development while axon pathfinding is 
occurring (Kodelja et al., 1986), and is important for trophoblast invasion during implantation 
(Esadeg et al., 2003).  Whether α2M is directly involved in axon pathfinding processes 
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remains unknown.  α2M has been shown to promote migration of many cell types, including 
Schwann cells, Müller glial cells and neutrophils (Hakansson and Venge, 1983, Mantuano et 
al., 2010, Barcelona et al., 2013). α2M affects cell migration both directly and indirectly 
through modulating activity and expression of other proteinases and cytokines, or by binding 
other proteins; for example, α2M indirectly promotes macrophage migration by binding type 
I collagen (Larin et al., 2002).  Given that most chemotactic cues to growth cones require 
Ca
2+
 as a second messenger to initiate turning, it is interesting to note that microapplication of 
α2M results in a transient calcium influx in mouse cortical neurons via NMDA receptors 
(from 88 ± 29nM to 396 ± 22nM) (Bacskai et al., 2000).  NMDA receptors are involved in 
growth cone migration in Xenopus spinal neurons (Zheng et al., 1996) and are present and 
functional on mammalian and hippocampal neurons (Wang et al., 2011).  Although NMDA 
receptors are not established mediators of growth cone guidance in mammalian DRG 
neurons, they have well characterised functional roles in this cell type (Liu et al., 1997, 
Coggeshall and Carlton, 1998, Kung et al., 2013).  As such, NMDA receptor activity may 
relate to a novel mechanism of LRP-mediated growth cone repulsion. 
tPA has well established roles in axon pathfinding, via secretion at the growth cone tip and 
thus modulating the extracellular environment and facilitating advancement of the growth 
cone (Krystosek and Seeds, 1981, 1984, 1986).  The observation that microapplication of tPA 
directly resulted in growth cone repulsion therefore was surprising.   It is known that tPA is 
able to proteolytically cleave many proteins, including laminin immobilised on a substrate 
base (Salonen et al., 1984).  The growth cone turning assay requires laminin as the primary 
cell adhesion substrate for growth cones.  Therefore, the observation that growth cones were 
repulsed from a gradient of tPA, may in fact be secondary to tPA cleaving the laminin 
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substrate, and as such, making the substrate closest to the micropipette inhibitory to growth 
cones, culminating in growth cone repulsion. 
Previous studies using surface plasmon resonance have demonstrated that MTII associates 
with LRP1 and LRP2 in neurons (Ambjorn et al., 2008), hence it was perhaps not surprising 
that both these receptors proved necessary for growth cone responses to MTII.  Reduction of 
LRP1 or LRP2 expression abolished the turning response to MTII; these data suggest that 
LRP1 and LRP2 are part of a heterogenous signalling hub. Indeed, immunocytochemical 
staining corroborated these results, demonstrating that LRP1 and LRP2 were co-localised in 
growth cones, indicative of a close physical association. It is pertinent to mention our 
laboratory has established that LRP1 knockdown does not affect LRP2 expression, and vice 
versa (Pavez, 2013).  Although it is well established that LRP receptors are capable of 
forming complex signalling domains by recruiting co-receptors, it is currently unknown 
whether LRP1 and LRP2 may recruit each other. The only suggestion in the literature that 
LRP1 and LRP2 may signal in a complex is from Vaillant and colleagues who reported that 
protease nexin 1, which is endocytosed by LRP1, modulated sonic hedgehog (Shh) signalling 
(Vaillant et al., 2007). Shh is a morphogen with important roles in neuronal development, and 
binds LRP2 with high affinity, sequestering it in a complex with co-receptor, patched 1 
(Christ et al., 2012).  Vaillant and colleagues did not discuss the unusual result of an LRP1 
ligand modulating an LRP2-dependent process; however their findings support the notion of 
LRP1/LRP2 receptor crosstalk.  Taken together, these results, along with the data within this 
chapter, support a putative role of LRP1 and LRP2 in axon guidance. 
MTIII shares significant structural homology with MTII however it was found to have 
contrasting chemorepulsive effects on growth cones.  It has not been previously determined 
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whether LRP1 or LRP2 are receptors for MTIII. TrkA, a neurotrophin receptor, has been 
identified as a receptor necessary for MTIII to mitigate its anti-apoptotic effects in neurons 
(Kim et al., 2009). Reduced expression of LRP1 or LRP2 in growth cones exposed to a 
microgradient of MTIII resulted in a switch from repulsion to attraction.  Furthermore, 
simultaneous reduction of both LRP1 and LRP2 expression reverted the growth cone turning 
response back to repulsion, albeit, attenuated.  Although this suggests involvement of LRP1 
and LRP2, the mechanism appears to be much more complex than MTII and likely involves 
other co-receptors such as TrkA. From the data in this thesis, it is evident that growth cone 
turning in response to LRP ligands occurs through highly complex signalling pathways.  This 
phenomenon will be investigated in more detail in Chapter 3. 
Not surprisingly, although many of these ligands have been described to promote neurite 
outgrowth in vitro, not many ligands were observed to promote neurite outgrowth in this 
acute model of ligand exposure. Given that growth cones are only measured for 30 minutes, it 
is highly unlikely that typical transcriptional events leading to enhanced neurite outgrowth 
(such as CREB activation) are engaged (Nakajima et al., 2013).  Instead one might postulate 
involvement of local mediators of cytoskeletal assembly, such as enhanced activation of 
phosphatases involved in microtubule stabilisation (Bentley and O'Connor, 1994) and 
assembly and hence neurite outgrowth.  
Whether these chemotactic effects on growth cones in response to MTII, MTIII, tPA, or α2M 
have physiological significance in vivo remains to be determined. It is likely that the 
molecules that are able to promote growth cone turning include many more in addition to the 
classical chemotactic guidance cues with established roles in development, such as BDNF 
and Semaphorin3a.  Furthermore, chemotactic guidance cues are conceivably specific for 
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different contexts:  for example, the extracellular environment associated with growth cones 
in the developing nervous system is likely to be very different to that found in the mature 
brain, in neuropathy, or in the vicinity of regenerating neurons following physical injury.  
This raises the question whether other receptor-ligand systems outside those established in 
developmental axon pathfinding, such as the LRP-MTII system, may be involved in, for 
example, regenerative processes.  Recently, the role of MTs in mediating regenerative growth 
of injured neurons has been a topic of investigation (Giralt et al., 2002b, Carrasco et al., 2003, 
Chung et al., 2003, Fitzgerald et al., 2007, Asmussen et al., 2009a, Leung et al., 2012 ), so it 
is possible that the LRP-MT signalling system may function in vivo in neuronal regeneration. 
The finding that MTII is chemoattractive to growth cones raises particular interest from a 
therapeutic context.  Neurite chemotaxis is a functionally important component of neuronal 
regeneration, as regrowth must be directed to the lesion site, so that appropriate sprouting can 
occur and ultimately connections can be re-formed (Alto et al., 2009). MTII has been 
implicated in nerve regeneration in vivo, and given the ability of MTII to induce neurite 
chemoattraction, we propose MTII as a possible therapeutic in neuropathies and neuronal 
injury.  The finding that MTII can induce attraction of neurites in vitro is novel, but whether 
MTs in the extracellular environment support tropic regrowth and regeneration of neurons 
into the site of injury in vivo remains unknown and will be the subject of further investigation 
in chapter 5 of this thesis. Since the processes that are involved in neurite regeneration 
closely recapitulate those that occur during neurite outgrowth in development (Dyson et al., 
1988), the chemotactic effects of MTs observed here in developing sensory neurons in vitro 
may also be applicable to neurites that have re-sprouted during post-injury regeneration in 
vitro or in vivo.  
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Understanding the mechanisms by which MTs elicit these responses in neuronal growth 
cones has important implications for future therapeutic developments of MTs in neuropathies 
and neuronal injury.  Hence, the following chapter will examine the underlying mechanism of 
MT-mediated growth cone turning. 
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CHAPTER 3 
THE DOWNSTREAM SIGNALLING MECHANISMS THAT MEDIATE LRP 1 AND 
LRP2 SIGNALLING IN SENSORY GROWTH CONE NAVIGATION 
3.1 INTRODUCTION 
The findings in Chapter 2 suggest that LRP ligand, MTII, is a candidate disease-modifying 
agent for the injured peripheral nervous system. The finding that MTII has a chemoattractive 
effect on peripheral sensory neurites alludes to therapeutic potential in regenerating nerves 
damaged after local insult or toxicity. As LRP-MTII signalling represents a novel, non-
classical axon guidance system, investigating the mechanism of action at the intracellular 
level is pertinent to developing MTII as a therapeutic.  The finding that MTIII, a protein 
structurally similar to MTII (Shi et al., 2002), had opposing effects was an intriguing result, 
and therefore was also investigated.  To the best of our knowledge, there is no evidence of a 
known mechanism by which LRP1 and LRP2 could promote growth cone turning and axon 
guidance, despite the known involvement of LRP1 and LRP2 in cell migration (Lillis et al., 
2005).   
The signalling pathways that underlie growth cone navigation are not completely understood.  
Growth cone guidance cues are often described as Ca
2+
 dependent and Ca
2+
 independent 
(Song and Poo, 1999). Given that LRPs coordinate Ca
2+
 as part of their secondary structure 
(Simonovic et al., 2001, Andersen et al., 2003), it is likely that MTII and MTIII growth cone 
chemotaxis is Ca
2+
 dependent.  The involvement of Ca
2+
 in LRP1 and LRP2 ligand mediated 
neurite chemotaxis was examined, as was the downstream calcium dependent signalling 
protein, Ca
2+
/calmodulin-dependent kinase II (CaMKII).    
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While Ca
2+
 signalling pathways represent traditional growth cone signalling pathways, LRPs 
are known to interact with a variety of other intracellular signalling molecules.  By virtue of 
their long intracellular domains, LRP1 and LRP2 are capable of forming complex signalling 
domains by recruiting co-receptors and eliciting a wide array of effects within the cell 
(Beffert et al., 2004).  LRP activity in growth cone navigation likely involves interactions 
with other co-receptors and intracellular binding partners.  One such binding partner is TrkA, 
the nerve growth factor neurotrophin receptor which has established roles in growth cone 
guidance (Gundersen and Barrett, 1980, Gallo et al., 1997).  Kim and associates (2009) 
recently identified TrkA, as a putative MTIII receptor.  Furthermore, it has been shown that 
TrkA receptors can be transactivated by LRP1 (Shi et al., 2009).  In light of this work, the 
interaction of TrkA with LRP-MT signalling was investigated in both MTII and MTIII 
mediated chemotaxis.   
Clues into the mechanisms of LRP signalling in growth cones may come from studies 
looking at the signalling pathway of MTI/II in the context of neuronal protection.  The 
association of MT I/II with LRP1 and LRP2 receptors promotes neurite outgrowth and 
transiently activates Akt and ERK, which belong to the mitogen activated protein kinase 
(MAPK) and the phosphoinositide-3 kinase/Akt (PI3K/Akt) intracellular signalling pathways, 
and are required in neuronal differentiation and survival respectively (Brunet et al., 2001, 
Chang and Karin, 2001, Ambjorn et al., 2008).  These pathways culminate in the activation of 
the transcription factor, CREB, which alters gene transcription of proteins that are conducive 
to sustaining neuroprotection and neurite outgrowth (Chang and Karin, 2001, Ambjorn et al., 
2008).  MAPK pathways have been implicated in growth cone turning (Doherty et al., 2000), 
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and in light of this, MAPK involvement in MT-mediated growth cone turning was also 
investigated. 
Anchoring points between the cell and its surrounding environment (focal adhesions) are 
important for growth cone motility (Conklin et al., 2005).  An investigation of the turning 
response of growth cones from LRP1 and LRP2 knockdown cultures yielded unexpected 
observations.  Anomalies in the morphology of these knockdown cultures were observed.   
As LRPs are intimately associated with focal adhesions (Orr et al., 2003), this chapter will 
also address the question whether LRP1 or LRP2 receptor knockdown results in 
morphological changes to the growth cone.  The data in this chapter demonstrates that LRP-
MT signalling is Ca
2+ 
dependent and functions through complex receptor interactions. 
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3.2 EXPERIMENTAL PROCEDURES & MATERIALS 
3.2.1 In vitro growth cone turning assay 
Primary DRG neuron culture was performed as per section 2.2.2 
The growth cone turning assay was performed as per section 2.2.4, however additional 
pharmacological agents were used.  Bath applied pharmacological agents added to the culture 
media were: KN93 (5µM, Calbiochem, CA, USA), KN92 (5µM, Calbiochem, CA, USA), 
SKF953659636 HCl (TOCRIS, Bristol, UK) and K525a (100nM, Calbiochem, CA, USA).  
Pharmacological inhibitors were added to the culture media 20 minutes prior to imaging.   
All growth cone assays were conducted in cultures grown in SNM, except for ‘Low 
extracellular calcium’ media turning assays. In the instance of a ‘Low [Ca2+]EC’ media 
turning assay, the SNM was removed immediately prior to imaging, and replaced with Ca
2+
 
free Hank’s Balanced Salt Solution (HBSS), or modified 1mM Ca2+ Ringers solution.  There 
was no statistical difference in turning angles between the two groups and thus results were 
pooled. HBSS comprises of Hank’s Balanced Salt Solution Ca2+ and Mg2+ free media  (Gibco 
Biosciences, CA, USA), Penicillin G (100U/mL) and streptomycin (100µg/mL) (Gibco 
Biosciences, CA, USA), nerve growth factor (50ng/mL; Sigma-Aldrich, MO, USA), and N2 
neural medium supplement (Gibco Biosciences, CA, USA).  1mM Ca
2+
 modified Ringer’s 
solution (Ming et al., 1999) comprises 140 mM NaCl, 1 mM MgCl2, 0.9 mM CaCl2, 5mM 
KCl, 4 mM EGTA, and 10 mM HEPES (pH 7.4). siRNA knockdown of LRP-1 and LRP-2 
was performed as per section 2.2.3. 
Statistical analysis was performed as per section 2.2.8. 
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Table 3.1 Pharmacological agents used to probe LRP-MT mediated growth cone 
navigation 
 
 
 
 
 
 
 
3.2.2 Immunocytochemistry 
Immunocytochemistry was performed as per section 2.2.4.  Anti-FAK antibody (clone 4.47, 
Merck Millipore, Darmstadt, Germany) was used in addition to the listed primary antibodies. 
 
3.2.3 Analysis of immunoreactivity, area and filopodia on growth cones  
DRG cultures were treated with control or specific LRP1 and LRP2 morpholino 
oligonucleotides using protocols described in section 2.2.3. Immunocytochemistry was 
performed as per section 2.2.4. Images of LRP1 and LRP2 immunoreactivity were acquired 
across all treatment groups were acquired using a cooled CCD 16-bit camera (Optronics, CA, 
USA) on an Olympus BX-50 microscope and 60x water immersion objective using identical 
acquisition settings (1sec). Images of F-actin distribution were acquired in parallel.  Growth 
Low [Ca
+2
]EC Recapitulates the effect of a 
low extracellular Ca
2+
 
environment 
KN93 Inhibitor of CaMKII 
KN92 Inactive analogue and control 
for KN93 
K252a Inhibitor of TrkA tyrosine 
phosphorylation 
SKF95365 Inhibitor of most TRP  Ca
2+
 
channels and some voltage 
gated  Ca
2+ 
channels 
PD98059 Inhibitor of MAPK Kinase 
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cone area was calculated from f-actin images, and the number of filopodia per growth cone 
were counted.  From overlaid F-actin images, the LRP1 and LRP2 average immunoreactivity 
were calculated  and expressed as a function of area.  Unpaired t-test was used to compare 
average immunoreactivity between groups. 
3.2.4 Analysis of FAK puncta  
Focal adhesion kinase (FAK) analysis of rat DRG growth cones was performed using ImageJ 
(NIH, MD, USA). Briefly, DRG cultures were treated with control or specific LRP1 and 
LRP2 morpholino oligonucleotides using protocols described in section 2.2.3. Localisation of 
FAK puncta was performed using standard immunocytochemical protocols. Images of FAK 
immunoreactivity across all treatment groups were acquired using a cooled CCD 16-bit 
camera (Optronics, CA, USA) on an Olympus BX-50 microscope and 60x water immersion 
objective using identical acquisition settings (1sec). Images of F-actin distribution were 
acquired in parallel to FAK immunoreactivity.  
The following image analysis were performed by Dr. Robert Gasperini: FAK images were 
first background corrected using a 5-pixel rolling ball radius, followed by binary 
thresholding. Particle analysis was subsequently used to quantitate numbers of FAK puncta 
(9-50 pixel
2
 and circularity 0.3-1.0). Growth cone area was calculated from an overlaid f-
actin image allowing the calculation of FAK density (puncta/μm2 ) in DRG growth cones. 
FAK density across treatment groups was compared using a Mann-Whitney U test (IgorPro, 
Wavemetrics, OR, USA) 
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3.3 RESULTS 
3.3.1 Determine whether LRP-mediated growth cone guidance a calcium dependent 
process 
It is well established that Ca
2+
 is an early second messenger in growth cone navigation (Song 
and Poo, 1999, Bootman et al., 2001). Determining whether the LRP-mediated turning 
response was dependent on extracellular Ca
2+
 may provide important clues about the 
underlying intracellular signalling pathways.  In low extracellular Ca
2+
 media, the LRP-
mediated turning response was switched: For MTIII, growth cones switched from an average 
turning angle of -13.2°±2.0 to +12.4°±3.6, P<0.0001; conversely for MTII, growth cones 
switched from an average turning angle of +11.6°±2.2, to -8.1° ± 3.8; P<0.0001 (Fig 3.1A 
and 3.2A).   This switch in the turning angle is reminiscent of the molecular switch formed by 
the alternate activation of the repulsion-inducing Ca
2+
-binding protein, calcineurin (CaN) and 
attraction-evoking Ca
2+
/calmodulin-dependent kinase II (CaMKII) (Wen et al., 2004).  As 
such, the requirement of CaMKII in response to LRP-MT signalling was assessed. 
3.3.2 Establish whether CaMKII is required for LRP-mediated growth cone turning 
CaMKII activation is required for growth cone attraction towards a guidance cue gradient 
(Wen et al., 2004, Tojima et al., 2011).  To confirm whether CaMKII is required for LRP-
mediated turning response, cultures were incubated with CaMKII inhibitor, KN93.  Inhibition 
of CaMKII resulted in a switch in the chemotactic response to MTII (+11.6°±2.2 to -10.4° ±  
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Figure 3.1. LRP-MTII mediated growth cone turning is Ca
2+ 
dependent 
Growth cone turning was measured in response to a chemical gradient of MTII. All 
experiments were performed in normal sensory media with normal calcium concentration, 
except for Low Ca
2+
 EC medium. (A) Reduction of extracellular Ca
2+
 with Low Ca
2+
 EC 
medium  abolished growth cone turning towards MTII.  Inhibition of calcium-calmodulin 
dependent kinase, CaMKII, with KN93, induced growth cone repulsion to MTII.  In the 
presence of KN92, an inactive analogue of KN93, the turning response was unperturbed. The 
general non-selective Ca
2+
 channel inhibitor SKF95365, did not abrogate the turning response 
to MTII. (B) Axon extension for the same growth cones were analysed and did not differ 
significantly after 30 minutes of imaging. ****P<0.0001. Error bars represent SEM.  
Numbers within parentheses indicate the number of growth cones that were analysed per 
treatment group and apply to both (A) & (B).  
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Figure 3.2. LRP-MTIII mediated growth cone turning is Ca
2+ 
dependent 
Growth cone turning was measured in response to a chemical gradient of MTIII. All 
experiments were performed in normal sensory media with normal calcium concentration, 
except for [Low Ca
2+
]EC medium. (A) Reduction of extracellular Ca
2+
 with [Low Ca
2+
]EC 
medium reversed the growth cone turning response to MTIII.  Inhibition of calcium-
calmodulin dependent kinase, CaMKII, with KN93, reversed the growth cone turning 
response to MTIII.  In the presence of KN92, an inactive analogue of KN93, the turning 
response was unperturbed.  (B) Axon extension for the same growth cones were analysed and 
did not differ significantly after 30 minutes of imaging with the exception of KN93 treatment. 
Error bars represent SEM.  ****P<0.0001. Numbers within parentheses indicate the number 
of growth cones that were analysed per treatment group and apply to both (A) & (B). 
Inhibitors are summarised in Table 3.1. 
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2.0, P<0.0001) and MTIII (-13.2°±1.9 to + 6.4° ± 1.2, P<0.0001) (Fig 3.1A and 3.2A).  
KN92, the inactive analogue of KN93, was used as a control, and had no significant effect on 
the turning response of either MTII or MTIII.  This result further supports the hypothesis that 
LRP signalling is Ca
2+
 and CaMKII dependent, requiring the activation of classical Ca
2+
 
signalling pathways.  Furthermore, axon extension did not differ (Fig 3.1B), demonstrating 
the effect was specific to growth cone motility. 
Given that LRP-MT signalling requires influx of extracellular Ca
2+
to activate intracellular 
Ca
2+
 binding proteins, I next asked whether TRP Ca
2+
 channel activation was required.  The 
requirement Ca
2+
 channels was investigated using SKF95365, which is a non-selective 
inhibitor of several Ca
2+
  channels, including TRP channels, which are implicated in growth 
cone turning (Singh et al., 2010). Addition of SKF95365, however, did not alter the turning 
response of growth cones to MTII (Fig 3.1A), suggesting that Ca
2+
 influx is via other Ca
2+
 
channels. 
3.3.3 Determine whether TrkA is required for LRP-MT mediated chemotaxis 
TrkA is a well-established neurotrophin receptor, and putative receptor for MTIII (Kim et al., 
2009). There is also evidence that LRP-1 receptors crosstalk with TrkA receptors (Shi et al., 
2009). Given the structural similarity of both MTII and MTIII and possible overlap in 
signalling processes, the involvement of TrkA in both MTII and MTIII-mediated growth 
cone turning was examined.  K252a, an inhibitor of tyrosine phosphorylation, blocks TrkA 
signal transduction but is known to also have more general actions, such as inhibiting protein 
kinases such as PKA (Zong et al., 1994). K252a was used to determine whether TrkA was  
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Figure 3.3 Inhibition of TrkA perturbed growth cone turning in response to LRP-MT 
Growth cone turning was measured in response to a chemical gradient of MTII and MTIII. 
(A) Average turning angles of growth cones in response to MTII and MTIII in the presence 
of bath-applied TrkA inhibitor, K252a, with or without reduced LRP1/2 expression. In the 
presence of K252a, growth cones exposed to a concentration gradient of MTII trended 
towards growth cone repulsion.  Reduced LRP1/2 expression combined with bath-applied 
K252a abolished turning towards MTII. Reduced LRP1/2 expression combined with bath-
applied K252a abolished turning towards MTIII. (B) Axon extension for the same growth 
cones were analysed and did not differ significantly after 30 minutes of imaging. 
****P<0.0001, ***P<0.0005, **P<0.002.  Error bars represent SEM.  Numbers within 
parentheses indicate the number of growth cones that were analysed per treatment group and 
apply to both (A) & (B).  
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important for LRP-MT-mediated chemoattraction (Fig 3.3.A). The addition of K252a to the 
culture medium resulted in an apparent switch in the turning angle of growth cones in 
response to MTII (from 11.6°±2.2 to -8.8°±3.1, P<0.0001, Fig 3.3).  Bath-applied K252a 
abolished the turning effect of growth cones exposed to a concentration gradient of MTIII 
(from -13.2°±1.9 to -1.8°±3.3, P<0.002, Fig 3.3).  Furthermore, reduced expression of both 
LRP1 and LRP2 in growth cones, in conjunction with bath applied K252a, abolished the 
turning effect of MTII, as was predicted (Fig 3.3A). Taken together, these results suggest 
complex receptor interplay between LRP1, LRP2, TrkA, and other as yet unknown receptors. 
3.3.4 Establish whether MAPK pathways function in LRP-MT mediated chemotaxis 
MAPK pathways have been implicated in growth cone turning, and have been demonstrated 
as downstream effectors of MTII in neurite extension and neuroprotection (Leung et al., 2012 
). Inhibition of the p38/p42 MAPK pathway with PD98059 had no significant effect on the 
response of growth cones turning towards MTII, although there was a non-significant trend 
towards decreasing the turning response (11.6°±2.2 to 5.1°±2.2, P<0.054, Fig 3.4).  However, 
Inhibition of MAPK growth caused a switch in the turning effect in response to MTIII (-
13.2°±1.9 to +13.1°±3.7, P<0.0001, Fig 3.4).   This observation implicates very different 
signalling processes for MTII and MTIII.  The requirement of MAPK in response to MTIII 
and not MTII suggests that the binding of MTII and MTIII results in the recruitment of 
different co-receptors or phosphorylation events, thereby activating separate or additional 
downstream signalling pathways. 
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Figure 3.4 Inhibition of MAPK perturbed growth cone turning in response to LRP-MT 
Growth cone turning was measured in response to a chemical gradient of MTII and MTIII. 
(A) Average turning angles of growth cones in response to MTII and MTIII in the presence 
of MAPK inhibitor PD98059 demonstrate that the response of growth cones to MTII is 
unperturbed (although a reduced trend is appreciated), while MAPK inhibition reversed 
turning in response to MTIII.  (B) Axon extension for the same growth cones were analysed 
and did not differ significantly after 30 minutes of imaging. ****P<0.0001.  Error bars 
represent SEM.  Numbers within parentheses indicate the number of growth cones that were 
analysed per treatment group and apply to both (A) & (B).  
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3.3.5 Determine whether reduced expression of LRP1 or LRP2 alters the morphology of 
growth cones 
Reducing the expression of LRP1 or LRP2 in growth cones cultures yielded unexpected 
observations: anomalies in the morphology of growth cones. Fig 3.5 demonstrates the change 
in morphology after 6 hours of receptor knockdown.  After 6 hours, growth cone 
immunoreactivity for LRP1 and LRP2 was reduced by 75 and 73%, respectively, in 
conjunction with a significant concomitant decrease in growth cone area and filopodia 
number (Figure 3.5 A-C).  These findings suggested LRP1 and LRP2 mitigate a change in 
cytoskeletal or substrate interactions.  Due to the intimate relationship ascribed between 
LRP1 and focal adhesions (Orr et al., 2003), focal adhesion kinase (FAK) immunoreactivity 
was examined in control cultures and cultures with reduced LRP1 or LRP2 expression.  FAK 
immunoreactivity was reduced in growth cones with reduced LRP1 expression, but not 
reduced LRP2 expression.   Furthermore, a significant decrease in puncta size was observed 
in LRP1 KD growth cones (p<0.005) (puncta size analysis by R. Gasperini), suggesting that 
LRP1 signalling is important for assembly of FAK-immunopositive puncta in navigating 
growth cones.  Furthermore, the observation that reduced LRP2 expression was associated 
with reduced area and filopodia number suggest a possible undocumented direct interaction 
with focal adhesions, or modulation of focal adhesions indirectly through LRP1. 
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Figure 3.5.  Reducing LRP1 or LRP2 expression changed morphology of growth cones. 
(A-D) Quantification of growth cones with reduced LRP1 and LRP2, compared to growth 
cones with control siRNA.  (A) Significant decrease in LRP1 and LRP2 immunoreactivity in 
growth cones with reduced LRP1 and LRP2 expression (B) Reduction of LRP1 or LRP2 
results in a significant decrease in growth cone size. (C) Reduction of LRP1 or LRP2 results 
in a significant decrease in the number of filopodia per growth cone. (n = 5 cultures, 15-30 
growth cones). (D) Significant decrease in the average number of FAK positive puncta per 
µm
2
 per growth cone in growth cones with reduced LRP1 expression. (E-G) Representative 
images of growth cones 6 hours after siRNA transfection. (E) FAK immunopositive puncta in 
control growth cones. (F) Reduced FAK immunopositive puncta per µm
2
 in growth cones 
with reduced LRP1. (G) FAK immunopositive puncta in growth cones with reduced LRP2. 
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3.4 DISCUSSION  
In Chapter 2, it was identified that LRP-MTII induced growth cone attraction, whereas LRP-
MTIII induced potent growth cone repulsion.  Consistent with the contrasting effects of MTII 
and MTIII, in Chapter 3, a divergence in their downstream signalling pathways was 
established.  While both MTII and MTIII signalled in a Ca
2+-
dependent manner, MTII 
signalling occurred through established Ca
2+
 signalling pathways, MTIII chemorepulsion was 
dependent on kinase activity. 
In growth cone chemotaxis, receptor activation results in the initiation of a downstream 
intracellular cascade, culminating in cytoskeletal reorganisation and orientation of the growth 
cone towards or away from the trophic molecule.  In the majority of instances, calcium ions 
(Ca
2+
) are an important intracellular mediator of this process (Tojima, 2012).  LRP ligands 
such as tPa and α2m have been shown to induce calcium influxes in neurons (Bacskai et al., 
2000, Samson et al., 2008).  Spatial and temporal fluxes of intracellular Ca
2+
 concentration 
([Ca
2+
]i) in the growth cone are able to trigger both attraction to and repulsion from 
chemotactic agents (Zheng, 2000).  This is in part due to the activation of differentially 
sensitive calcium-dependent binding proteins, such as CaN and CaMKII (Wen et al., 2004, 
Gomez and Zheng, 2006).  Both MTII and MTIII were dependent on an influx of 
extracellular Ca
2+
 ions for initiation of chemotactic effects on growth cones.  When Ca
2+
 ions 
were reduced, a directional switch was observed in response to MTII and MTIII.  MTII, 
which was inherently attractive, caused growth cone repulsion in the presence of low 
extracellular calcium.  This phenomenon was consistent with the CaN/CaMKII switch 
reported by Wen and associates (2004).  CaN is highly sensitive to Ca
2+ 
and mediates growth 
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cone repulsion; where the influx of [Ca
2+
]i in response to a chemotrophic cue is modest, the 
growth cone will be repelled. Conversely, if the influx is large, CaMKII tends to be activated 
preferentially, resulting in attraction.  As global intracellular calcium levels had been reduced 
by the use of low-Ca
2+
 media, and the extracellular concentration of Ca
2+
 was low, it is likely 
that the change in [Ca
2+
]I was only small, hence the CaN pathway was activated 
preferentially.   
To confirm involvement of the CaN/CaMKII switch, inhibitor of CaMKII, KN93, was added 
to the media, and the effect on MTII-mediated growth cone turning was assessed.  Inhibition 
of CaMKII reversed MTII-mediated chemotaxis. This may indicate that in the absence of 
CaMKII activation the repulsive CaN-mediated pathway was initiated.  This data is in part 
supported by the finding that CaMKII is activated in response to MTII application, and 
CaMKII inhibition blocks MT-II mediated neuroprotection and neurite outgrowth (Asmussen 
et al., 2009b).   
Given the established role of CaMKII in attractive growth cone turning, inhibition of CaMKII 
was not predicted to have an effect on repulsive LRP-MTIII signalling.  However, CaMKII is 
known to bind LRP-1, although the functional significance of this relationship is unknown 
(Guttman et al., 2010).  A direct interaction of LRP1 and CaMKII may explain why 
inhibition of CaMKII reversed turning in response to MTIII.  For example, in LRP-MTIII 
signalling, CaMKII may be recruited to the receptor complex, where it facilitates 
phosphorylation of other co-receptors.  The ability of CaMKII to activate the cytoskeletal 
processes that direct growth cone turning may represent a direct link between LRP1 and 
growth cone motility. 
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The requirement of Ca
2+ 
channels in MTII-mediated growth cone attraction was also 
investigated. SKF95365 is a non-selective inhibitor of Ca
2+ 
entry via most TRP channels, and 
some voltage gated Ca
2+
 channels (Merritt et al., 1990, Kiselyov et al., 1998, Singh et al., 
2010). TRP channels comprise 6 subfamilies, including TRP canonical (TRPC), TRP 
vanilloid (TRPV), TRP melastatin (TRPM) and TRP ankyrin (TRPA).  TRP channels have 
been implicated in growth cone turning in response to several guidance cues: for example, 
BDNF, a chemoattractive guidance cue that signals through TrkB, has been demonstrated to 
require TRPC to elicit this effect in growth cones (Li et al., 2005).  However, addition of 
SKF95365 did not affect the turning response of growth cones to MTII, suggesting 
involvement of other calcium channels. It is possible that the Ca
2+
 influx required for MTII-
mediated growth cone attraction may involve, for example, TRPA or NMDA channels.  A 
recent study has suggested that MTIII is able to activate TRPA directly (Ghasemlou et al., 
2012); furthermore SKF95365 has not been shown to inhibit TRPA, revealing this as a 
promising candidate.  Furthermore, there is ample evidence demonstrating the involvement of 
LRP1 in Ca
2+
 influx via NMDA receptors (Qiu et al., 2002a, Martin et al., 2008, Maier et al., 
2013, Mantuano et al., 2013, Nakajima et al., 2013). Although NMDA receptors are not 
established mediators of growth cone guidance in mammalian DRG neurons, they have been 
shown to mediate growth cone guidance in Xenopus spinal neurons (Zheng et al., 1996). 
NMDA receptors are present and functional in DRG (Liu et al., 1997, Coggeshall and 
Carlton, 1998, Kung et al., 2013), and as such this adds weight to a possible novel 
mechanism involving NMDA receptors in mammalian growth cone navigation. 
MTIII-mediated chemorepulsion was switched from repulsion to attraction in Ca
2+
 depleted 
media.  Although it is unlikely that the classical CaN/CaMKII molecular switch accounts for 
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this response, cyclic nucleotides (cAMP and cGMP) can be modulated by Ca
2+
 levels and 
have also been determined as downstream effectors of growth cone turning (Nishiyama et al., 
2003).  Together, Ca
2+ 
and cyclic nucleotides are crucial for growth cone turning (Togashi et 
al., 2008, Akiyama et al., 2009).
 
Differences in cAMP:cGMP can dictate the turning response 
of a growth cone, such that when the local ratio of cGMP to cAMP is high, neurites are 
repulsed, but when the ratio is low, neurites are attracted (Wen et al., 2004).  It is known that 
Ca
2+  
signalling is able to interact with cyclic nucleotide ratios by controlling adenylate 
cyclase and guanylyl cyclases, which generate cAMP and cGMP, respectively (Lolley and 
Racz, 1982, Koch and Stryer, 1988, Xia and Storm, 1997). Activation of cAMP or cGMP 
pathways results in reciprocal inhibition, such that elevated cAMP reduces cGMP levels and 
vice versa, by phosphodiesterase activity (Shelly et al., 2010). The switching phenomenon in 
LRP-MTIII signalling is potentially due to spatial and temporal shifts in the ratio of cyclic 
nucleotides in the growth cone, which is perturbed when using various Ca
2+ 
channel and 
binding protein inhibitors.  
The involvement of TrkA in the trophic responses elicited by MTs was examined. It has been 
established that TrkA can be transactivated by LRP-1 (Shi et al., 2009). Given that inhibition 
of TrkA with K252a alters the response of growth cones to MTII or MTIII, we propose that 
LRP-mediated chemoattraction occurs via a TrkA-dependent mechanism.  LRP-MTII 
mediated growth cone turning was switched after TrkA inhibition, suggesting that TrkA 
activation occurs downstream of LRP1/2 signalling.   However, inhibition of TrkA abolished 
the turning response of growth cones to MTIII, which may suggest that TrkA has a primary 
role in MTIII signalling, with crosstalk occurring between TrkA, LRP1 and LRP2.  It has 
been previously demonstrated that MTIII interacts directly with TrkA (Kim et al., 2009), and 
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these findings support these observations. Furthermore, LRP2 has been shown to sequester 
ligands such as sonic hedgehog to facilitate binding of sonic hedgehog to its co-receptor 
(Christ et al., 2012).  It is possible that a similar mechanism is involved in LRP2/TrkA/LRP1 
signalling.  It is pertinent to mention that k252a, which is used as an inhibitor of TrkA, can 
also inhibit tyrosine kinase phosphorylation and inhibits PKA and CaMKII at the 
concentration used.  It is therefore possible that the results observed are due to manipulation 
of the LRP-MTII downstream signalling pathways, rather than purely a blockade of TrkA 
signalling.  Future work would require the use of more specific inhibitors.  The potential LRP 
signalling pathways are summarised in Fig 3.6 and 3.7. 
Unexpectedly, LRP1 and LRP2 deficient growth cones were found to be significantly smaller 
and less dense in filopodia (all P<0.0001), suggesting an undefined role for LRPs in growth 
cone morphology. Given that growth cones with reduced expression of both LRP1 and LRP2 
behaved normally in response to non-LRP dependent guidance cue Netrin, (see Fig 2.5), the 
change in morphology likely did not have functional consequences in growth cone motility in 
response to soluble guidance cues.  A decrease in lamellipodia has been reported after LRP1 
knockdown in smooth muscle cells, although an increase has been reported in Schwann cells, 
so the effect on lamellipodia is likely cell-type specific (Mantuano et al., 2010, Revuelta-
Lopez et al., 2013). LRP1 and LRP2 have important roles in lipid and cholesterol metabolism 
in the body (May et al., 2005). Forebrain specific knockout of LRP1 is enough to disrupt the 
entire lipid balance in the brain and contribute to severe effects within neuronal function (Liu 
et al., 2010).  Therefore, the observation of small growth cones in LRP1 and LRP2 knock 
down neurons maybe due to disruption of membrane synthesis and composition. However, as 
cholesterol-rich lipid rafts are important for chemotropic guidance of neuronal growth cones, 
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if this was the case we would expect to see perturbed signalling to netrin as well (Guirland et 
al., 2004). Furthermore, LRP1 has been shown to act as a survival signal in cells (Yamauchi 
et al., 2013), and as such, its knockdown may reduce cell viability, reflected as a decrease in 
growth cone size.  Alternatively, the change in morphology may result from disruption of 
focal adhesions.  LRP1 associates with calreticulin, and through this interaction regulates the 
assembly of focal adhesions (Orr et al., 2003).  Focal adhesions are contact points between 
the cytoskeleton and the receptors binding the extracellular substrate and are well known to 
be vital for growth cone motility (Chang et al., 1995, Navarro and Rico, 2014).  LRP1, but 
not LRP2 knockdown growth cones, had a significant decrease in focal adhesion kinase 
puncta.  Fewer adhesions would help account for the decrease in growth cone size and 
filopodia.  The decrease in area and filopodia number in growth cones with reduced LRP2 
suggests a possible undocumented direct interaction between LRP2 and focal adhesions, or 
modulation of focal adhesions indirectly as a result of LRP1/LRP2 receptor crosstalk.  
The switch phenomenon is a recurrent theme with MTIII-mediated growth cone turning in 
the presence of all inhibitors and receptor knockdown methods used in this thesis (Fig 2.6, 
3.2, 3.3, 3.4).  The requirement of CaMKII and MAPK highlights the importance of 
phosphorylation events in this signalling cascade.  These findings suggest that the effect 
elicited by MTIII on ‘normal’ cells is likely a threshold dependent process, whereby a full 
strength signal is required to initiate chemorepulsion, whereas a partial signal activates a 
default attractive response.  This may have implications for physical or chemical neuronal 
injury, where the normal homeostatic balance of intracellular messengers and receptors 
becomes disrupted, allowing an individual protein to have a multifaceted response depending 
on the demands of the both the intra- and extracellular environment. 
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To the best of our knowledge, there is no prior evidence of a mechanism by which LRP1 and 
LRP2 promote growth cone motility. Based on evidence within this chapter, I have proposed 
the concept of LRP1 and LRP2 receptor crosstalk, and suggest their formation of a 
heterogeneous signalling hub with other co-receptors, including (but not necessarily limited 
to) TrkA.  Consistent with the contrasting effects of MTII and MTIII, this chapter reveals a 
disparity in their downstream signalling pathways.  For the first time, I provide evidence that 
MTIII-LRP signalling requires kinase activity, suggesting that phosphorylation is a key 
mediator of the downstream pathway.  MTII- and MTIII-LRP signalling requires Ca
2+
 and 
Ca
2+
 binding proteins, suggesting signalling via classical and non-classical signalling 
pathways. 
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Figure 3.6 Putative signalling pathway for MTII-LRP chemotaxis 
(A) MTII binds LRP1 and LRP2, which engage in receptor crosstalk, recruiting TrkA. This 
pathway likely activates Ca
2+
 channels and release of Ca
2+ 
from internal stores such as the 
endoplasmic reticulum (ER) resulting in a large change in intracellular Ca
2+ 
levels.  This 
would activate CaMKII and culminate in growth cone attraction.  (B) In the event of a loss of 
LRP1 or LRP2, the receptor crosstalk cannot occur and thus there is no growth cone turning. 
If TrkA is inhibited, it is likely that a small influx of Ca
2+ 
occurs through a TrkA-independent 
LRP1/2 dependent process, activating CaN and the repulsive pathway. 
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Figure 3.7 Putative signalling pathway for MTIII-LRP chemotaxis 
MTIII likely initially interacts with TrkA, recruiting LRP1 and LRP2 or facilitating binding 
to LRP1 and LRP2. LRP1, LRP2 and TrkA engage in receptor crosstalk and likely recruit 
additional co-receptor/s. This pathway likely activates Ca
2+
 channels and results in a modest 
change in intracellular Ca
2+ 
levels.  This would activate CaN and the repulsive pathway.  
Phosphorylation of co-receptors or downstream signaling targets may be mediated by kinases 
including CaMKII and MAPK.  Furthermore, cGMP could contribute to this signalling 
pathway if produced by a co-receptor, creating a high cGMP:cAMP and propagating the 
repulsive pathway.  In the event that TrkA is lost, the receptor crosstalk cannot occur and 
there is no LRP-MTIII signalling.  LRP1 or LRP2 receptors are lost, the receptor crosstalk 
that would facilitate binding of an additional binding partner (which, for example, generated 
cGMP) is lost.  The pathway at present is difficult to consolidate and requires further 
investigation. 
3.5 CONCLUSION 
In the present study, for the first time, I have described the novel involvement of LRP1 and 
LRP2 in growth cone turning. Furthermore, I propose that LRP1 and LRP2 engage in 
receptor crosstalk.  Finally, I have identified a novel chemoattractive protein, MTII, which 
has therapeutic potential. Growth cone chemotaxis is a functionally important component of 
neuronal regeneration, as regrowth must be directed to the lesion site, so that appropriate 
sprouting and ultimately new connections can be re-formed.  Developing a method to 
regenerate and guide neurons after injury has been pursued by neuroscientists for decades.   
Damage to neural tissue in the CNS is virtually irreparable, and even in the PNS, the ability 
  
 
125  |     Chapter 3 
 
to repair and recover from damage is often limited. Therefore, therapeutic intervention to 
enhance repair of these tissues would have great implications in some neuropathies or in re-
innervating tissues after traumatic injury.  The involvement of MTs in recovery after CNS 
injury has been explored; for example, it is known that MTI/II are required for optimal 
recovery post-CNS injury (Giralt et al., 2002b).  Since the processes that are involved in 
neurite regeneration closely recapitulate those that occur during neurite outgrowth in 
development (Hoffmann, 1988), I hypothesise that the chemotactic effects of MTII may be 
applied to both developing peripheral neurons and peripheral axons that have re-sprouted 
during post-injury regeneration.  Whether MTII in the extracellular environment may support 
the regeneration of neurons into the site of injury in vivo remains unknown, and forms the 
basis of the following chapters within this thesis. Understanding the mechanisms by which 
MTII elicits this response in the neuronal growth cone offers the opportunity to not only use 
MTII itself, but also other agents that manipulate the same signal transduction pathways, as 
therapeutics for a wide range of peripheral nerve diseases and insults. 
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CHAPTER 4 
SITE-DIRECTED DELIVERY OF MTII AND SYNTHETIC MTII ANALOGUE, 
EMTINB, INTO THE SKIN. 
4.1 INTRODUCTION 
The overarching aim of the translational side of my project was to establish whether MTII 
and its synthetic analogue, EmtinB, could act as disease-modifying small molecules for small 
fibre peripheral neuropathies in vivo.  In order to test this hypothesis, I first must expose 
epidermal nerve fibre termini to MTII or EmtinB, and most preferably, do so in a fashion that 
produces a microgradient, in order to create an in vivo paradigm similar to conditions under 
which MTII stimulates chemoattraction of sensory neurites in vitro (Chapters 2-3).     
Small fibre peripheral neuropathies such as diabetic neuropathy are characterised 
histologically by the presence of aberrant nerve fibres which terminate prematurely beneath 
their correct anatomical location in the epidermis (as shown in Chapter 1, Fig 1.5), leading to 
the pain syndromes associated with the disease (Polydefkis et al., 2004, Shun et al., 2004). 
Diseases affecting the skin, including small fibre peripheral neuropathies, lend themselves to 
topical drug delivery approaches.  My hypothesis is that chemoattractive property of MTII 
observed in vitro (as shown in Chapter 2, Fig 2.2) may be present in vivo, thereby attracting 
regenerative growth of nerve fibres back into the correct anatomical location in the epidermis, 
ameliorating the pathology (Figure 4.1).  Furthermore, as previous work on MTII in sensory 
neurons and other neuronal types indicate a role of MTII in promoting axon extension 
(Fitzgerald et al., 2007, Ambjorn et al., 2008, Chung et al., 2008, Leung et al., 2012 ), I 
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hypothesise that an outcome of administration of MTII would include stimulation of axon 
outgrowth.  The finding that MTII is chemoattractive along a concentration gradient in vitro 
(Chapter 2, Fig 2.2) has implications for its mode of administration and delivery in vivo.  The 
aim was to dispense the MTII in a fashion that would result in a local concentration gradient 
being formed inwards from the outermost layer of the skin, and therefore represent the ideal 
system with which the chemotactic effect can be harnessed (as shown in Chapter 1, Fig 1.6).  
In order to establish whether MTII exerts chemotactic effects in vivo, it is first necessary to 
establish a means of delivery across the skin barrier into the epidermis in a manner that 
produces a concentration gradient.  
EmtinB is a synthetic analogue of MTII which retains neuroprotective and growth promoting 
properties (Ambjorn et al., 2008), but lacks chemotactic effects on the neuronal growth cone 
(Chapter 2, Fig 2.3).  The lack of chemotactic ability of EmtinB would allow a distinction 
between the effects of regeneration due to chemotactic guidance, versus growth promotion 
(exhibited by both EmtinB and MTII), to be elucidated in vivo, and therefore is included in 
this chapter. 
The most simple and obvious method would be to apply MTII topically.  A major function of 
skin is that of a protective barrier, with a lipid-rich, keratinised layer that is impervious to 
most molecules. Transdermal delivery of proteins has always been particularly challenging 
due to their physicochemical properties (Prausnitz and Langer 2008).  In order to successfully 
deliver MTII to the region of interest affected in small fibre peripheral neuropathies 
(epidermis and underlying dermis), a system is required to effectively transport small 
molecules across this barrier. The aim within this chapter is to establish a method for 
delivering MTII and EmtinB into the superficial layers of the skin in a manner that produced 
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a concentration gradient.  Several approaches were taken.  Initially, topical preparations using 
established carrier vehicles such as oleic acid and DMSO, which are known to enhance the 
penetration of many molecules topically (Benson, 2005), were trialled. A specialised carrier 
peptide, which was recently demonstrated to effectively transport green fluorescent protein 
into human cells (Liu et al., 2011, Liu et al., 2012), was also tested.  Iontophoresis was 
trialled as a non-invasive approach to deliver charged molecules (including proteins) into the 
skin using a low-intensity electric current (Prausnitz and Langer, 2008).   Finally, intradermal 
injection bypasses the stratum corneum, and was used as a robust technique for delivering 
MTII and EmtinB directly into the skin. 
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4.2 METHODS: 
4.2 1. Disclosure 
All rat procedures were conducted with the approval of the University of Tasmania Animal 
Ethics Committee (approval numbers #A13109 and #A11302), and are compliant with the 
Australian NHMRC Code of Practise for the Care and Use of Animals for Scientific 
Purposes.  Rats were supplied water, food ad libitum and had a 12 h light/dark cycle. 
4.2.2 Biotinylation of MTII and EmtinB 
This procedure was carried out using the ImmunoProbe Biotinylation Kit (Sigma-Aldrich, 
MO, USA) according to the supplier’s manual (all procedures and the respective results are 
shown in Appendix 2). Briefly, 10.8mg of EmtinB dimer was dissolved in 400µL of sterile 
PBS, and 5mg MTII was dissolved in 2mL basic PBS, pH9 (1 drop 1M NaOH, Sigma-
Aldrich, MO, USA). Both EmtinB and MTII were prepared separately as follows. 5mg of 
biotinamidohexanoic acid 3-sulfo-N-hydroxysuccinimide ester were dissolved in 30µL of 
dimethyl sulfoxide (DMSO; Sigma-Aldrich, MO, USA) and 470µL of PBS (pH 7.4; 
comprising 10mM Na2HPO4, 1.8mM KH2PO4, 137mM NaCl and 2.7mM KCl, all from 
Sigma-Aldrich, MO, USA). The ester was then gently combined with MTII or EmtinB and 
incubated on a horizontal shaker in ice for 2 hours. To isolate the labelled protein, a 
sephadex-G25M column (Sigma-Aldrich, MO, USA) was equilibrated in 6 x 5mL of PBS 
(30mL total) and the reaction mixture was applied. The column was then eluted with 10x 
1mL PBS and collected in 1mL fractions.  Protein content in the fractions was measured 
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using a BCA protein assay, read on a microplate reader (TECAN GENios) at an absorbance 
of 562nm, and pooled. Biotinylation was confirmed according to manufacturer’s instructions. 
4.2.3 Preparation of skin 
Rats were anaesthetised under isofluorane (Piramal Healthcare limited, Mumbai, India), 
placed in the prone position on a heated pad (37°), and maintained under (2-3.5%) 
isofluorane inhalation.  Breathing and responsiveness was monitored closely through the 
duration of the experiment and the percentage of isofluorane adjusted accordingly. The dorsal 
region of the skin was shaved and depilatory cream applied for 5 minutes (or until depilation 
was complete when tested).  The depilatory cream was thoroughly removed with tissues 
moistened with water.  The final step of skin preparation involved consecutively applying and 
removing sticky tape (Scotch Tape, 3M, St. Paul, MN) applied to the surface of skin, twice in 
the same area. 
4.2.4 Topical application 
Skin was prepared as per section 4.2.3; however, depilatory cream was omitted from the 
procedure. 1cm
2
 regions of skin were demarcated and treated with 50µL of various topical 
preparations, for 20, 40 or 60 minutes.  Topical preparations were: (either combined with or 
without 1mg/mL MTII); water; 0.9% saline; 100% ethanol; 30% acetone/70% olive oil; lipid 
carrier Intralipid® 20%; 8% oleic acid/5%DMSO;  or 5% DMSO in saline (all supplied by 
Sigma-Aldrich, MO, USA). Furthermore, Intralipid® 20%; 8% oleic acid and 5% DMSO 
preparations were also trialled with 1mg/mL biotinylated MTII.  At the end of treatment (20, 
40 or 60 minutes), excess topical preparation was blotted.  The animal was immediately 
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euthanised by CO2 inhalation, with the skin harvested and placed in 4% paraformaldehyde as 
rapidly as possible. 
4.2.5 Topical application with carrier peptides 
Skin was prepared as per section 4.2.3; however, depilatory cream was omitted from the 
procedure. A cell penetrating peptide, HR9, (Genscript, NJ, USA) with the peptide sequence 
CHHHHHRRRRRRRRRHHHHHC, was combined with 1mg/mL Biotinylated MTII or 
1mg/mL biotinylated EmtinB in PBS, in either a 1:3 or 1:6 molecular ratio of Protein:HR9, 
and placed on a rotator at room temperature for 1h.  This preparation was then used 
immediately, as per the topical application protocol described above. Briefly, 1cm
2
 regions of 
skin were demarcated and treated with 50µL of biotinylated MTII:HR9 1:3, Biotinylated 
MTII:HR9 1:6, biotinylated EmtinB:HR9 1:3, or biotinylated EmtinB:HR9 1:6, for 20, 40 or 
60 minutes.  At the end of treatment, excess topical preparation was blotted.  The animal was 
immediately euthanised by CO2 inhalation, with the skin harvested and placed in 4% 
paraformaldehyde as rapidly as possible. 
4.2.6 Iontophoresis 
Skin was prepared as per section 4.2.3. Skin from the thoracolumbar dorsal region of rats was 
shaved and hair removal cream applied for 5 minutes or until depilation was complete.  The 
hair removal cream was then removed and the area cleaned with tissues saturated with warm 
water, followed by a final wipe with sterile ethanol sheets. Skin was allowed to dry before 
proceeding. Iontophoresis experiments were performed in vivo using iontophoresis rig 
MIC2™ (Moor Instruments, Devon, UK). An electrode (connected to either the positive or 
negative pole) was placed approximately 5 cm from the iontophoresis chambers (connected 
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to the negative or positive pole, respectively).  Both the electrode and the iontophoresis 
chambers were placed on the same side of the animal, to avoid the conducted charge crossing 
the heart.  Iontophoresis was performed using 1mg/ml MTII in either MQ water, NaCl 0.9% 
or NaCl 0.9%/5%DMSO solution.  Iontophoresis was performed with a current intensity set 
at 100µA, at a rate of one 20second pulse per minute (and either 10 or 20 pulses).  
4.2.7 Intradermal injection 
Skin was prepared as per section 4.2.3; however, depilatory cream was omitted from the 
procedure. A 31G needle filled with 1mg/mL biotinylated-MTII was placed bevel side down 
and inserted into the skin at a shallow angle (approximately 5° to the skin surface).  As the 
epidermis and underlying dermis is only 1-2mm thick, as soon as resistance from the skin 
was felt, the needle had penetrated the skin sufficiently. At this point, the depth was 
appropriate to successfully inject intradermally, with 25ul deposited at each injection site.   
4.2.8 Tissue processing 
Skin sheets were harvested and fixed in 4% PFA (Sigma-Aldrich, MO, USA) in PBS (pH 7.4; 
comprising 10mM Na2HPO4, 1.8mM KH2PO4, 137mM NaCl and 2.7mM KCl, all from 
Sigma, MO, USA) at 4°C for 2 hours.  Post fixation, tissue was washed several times in PBS. 
Samples were then cryoprotected with 30% sucrose in PBS pH7.4 until samples sank into the 
liquid.  Tissue was then embedded in optimal cutting temperature compound (ThermoFisher 
Scientific, MA, USA) at -25°C. 50-µm cryosections were obtained in a Leica CM1850UV 
sliding microtome (Wetzlar, Germany). To ensure adequate sampling, each slide contained 
several sections, each with profiles from different regions of the same sample.   Prepared 
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slides were dried overnight at 37°C.  Excess OCT was removed with PBS prior to 
immunolabelling. 
4.2.9 Fluorescence immunohistochemistry 
Samples were permeabilised in 0.4% Triton-X (Sigma-Aldrich, MO, USA) in PBS for 4 
hours, before being transferred to 5% goat serum in PBS blocking agent for 30 minutes. 
Samples were then incubated overnight at 4°C with either mouse anti-Metallothionein 
antibody (1:200, Dako, Glostrup, Denmark) diluted in PBS with 5% goat serum (Invitrogen, 
ThermoFisher Scientific, MA, USA) or Alexa 488 conjugated-streptavidin (1:1000, 
Molecular probes, OR, USA), depending on whether the sample used MTII or biotinylated 
MTII, respectively.  Controls for immunolabelling were performed by using untreated tissue.  
After washing in 0.5 M Tris buffer (pH 7.4; 50mM Tris and 150mM NaCl, both from Sigma, 
MO, USA), the cells treated with anti-metallothionein antibody were incubated with the 
secondary antibody, fluorescent Alexa 488-conjugated goat anti mouse (1:1000, Molecular 
Probes, OR, USA), in the dark, overnight at 4°C, or at room temperature for 4 hours. Tissue 
sections were washed in Tris pH 7.4 and allowed to dry, then mounted with DPX fluorescent 
mounting media (Koch-Light Laboratories, England, UK). 
4.2.10 Fluorescence microscope image acquisition 
Fluorescence images were acquired using an Olympus BX50 microscope, equipped with a 
UP-lanSApo 40x-1.35 lens (Olympus, Tokyo, Japan), and captured with MagnaFire V2.1c 
(Optronics, CA, USA), with a cooled CCD camera (Optronics, CA, USA).  During image 
capture the exposure time was set so that cells would not be over exposed and the pixels not 
saturated, to produce the most natural depiction of the area of interest.  All images were 
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captured with the same exposure. Images were processed using Image J (NIH, MD, USA) 
and JASC Paint Shop Pro V 9.0 (JASC Software Inc., MN, USA). 
4.2.11 Chromogenic immunohistochemistry 
Samples were permeabilised in 0.4% Triton-X (Sigma-Aldrich, MO, USA) in PBS for 4 
hours, before being transferred to 5% goat serum in PBS blocking agent for 30 minutes. 
Samples were then incubated overnight at 4°C with either mouse anti-Metallothionein 
antibody (1:200, Dako, Glostrup, Denmark) diluted in PBS with 5% goat serum (Invitrogen, 
ThermoFisher Scientific, MA, USA) or HRP-streptavidin (1:1000, Molecular probes, OR, 
USA), depending on whether the sample used MTII or biotinylated MTII, respectively.  
Controls for immunolabelling were performed by using untreated tissue.  After washing in 
Tris buffer, the cells treated with anti-metallothionein antibody were incubated with the 
secondary antibody, or HRP-streptavidin (1:1000, Molecular probes, OR, USA), overnight at 
4°C, or at room temperature for 4 hours. Tissue sections were washed in Tris buffer, then 
exposed to DAB substrate (Vector Laboratories, CA, USA), and counterstained with 
haematoxylin or nuclear fast red.  Tissue sections were washed in Tris buffer and allowed to 
dry, then mounted with Pertex mounting media (ThermoFisher Scientific, MA, USA). 
4.2.12 Light microscope image acquisition and analysis 
Fluorescence images were acquired using a Leica DM2500 microscope  (Leica 
Microsystems, Wetzlar, Germany), equipped with a Leica HC-PL FLUOTAR 40x lens, and 
captured with Leica ApplicationSuite software with a Leica DFC495 camera.  During image 
capture the exposure time was set so that cells would not be over exposed and the pixels not 
saturated, to produce the most natural depiction of the area of interest.  All images were 
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captured with the same exposure. Images were processed using Image J (NIH, MD, USA) 
and JASC Paint Shop Pro V 9.0 (JASC Software Inc., MN, USA). 
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RESULTS: 
4.3.1 Intradermal injection 
Intradermal delivery was used as a positive control for the direct administration of MTII and 
EmtinB to the epidermis and dermis. Rat skin was injected with MTII, biotinylated MTII or 
biotinylated EmtinB.  The presence of biotin was detected using both chromogenic and 
fluorescent staining (Fig 4.1). Strong positive staining for MTII, biotinylated MTII and 
biotinylated EmtinB was detected within the epidermis, dermis, and diffused into the 
underlying subcutaneous tissues. Biotinylated protein was used as it allowed the 
differentiation of endogenous and injected MTII; EmtinB was biotinylated to facilitate 
detection as there is no antibody for EmtinB.  Negative control tissue was injected with saline 
only and demonstrated almost negligible levels of endogenous MT (primarily localised to 
hair follicle) and undetectable levels of endogenous biotin.  Autofluorescence was detected in 
the stratum corneum (the outer layer of the skin) of all sections viewed under green 
fluorescence.  These data demonstrate that intradermal injection is a robust delivery method 
for MTII and EmtinB. 
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Figure 4.1. Rat skin with 25ul intradermal injection of biotinylated MTII and MTII  
Dorsal skin (A) injected with saline; brown DAB staining endogenous MTII, indicating 
background levels of staining. (B) Injected with saline; green fluorescent staining indicating 
background levels of MTII and autofluorescence.  (C)  Injected with 25uL bolus of 1mg/mL 
biotinylated MTII. Brown DAB staining indicating presence of MTII (D) Injected with 
biotinylated MTII bolus. Green fluorescent staining indicating presence of exogenous and 
endogenous MTII. (E-G)  Injected with 25uL bolus of 1mg/mL MTII. Brown DAB staining 
indicating presence of excess MTII.  A gradient of MTII expression into the surrounding 
tissue is observed.  All panels represent distribution 20 minutes after injection. Scale bars are 
300µm. Scale bar in D applies to A-D, scale bar in F applies to E-F. 
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4.3.2 Topical application 
To investigate whether biotinylated MTII and biotinylated EmtinB could be delivered into the 
skin topically, formulations of MTII and EmtinB proteins were prepared. Preparations of 
MTII and EmtinB were formulated with agents known to enhance passage of proteins and 
peptides through the corneum stratum into deeper skin layers. 
Preparations of varying complexity were developed, initially using basic vehicles and carriers 
(water, ethanol and 30% acetone/70% olive oil) to deliver MTII into the skin.  Ethanol may 
enhance transdermal delivery by decreasing surface tension, allowing the solution to spread 
and absorb better.  Acetone/olive oil preparations deliver hydrophilic protein into the lipid 
phase – with lipid preparations being optimal for topical drug delivery.  However, after one 
hour of application, MTII was not detected in the deep epidermis or underlying dermis.  
Exogenous MTII was visualised as a crust on the stratum corneum, indicating failure to 
penetrate.  The findings demonstrated that these approaches were unable to deliver MTII into 
the skin (Fig 4.2).  
In an effort to improve MTII topical delivery, preparations were seeded with well-established 
chemical penetration enhancers, 5% dimethylsulphoxide (DMSO), Intralipid emulsion, and 
8% oleic acid.  Intralipid and oleic acid preparations were also combined with 5% DMSO, as 
this was required to make the preparation miscible with the hydrophilic MTII and EmtinB 
proteins. However, after one hour of application of 5% DMSO (only) preparations, 
exogenous EmtinB and MTII were observed within the stratum corneum and into the hair 
follicle shaft. No EmtinB or MTII were detected in the deep epidermis or underlying dermis 
after 1 hour of application.  EmtinB and MTII were detected within the epidermis and hair 
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follicle shaft only, suggesting that these approaches were unable to deliver EmtinB or MTII 
into the skin (Fig 4.3-4.4).  
Lipid preparations are much more likely to combine with endogenous lipids in the skin to 
facilitate transdermal delivery into the underlying tissue. Lipid emulsions have the ability to 
enhance permeation of MTII into the skin through two mechanisms: by carrying hydrophilic 
proteins (such as MTII) in a lipid shell, and through solubilisation of the lipid rich stratum 
corneum via surfactants inherently present in all emulsions.   Both oleic acid and Intralipid® 
appeared unable to deliver MTII into the underlying dermis (Fig 4.5-4.8), again, leaving a 
detectable crust of MTII and EmtinB on the skin surface.  As a result, different approaches 
for getting MTII and EmtinB into the skin were trialled (summarised in Table 4.1). 
Table 4.1. Summary of topical vehicles used and outcomes 
Vehicle/carrier MTII EmtinB 
H20 No increase in 
skin permeability 
 
Ethanol No increase in 
skin permeability 
 
30%Acetone/70%Ethanol No increase in 
skin permeability 
 
5% DMSO No increase in 
skin permeability 
No increase in skin 
permeability 
8% Oleic acid/5% DMSO No increase in 
skin permeability 
No increase in skin 
permeability 
66% Intralipid/5% DMSO No increase in 
skin permeability 
No increase in skin 
permeability 
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Figure 4.2  Water, ethanol and acetone/ethanol preparations are not suitable carriers for 
MTII.  
Representative images of dorsal skin (A) with no treatment. Brown DAB staining indicating 
presence of endogenous MTII.  (B) Injected with MTII. Brown DAB staining indicating 
presence of excess exogenous MTII.   (C)  MTII applied topically in water vehicle.  MTII is 
visualised above the stratum corneum. (D) MTII applied topically in ethanol vehicle.  MTII is 
visualised above the stratum corneum. (E) MTII applied topically in a 30% acetone/70% 
olive oil emulsion. All panels represent distribution 60 minutes after application. Counter 
stain is haematoxylin. Scale bar is 200um. 
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Figure 4.3. 5% w/w DMSO is not an effective topical carrier for MTII after 1 hour of 
treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated MTII. Brown DAB staining indicating 
presence of excess exogenous MTII.   (D) Injected with 25uL bolus of 1mg/mL biotinylated 
MTII. Green fluorescent staining indicating background staining.  (E-J)  Biotinylated MTII 
applied topically in 5% DMSO vehicle for (E-F) 20 minutes (G-H) 40 minutes and (I-J) 60 
minutes.  Crust of biotinylated MTII visualised on stratum corneum.  Counter stain is Fast 
Red.  Scale bar is 200um and applies to all images. 
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Figure 4.4. 5% w/w DMSO is not an effective topical carrier for EmtinB after 1 hour of 
treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated EmtinB.   (D) Injected with 25uL bolus of 
1mg/mL biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-
J)  Biotinylated EmtinB applied topically in 5% DMSO vehicle for (E-F) 20 minutes (G-H) 
40 minutes and (I-J) 60 minutes.  Crust of biotinylated EmtinB visualised on stratum 
corneum.  Counter stain is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.5. 8% w/w Oleic acid/5%DMSO is not an effective topical carrier for MTII after 1 
hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated MTII. Brown DAB indicating presence 
of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated MTII. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated MTII applied topically in 8% oleic acid/5% DMSO vehicle for (E-F) 20 minutes 
(G-H) 40 minutes and (I-J) 60 minutes.  Crust of biotinylated MTII visualised on stratum 
corneum.  Counter stain is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.6. 8% w/w Oleic acid/5%DMSO is not an effective topical carrier for EmtinB 
after 1 hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated EmtinB.   (D) Injected with 25uL bolus of 
1mg/mL biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-
J)  Biotinylated EmtinB applied topically in 8% oleic acid/5% DMSO vehicle for (E-F) 20 
minutes (G-H) 40 minutes and (I-J) 60 minutes.  Although there appeared to be an increase 
in EmtinB positive staining in image (I), this was not corroborated with the respective 
fluorescence image (J).  Crust of biotinylated EmtinB visualised on stratum corneum.  
Counter stain is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.7. Intralipid is not an effective topical carrier for MTII after 1 hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated MTII. Brown DAB indicating presence 
of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated MTII. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated MTII applied topically in 66% Intralipid/5% DMSO vehicle for (E-F) 20 
minutes (G-H) 40 minutes and (I-J) 60 minutes.  Crust of biotinylated MTII visualised on 
stratum corneum.  Counter stain is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.8. Intralipid is not an effective topical carrier for EmtinB after 1 hour of 
treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated EmtinB applied topically in 66% Intralipid/5% DMSO vehicle for (E-F) 20 
minutes (G-H) 40 minutes and (I-J) 60 minutes.  Crust of biotinylated EmtinB visualised on 
stratum corneum.  Counter stain is Fast Red.  Scale bar is 200um and applies to all images. 
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4.3.3 Topical application with cell penetrating peptides (HR9 peptide) 
Cell penetrating peptides (also known as protein transduction domains), have been 
demonstrated to effectively deliver molecules into the skin through an as yet undetermined 
mechanism (Vasconcelos et al., 2013). To determine whether cell penetrating peptides could 
serve as carriers for MTII and EmtinB topically, the ability of the HR9 peptide to facilitate 
transport of MTII and EmtinB across rat skin was tested. HR9 peptide was chosen in favour 
of the well described cell penetrating peptide, TAT, for several reasons.  MT-TAT fusion 
proteins have limited ability to cross lipid bilayers (Lim et al., 2010, Park et al., 2011).  
Furthermore, Liu and colleagues have reported that TAT-mediated uptake of HIV-1 virus via 
LRP1 inhibits binding, uptake and degradation of physiological ligands for LRP, including 
α2M, and thus may have off target effects (Liu et al., 2000b).  The dorsal region of rats were 
treated with 1cm
2
 regions of biotinylated EmtinB or biotinylated MTII with either 1:3 (Fig 
4.0-4.10) or 1:6 ratio (Fig 4.11-4.12)  of protein:HR9, for 20, 40 or 60 minutes. Tissue was 
examined by light and fluorescent microscopy. Although this preparation was rapidly 
absorbed into the skin (15 minutes), the skin treated with all formulations resulted in 
fluorescence in the stratum corneum only. These results demonstrated that the HR9 protein 
carrier was unable to deliver EmtinB or MTII to the skin when combined non-covalently and 
applied for at least 60 minutes.  Further work may be required trialling these protein carrier 
mixtures combined with penetration enhancers such as oleic acid. 
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Figure 4.9. MTII:HR9 (1:3) is not an effective after 1 hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated MTII:HR9 (1:3) applied topically in for (E-F) 20 minutes (G-H) 40 minutes and 
(I-J) 60 minutes.  Crust of biotinylated EmtinB visualised on stratum corneum.  Counter stain 
is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.10. EmtinB:HR9 (1:3) is not an effective after 1 hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated EmtinB:HR9 (1:3) applied topically in for (E-F) 20 minutes (G-H) 40 minutes 
and (I-J) 60 minutes.  Crust of biotinylated EmtinB visualised on stratum corneum.  Counter 
stain is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.11. MTII:HR9 (1:6) is not an effective after 1 hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated MTII:HR9 (1:6) applied topically in for (E-F) 20 minutes (G-H) 40 minutes and 
(I-J) 60 minutes.  Crust of biotinylated EmtinB visualised on stratum corneum.  Counter stain 
is Fast Red.  Scale bar is 200um and applies to all images. 
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Figure 4.12. EmtinB:HR9 (1:6) is not an effective after 1 hour of treatment 
Representative images of dorsal skin (A) Injected with saline. Brown DAB indicating 
background levels of staining from endogenous biotins.  (B) Injected with saline. Green 
fluorescence indicating background staining and autofluorescence of the stratum corneum.  
(C) Injected with 25uL bolus of 1mg/mL biotinylated EmtinB. Brown DAB indicating 
presence of excess exogenous biotinylated MTII.   (D) Injected with 25uL bolus of 1mg/mL 
biotinylated EmtinB. Green fluorescent staining indicating background staining.  (E-J)  
Biotinylated EmtinB:HR9 (1:6) applied topically in for (E-F) 20 minutes (G-H) 40 minutes 
and (I-J) 60 minutes.  Crust of biotinylated EmtinB visualised on stratum corneum.  Counter 
stain is Fast Red.  Scale bar is 200um and applies to all images. 
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4.3.4 Iontophoresis 
Iontophoresis provides an electrical force for transport of charged molecules through the 
stratum corneum into the underlying epidermis and dermis, and is used experimentally and 
clinically to treat a number of indications.  For example, in 1995 iontophoresis of 
Lidocaine/epinephrine (Iontocaine®) for local dermal analgesia was patented (Prausnitz and 
Langer, 2008). The objective of this experiment was to determine the efficacy of 
iontophoretic transfer of biotinylated MTII into rat skin. 
Iontophoresis of the rat dorsum was well tolerated, with no sign of irritation or erythema 
observed after applying the iontophoretic well.  Anodal and cathodal iontophoresis was 
applied for 10 or 20 minutes, with 1x20 second 100mV pulse per minute (Fig 4.14).  Given 
that MTII has 8 positively charged amino acid residues (Arg + Lys), and contains 4 
negatively charged residues (Asp + Glu) within the core of the proteins secondary structure, 
the overall charge of MTII is positive.  However, MTII has a net negative charge when bound 
to zinc ions, due to ionisation of cysteine residues.  Given that net charge of MTII can vary 
according to metallation status and pH, both anodic and cathodic iontophoresis was 
examined.  No clear evidence of biotinylated MTII delivery into in the skin was observed, 
with positive staining for biotinylated MT both absent from the dermis and lower epidermis, 
and only observed as a film on the surface of the stratum corneum. 
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Figure 4.13.  Iontophoresis is unable to deliver biotinylated MTII into the skin at the 
parameters tested. 
Representative images of dorsal skin treated with iontophoretic delivery of biotinylated MTII 
in 0.9% saline. (A) Cathodic delivery of MTII, performed with 10x 100V pulses, each of 20 
second duration, over 10 minutes. (B) Cathodic delivery of MTII, performed with 20x 100V 
pulses, each of 20 second duration, over 10 minutes.  (C) Anode delivery of MTII,  
performed with 10x 100V pulses, each of 20 second duration, over 10 minutes (D) Anodic 
delivery of MTII, performed with 20x 100V pulses, each of 20 second duration, over 10 
minutes. Counter stain is Fast Red.  Scale bar is 200µm and applies to all images. 
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4.3.5 Intradermal injection 
Given the failure or unsuitability of the other approaches trialled, intradermal injection was 
investigated in more detail.  India ink was injected intradermally to visualise the spread of an 
injection bolus.  All injections raised a small lump, but this lump appeared to be absorbed 
into the surrounding tissue within 40 minutes.  India ink was clearly observed 
macroscopically and measured with a ruler.  A 25µl injection of india ink formed an initial 
bolus of 3 mm diameter.  30 min later, the bolus spread 5 mm.  A 50µl injection had an initial 
bolus of 5mm, which spread to a diameter of ~8mm 30 minutes later.  However, this diameter 
was irregular.  75µl bolus created a large amount of tissue distortion, raising a large, hard 
greyish lump that was likely impeding vascular flow to the area, and was therefore deemed 
unsuitable and not investigated any further. Given the greater predictability of spread for a 
25µl bolus, and the likelihood of this volume causing the least tissue disruption, this volume 
was used for further investigations (summarised in Table 4.2). 
Table 4.2. Visualised spread of india ink intradermal injection 
 
Bolus volume 
 
Initial diameter 
when injected 
intradermally (mm) 
 
 
Diameter 30 minutes after 
injection (mm) 
25µl 3 5 
50µl 5 7-9 (irregular) 
 
75µl 
9 
Bolus created large, 
hard lump 
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4.4 DISCUSSION 
 
The primary objective of this chapter was to develop a reproducible method of topical MTII 
and EmtinB delivery into the epidermis and underlying dermis of experimental animals, such 
that a concentration gradient forms from the outer to the deeper layers of the skin.  Methods 
examined included topical administration, including the use of penetration enhancers such as 
carrier peptides; Iontophoresis; and finally, direct intradermal injection.  The latter method 
provided the only robust and reproducible technique for administering MTII and EmtinB, 
although the potential exists for further optimisation of the other techniques.   
 
The results demonstrate that all the topical approaches trialled were ineffective at transdermal 
delivery of MTII and EmtinB into the epidermis and underlying dermis, at the timepoints and 
concentrations tested.   Lipophilic molecules have significantly higher success through 
transdermal drug delivery approaches, due to the nature of skin itself being lipid rich and 
having hydrophobic properties (Benson, 2005).  The grand average of hydropathicity 
(GRAVY) index indicates solubility of a protein, where a positive index indicates that the 
protein is hydrophilic, and a negative indicating hydrophobicity (or lipophilic nature) 
(Gasteiger et al., 2005). MTII has a GRAVY index of 0.131, meaning it is hydrophilic and 
therefore less amenable to transdermal delivery approaches (Gasteiger et al., 2005). The 
physicochemical properties of EmtinB have not been fully investigated, and therefore elude 
further comment. 
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Multiple preparations with and without chemical enhancers were used in an attempt to deliver 
MTII into the skin.   Carrier peptides have been previously established to deliver proteins into 
the skin rapidly (within minutes). The archetypal cell penetrating peptide, TAT, derived from 
HIV-1 virus, is widely exploited experimentally for its cell penetrating properties, but as it is 
known to reduce binding of LRP1 ligands it was not an appropriate candidate for MTII (Liu 
et al., 2000b).  Unexpectedly, the use of carrier peptides did not prove effective at delivering 
MTII or EmtinB transdermally, despite brisk absorption of the bulk of the preparation into 
the skin.  It has been previously demonstrated that the carrier peptide used in this study, 
histidine-rich nona-arginine (HR9), was able to deliver green fluorescent protein (GFP) into 
human cells with high efficacy in vitro (Liu et al., 2011, Liu et al., 2012), with similar 
peptides of even lesser efficacy tested in this in vitro approach (serine-rich nona-arginine) 
being able to deliver GFP into mouse skin in vivo (Hou et al., 2007).  Given that MTII is a 
quarter of the size of GFP (Yang et al., 1996), one might have predicted a much higher 
success rate at transdermal delivery using this technique.  However, it must be noted that 
GFP is hydrophobic (Yang et al., 1996), whereas, MTII is hydrophilic: this may be sufficient 
to cause the discrepancy between transdermal delivery successes. 
 
Iontophoresis is a non-invasive approach with the particular advantage of allowing the 
delivery of hydrophilic and charged drugs into the skin to be adjusted in real time.  Although 
the charge of MTII can vary depending on pH and metallation state,  it is likely that MTII has 
a negative charge overall. Negatively charged MTII may be repelled into the skin under the 
direct influence of the electric field of the cathode, or alternatively may be carried in solution 
with positively charged molecules at the anode, in a process called electro-osmosis. The 
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hydrophilic nature of MTII was likely sufficient in preventing the anode from effective 
transdermal delivery of MTII during Iontophoresis.  Iontophoresis may be affected by many 
factors, including the pH of the solution, skin temperature, physicochemical properties of the 
compound delivered (and its formulation), and the current strength (Dixit et al., 2007).  Only 
two sets of parameters were tested in this study and perhaps other permutations of voltage 
and time may have been successful at delivering MT or EmtinB into the epidermis.   
 
An important consideration regarding all transdermal drug delivery assessment is that the 
clearance of some molecules from the dermis may be rapid (Roustit et al., 2009), whereas 
others may remain for several days (Siddoju et al., 2011), and the speed at which clearance 
occurs is likely a function of blood flow and activity.  Therefore, it is possible that small 
amounts of MT or EmtinB entered the skin using the aforementioned approaches, but were 
cleared quickly (however the strong presence of MTII in the skin 60 minutes after 
intradermal injection, as seen in Fig 4.1 may suggest otherwise).  Alternatively, 
immunohistochemical techniques used in this chapter may have insufficient sensitivity to 
detect very low concentrations of MTII or EmtinB. 
 
The results demonstrate that all the non-invasive topical approaches trialled were ineffective 
at transdermal delivery of MTII and EmtinB into the epidermis and underlying dermis.  
However, intradermal injections were a reliable and robust approach, as they directly bypass 
the impervious stratum corneum and deliver a calculable set volume/concentration at the 
injection site.  However, as this method mechanically perforates skin, it may cause pain and 
localised trauma, and may result in the formation of scar tissue.  Of the approaches trialled, 
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intradermal injection is the most efficacious method for delivery of MTII and EmtinB into the 
superficial layers of the skin.  Given the kinetics of diffusion of india ink from the injection 
site, it is likely that 25ul injections of MTII or EmtinB 1cm apart will result in blanket 
coverage of the area treated.  Therefore, this will be the administration regime trialled in the 
investigations in the chapters to follow. 
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CHAPTER 5 
Development and characterisation of in vivo 
nerve injury models: Capsaicin-induced 
nerve retraction, diabetic neuropathy and 
focal denervation via blister formation 
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CHAPTER 5:  
DEVELOPMENT AND CHARACTERISATION OF IN VIVO NERVE INJURY MODELS:, 
CAPSAICIN-INDUCED NERVE RETRACTION, DIABETIC NEUROPATHY AND FOCAL 
DENERVATION VIA BLISTER FORMATION. 
5.1 INTRODUCTION 
Injuries to peripheral nerves (neuropathy) may result in the loss of motor, sensory and 
autonomic functions, or development of debilitating neuropathic pain distal to the injury site 
(Woolf and Salter, 2000).  These symptoms persist, as nerve regeneration after injury is often 
poor, absent, or aberrant (Flores et al., 2000).  Accurate nerve regeneration relies on directed 
guidance of regrowing axons to restore these connections (Alto et al., 2009).  In chapter 2 and 
3,  I demonstrated that the MTII-LRP signalling system is able to induce peripheral sensory 
neurite chemoattraction in vitro.  In this chapter, I propose to extend this work and 
demonstrate that MTII is a therapeutic candidate to guide regenerating neurons and repair 
nerves in peripheral neuropathy and traumatic denervation in vivo. 
The ultimate goal of this study is to establish the therapeutic value of MTII in diabetic 
peripheral neuropathy.  Diabetic peripheral neuropathy is developed as sequelae of diabetes 
mellitus and currently has no cure.  Resolution of the underlying disease (for example, by 
pancreatic islet transplant) has limited ability to reverse neuropathy in humans (Lee et al., 
2005), despite promising results in streptozotocin (STZ) induced diabetic rat models 
(Remuzzi et al., 2009, Figliuzzi et al., 2013). Although the exact pathogenesis of diabetic 
neuropathy is yet to reach scientific consensus, oxidative stress, excessive formation of 
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advanced-glycation end-products (AGEs), and deregulation of trophic factors are well 
established co-contributors. Furthermore, zinc dysregulation and deficiency is strongly 
implicated in diabetes and diabetic complications (Miao et al., 2013).  It has been proposed 
that targeting each of these individual pathogenic processes independently, is necessary to 
treat the disease (Farmer et al., 2012).  The indications for MTII as a candidate therapeutic in 
diabetic neuropathy are multifaceted; the work described earlier in this thesis demonstrates 
the ability of MTII to guide neuronal growth, and in addition, MTII is known to be a 
powerful antioxidant, to have protective roles against the effects of AGEs, to be 
neuroprotective, promotes neurite outgrowth and has essential roles in intracellular 
trafficking of zinc in vivo (Lim et al., 2008, West et al., 2008).  It has been reported that zinc 
has protective effects against the development of diabetic peripheral neuropathy in STZ-
diabetic rats via upregulation of MT (Liu et al., 2014).  Furthermore, MT and superoxide 
dismutase, when combined with cell penetrating peptides and delivered by intraperitoneal 
injection, delayed the development of diabetic neuropathy in Otsuka Long-Evans Tokushima 
fatty rats, a model of type 2 diabetes (Min et al., 2012).  The current body of knowledge thus 
strongly supports the therapeutic value of MTII in neuropathy; in particular, diabetic 
neuropathy. 
Normal skin is innervated by both unmyelinated and myelinated axons terminating in 
thermoreceptors, mechanoreceptors and nociceptors (Birder and Perl, 1994). Epidermal nerve 
fibres (ENFs) are primarily TRPV1+, unmyelinated C-fibres involved in thermal nociception, 
although lightly myelinated Aδ fibres are also present (Nolano et al., 1999, Malmberg et al., 
2004).  The cell bodies of these ENFs lie in the dorsal root ganglion.  TRPV1 cation channel 
positive neurons are particularly susceptible to stress-induced damage in diabetes (Hong and 
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Wiley, 2005), therefore it is not surprising that in diabetic neuropathy, a histological hallmark 
is significant loss of ENFs (Facer et al., 2007).  Damage to C-fibres is associated with the 
development of hyperalgesia, generalised pain and aberrant perception of temperature, 
whereas development of paresthesias (such as stabbing, burning or tingling sensations) and 
mechanical allodynia are largely associated with Aδ fibres (Tavee and Zhou, 2009).  One 
approach to ameliorating these symptoms is to restore ENF density, which may be possible if 
a chemotactic substance is applied topically, causing a directed regeneration of nerve fibres 
back into the epidermis.  However, this restoration of ENF density necessarily must be a 
tightly regulated process, as excess sprouting may result in hyperalgesia and/or allodynia 
(Taylor and Ribeiro-da-Silva, 2011).   
In this chapter, the aim was to examine the efficacy of MTII as a therapeutic agent in 
neuropathy and denervation in three different models, with changes in ENF density measured 
as the primary outcome.  The first model of nerve damage used chemically-induced 
denervation of the skin. Capsaicin is an agonist of TRPV1 cation channels, which are key 
mediators of pain in the C-fibre neurons which predominate within the epidermis (Caterina et 
al., 1997). Topical capsaicin treatment has been shown to cause a reversible retraction of 
TRPV1+ epidermal nerve fibres, which in humans regenerate after 50-100 days (Polydefkis 
et al., 2004, Anand and Bley, 2011).  Capsaicin is used clinically to ablate nerves in an 
excitotoxic fashion, thus reducing symptomatic pain in conditions such as post-herpetic 
neuralgia (Wallace and Pappagallo, 2011).  Topical capsaicin is also a validated experimental 
model of denervation (Rajan et al., 2003, Polydefkis et al., 2004, Ebenezer et al., 2011), that 
is highly reproducible and experimentally convenient model for screening the therapeutic 
effects of small molecules such as MTII. 
  
 
177  |     Chapter 5 
 
The second model of nerve damage, diabetic neuropathy, is clinically relevant.  Low-dose 
STZ-induced high-fat diet fed (HFD) rats are an experimental model of type 2 diabetes 
routinely used for testing anti diabetic agents (Reed, et al. 2000; Zhu, et al. 2010; Wang, et al. 
2009; Zhang, et al. 2008; Gaikwad, et al. 2007; Ding, et al. 2005).  STZ/HFD rats are ideal 
models because they develop complex pathophysiological sequelae that closely resemble 
symptoms of human disease, and include the common dietary confounder (a high fat diet). 
There is variability in the literature regarding the dose of STZ (“low dose” ranges between 
20-50mg/kg), the percentage of calories from fat in the diet (40-50%), as well as the age and 
species of the rat to best induce this model of diabetes (Reed et al., 2000, Islam and Choi, 
2007).  Experience from collaborators at our institute suggests that in Sprague-Dawley rats, a 
dual injection of 50mg/kg STZ, combined with a 23% fat diet (44% of calories from fat), 
produces a reproducible model of type II diabetes (Zhang et al., 2008). The STZ/HFD model 
develops mechanical allodynia and has a substantial loss of ENF secondary to characteristic 
insulin resistance, hyperglycemia and dyslipidemia (Reed et al., 2000).  
The final model is a novel technique that focally denervates the epidermis, by the formation 
of small blisters on the skin’s surface. Blisters separate the epidermis from the dermis directly 
along the basement membrane, dividing the two regions (Nanchahal and Riches, 1982).  
Within this void between dermis and epidermis lie the severed end terminals of ENFs which 
initially retract and form regenerative growth cones. Theoretically, it would be plausible to 
inject MTII into the void and thus directly to the site of interest, thereby creating a 
concentration gradient that could direct growth cone navigation.  Although the blister 
approach is not intended to be a viable drug delivery method in humans, it could serve as an 
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excellent “proof of concept” model for assessing the ability of MTII to direct the growth of 
growth cones on regenerating neurons in vivo (Fig 5.4)  
The efficacy of MTII in ameliorating denervation was measured by histological 
characterisation of skin biopsies, a method commonly used to evaluate nerve pathology and 
regeneration in both the experimental and clinical setting.   Punch biopsies allow for the 
evaluation of nerve branching, morphology, and density, as well as general skin architecture 
(Polydefkis et al., 2001).  Blister biopsies are a relatively new technique that is used to 
visualise the length of ENFs, and can be used to evaluate ENF density with greater accuracy 
(Kennedy et al., 1999, Panoutsopoulou et al., 2009).  This study focused on the distribution of 
neurons (stained by pan-neuronal marker, βIII-tubulin) in the rat PNS, and changes in 
peripheral nerve fibres in rats with diabetic neuropathy, or after capsaicin treatment.  In the 
diabetic neuropathy model, a means of functional assessment was also established.  Given 
that STZ/HFD model develops a widespread neuropathy, functional effects could be 
measured using well-validated plantar mechanical threshold tests.  Von Frey monofilaments 
can be used to measure the “paw withdrawal threshold,” which is a measure of sensitivity to 
mechanical touch. This behavioural test is widely used as a physiological measure of nerve 
sensation (Weinstein, 1993, Boric et al., 2013), and was used to assess whether there are 
changes in nerve sensation, such as development of mechanical allodynia, or as a result of 
nerve regeneration.  The data in this chapter provide support for the hypothesis that the MTII-
LRP chemotactic signalling system has therapeutic benefit in neuropathies in vivo. 
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5.2 METHODS 
5.2.1 Disclosure 
All rat procedures were conducted with the approval of the University of Tasmania Animal 
Ethics Committee (approval numbers #A13109 and #A11302), and are compliant with the 
Australian NHMRC Code of Practise for the Care and Use of Animals for Scientific 
Purposes.  Rats were supplied water, food ad libitum, were in a temperature controlled 
environment (22°) and had a 12 h light/dark cycle. 
5.2.2 Diet 
Male Sprague Dawley rats (6 weeks of age) were obtained from the Monash University 
Animal Services, Victoria. On arrival, the rats were allowed to acclimatise for a week, and 
were maintained on either a normal diet (ND; 4.8% fat wt./wt., 12% calories from fat; 
Gibsons, Hobart, TAS, Australia) or, where specified, switched to a high fat diet (HFD; 23% 
fat wt./wt., 44% calories from fat, SF01-025; Specialty Feeds, Glen Forrest, WA, Australia) 
for the duration of the study. 
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Table 5.1 Macronutrient composition of the Normal diet (ND) and high fat diet (HFD) as 
wt./wt 
 Normal diet 
(ND) 
High fat 
diet (HFD) 
Total Fat (%) 4.80 22.30 
Protein (%) 20.00 19.40 
Crude Fibre  (%) 4.80 5.30 
Digestible Energy (MJ / Kg) 14  18.5 
Total calculated digestible energy from lipids 
(%) 
12.00 44.00 
 
5.2.3 Synthesis of 8% w/w capsaicin cream and control cream 
Capsaicin was formulated as an 8% cream.  Capsaicin powder (Sigma-Aldrich, MO, USA) 
was weighed and dissolved in a nominal volume of ethanol (0.1%w/w).  Emulsifying 
ointment B.P. (BiotechPharm QLD, AUS) was gently warmed to a temperature of ~35 
degrees until liquid consistency was reached.  Liquid emulsion was added drop by drop to the 
capsaicin solution until the correct final weight was reached.  The emulsion was carefully 
agitated until fully combined.  Due to quick solidification of the emulsion, continued heating 
during this process is required.  Control cream was produced the same way; however 
capsaicin was omitted and only 0.1%w/w ethanol added. The cream was stored at room 
temperature. 
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5.2.4 Induction of capsaicin-induced denervation 
Rats were anaesthetised and skin was prepared as outlined in chapter 4 section 4.2.3.   
1 x 6cm rectangles, separated by 1.5cm were demarcated either side along the rat lumbo-
sacral dorsum using a permanent marker, overlaid by ordinary marker. Capsaicin cream was 
applied with a cotton swab to the left hand side, liberally, within the demarcated area, taking 
care to apply cream right to the boundaries. Control cream was applied in the same manner to 
the right hand side.  After 60 minutes, the creams were gently scraped off using cartridge 
paper, scraping in towards the centre of the demarcated area so as not to spread the cream.  
Owing to the use of an ordinary marker overlay which coloured the lipophilic emulsion at the 
boundaries, the extent of feathering/spread of the cream could be seen and accounted for (this 
was nominal, less than 1mm). The lipophilic cream was then progressively removed using 
several fresh alcohol wipes.  This removal process was done with great care to ensure no 
residual capsaicin remained on the skin which the rat may otherwise ingest during routine 
grooming.  The demarcated area was re-drawn with permanent marker, and rats were 
withdrawn from anaesthesia and allowed to recover. 
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Figure 5.1 An overview of the procedures for the capsaicin-induced denervation model  
 
 
5.2.5 Treatment of capsaicin-denervated skin with MTII or saline 
A cohort of 12 8-week old rats (approximately 500g) were divided into two groups, with 6 
being allocated to the saline treatment group, and 6 to the MTII treatment group.  Rats were 
anaesthetised, placed in the prone position on a heated pad (37°C), and maintained under (2-
3.5%) isofluorane inhalation, and shaved to expose the demarcated area (if required).  Skin 
was cleansed with an isopropanol wipe. Rats were injected with a total of 500μL 0.3mg/mL 
MTII (Zn7 form, Bestenbalt LCC, Tallinn, Estonia), or 0.9% normal saline on both the 
control cream and capsaicin treated regions of the dorsum (i.e. 250μL per side).  For an 
overview of treatment, see Fig 5.1. Injections sites were transiently visible, allowing 12 
equally spaced intradermal injections (approximate volume 20uL) to be given on each side to 
1 
•Anaesthetise rat, prepare skin 
•Apply capsaicin and control creams to opposing sides of the dorsum for 60 
minutes 
•Thoroughly remove creams  
•Allow rat to recover 
2 
•8 hours later, deliver first treatment of intradermal injections to both sides of 
the capsaicin/control treated skin 
•Continue delivery of treatment with intradermal injections 3x weekly  
3 
•1x punch and 1x blister biopsy taken from each treatment side 
(capsaicin/control) per rat every 7 days 
•Stain biopsies for ENFs and evaluate regeneration 
•Continue taking weekly biopsies until regeneration is complete in the saline 
treated capsaicin biopsies 
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each rat (Figure 5.3; Injections were performed three times weekly, for four weeks. The first 
injections were given 8 hours after capsaicin treatment.  
 
Figure 5.2 Example of treated skin immediately after intradermal injections  
 
5.2.6 Biopsies for histological evaluation of capsaicin-denervation model 
Biopsies were taken from both sides from each rat every 7 days for a total of 28 days or until 
regeneration is complete. Both a blister biopsy and a punch biopsy were taken from either 
side.  Punch biopsies were taken as per section 5.2.7. Blister biopsies were also taken, but not 
evaluated due to time constraints. 
5.2.7 Punch biopsy 
Rats were anaesthetised and skin was prepared as outlined in chapter 4 section 4.2.3.  Punch 
biopsies were taken by applying a sterile 3mm biopsy punch to the skin surface and rotating 
until the resistance of the skin was lost (indicating the punch had reached the hypodermis).  
The punch biopsy was then removed with forceps, gently severing the connective tissue, and 
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placed into Zambonis fixative immediately for a minimum of 2 hours and maximum of 5 
hours. Biopsies were washed in a fume hood using PBS, until the solution ran clear. Biopsies 
were then placed in 30% sucrose until processed. 
5.2.8 Induction of STZ/HFD diabetic model 
20 Sprague Dawley rats, (6-weeks old, approximately 250g), were randomly divided into 
four groups: 1) Control/saline group (CTRL/SAL; No STZ/HFD, saline injections), 2) 
Diabetic/saline group (DB/SAL; STZ/HFD, saline injections), 3) Diabetic/MTII group 
(DB/MTII; STZ/HFD, MTII injections), and 4) Diabetic/EmtinB group (DB/EmB; 
STZ/HFD, EmtinB injections). The control group was fed with ND, and the other four groups 
were given HFD.  After two weeks, STZ or control injections were given.  Following a 6 
hour fast, rats were individually weighed, then induced under isofluorane anaesthesia, and 
placed in the prone position. Tail vein blood was extracted using a 1mL syringe and 18-gauge 
needle, with blood glucose measured immediately using Accu-chek Performa blood glucose 
strips and testing device (Roche, NSW, Australia). The remaining blood was refrigerated.  
Rats in DB/SAL, DB/MTII, DB/EmB groups were injected intraperitoneally with 50mg/kg 
STZ (Sigma-Aldrich, MO, USA) in citrate buffer (0.9mg/mL saline, buffered with citric acid 
to pH 4.5, all from Sigma-Aldrich, MO, USA). Rats in CTRL/SAL group were injected with 
citrate buffer only. Rats were allowed to recover.  Blood samples were then spun in a 
centrifuge for 5 minutes at 15,000rpm, and the serum separated and stored at -80°C for 
insulin assays. A second STZ or control injection was given 3 days later using the same 
protocol. Top-up doses of STZ were given in the event that blood glucose levels returned to 
the normal range for two consecutive tests. The protocol for this model is outlined in Figure 
5.3. 
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5.2.9 Treatment of diabetic neuropathy hindlimb with MTII, EmtinB or saline 
Rats were anaesthetised, placed in the supine position on a heated pad (37°), and maintained 
under (2-3.5%) isofluorane inhalation.  Breathing and responsiveness was monitored closely 
through the duration of the experiment and the percentage of isofluorane adjusted 
accordingly. The hindlimb (anatomical left) was shaved and intradermal injections were 
given.  Rats were injected with a total of 500μL 0.3mg/mL MTII (DB/MTII group) or 0.9% 
normal saline (CTRL/SAL group or DB/SAL group) or 1mg/mL EmtinB (DB/EmB group 
Emtin B from Schafer N, Copenhagen, Denmark).  
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Figure 5.3 An overview of the procedures for the STZ/HFD diabetic model  
 
1 
• Allocate rats into 4 groups of 5 at random: control/saline, diabetic/saline, 
diabetic/MTII,  diabetic/EmtinB 
• Commence Von Frey mechanical sensation threshold testing, to be performed 
weekly 
• Start high fat diet for  the three diabetic groups 
2 
• Two weeks after commencing high fat diet,  administer initial STZ injection  
(50mg/kg) to diabetic rat groups, or a citrate buffer control solution to the 
control group.  Take baseline blood glucose reading immediately prior to first 
STZ injection, and extract blood serum for later evaluation of insulin 
• Three days after initial STZ injection, administer second STZ injection 
3 
• Two weeks after STZ injection, measure blood glucose levels to confirm 
establishment of diabetes 
4 
• When Von Frey measurements indicate divergence of mechanical sensory 
thresholds between control and diabetic groups for 4 weeks, take biopsy to 
confirm changes in ENF density 
• Commence treatment in these rats - intradermal injections applied to left 
hindlimb only 
5 
• For rats that  do not maintain diabetic state as per blood glucose measurements, 
maintain diabetic state by delivering a booster of STZ (50mg/kg) 
6 
• At the conclusion of the 4 week treatment period, rats were euthanased. 
Biopsies taken from hindlimbs for evaluation of ENFs 
• Spinal cords, hindpaw footpads, sciatic and sural nerves, eyes, kidneys, ears and 
blood sera were retained for later assessment 
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5.2.10 Blood glucose testing 
Rats were subject to weekly blood glucose tests (performed concurrently with intradermal 
injections).  Rats were tested prior to 10am in the morning to ensure they were not 
inadvertently in a fasting state. Rats were tested immediately after isofluorane induction so as 
not to allow anaesthesia to augment blood glucose. Tail vein blood was extracted by 
producing a shallow 5mm horizontal incision across the lower third of the tail, and then 
coaxed by applying pressure immediately proximal to the incision, until a droplet formed. 
Blood glucose measured immediately using Accu-chek Performa blood glucose strips and 
testing device (Roche, NSW, Australia). 
5.2.11 Functional evaluation of sensory thresholds in the rat hindpaw in diabetic 
neuropathy model 
Nerve sensory function (specifically, nociception) was assessed by analysing mechanical 
allodynia at weekly intervals, commencing prior to the first streptozotocin treatment (or the 
equal timepoint in control rats), and every week thereafter.  The paw withdrawal threshold 
method was used, which is a non-noxious measure of sensitivity to touch, and can be used as 
a non-invasive measure of nerve sensibility (Weinstein, 1993). The tactile sensory response 
to mechanical stimuli was evaluated by stimulation of both hind paw plantar surfaces with a 
calibrated set of von Frey filaments (Stoelting Co., Wood Dale, IL). Briefly, animals were 
placed in individual perspex chambers with a wire mesh floor (JD Built Custom Scientific, 
TAS, AUS) for at least 15 minutes to acclimatise. Filaments were then applied to the bending 
point for 3 s, and brisk paw withdrawal was considered as a positive response. The response 
threshold was determined as the lowest force that provoked a minimum of 50% positive 
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retractions from a total of 20 stimulations per paw.  To reduce variability, two training 
sessions were performed to acclimatise the animals to the procedure.  
5.2.12 Punch biopsy immunostaining 
Punch biopsies were processed and sectioned as outlined in chapter 4 section 4.2.19.  
Samples were permeabilised in 0.4% Triton-X in PBS for 4 hours, before being transferred to 
5% goat serum in PBS blocking agent for 30 minutes. Samples were then incubated overnight 
at 4°C with primary antisera.   Primary antisera included βIII-tubulin (mouse, 1:1000, 
Promega, WI, USA), CGRP (rabbit, 1:2000, Sigma), TRPV1 (goat, 1:5000, Santa Cruz 
Biotechnology, CA, USA).  Controls for immunolabelling were performed by using untreated 
tissue, or by using the respective IgG control sera in place of the primary antibody.  After 
washing three times in 0.5 M Tris buffer pH7.4 over 12 hours, the tissue were incubated with 
4,6-diamidino-2-phenylindole (DAPI; 1:1000, Sigma-Aldrich, MO, USA) and the secondary 
antibody, fluorescent Alexa 594-conjugated goat anti mouse (1:1000, Molecular probes, OR, 
USA), in the dark, overnight at 4°C. Tissue sections were washed in Tris over 12 hours and 
allowed to dry, then mounted with DPX fluorescent mounting media (Koch-Light 
Laboratories, England, UK). 
 
5.2.13 Image acquisition  
Fluorescence images were acquired using Volocity software (Perkin Elmer, MA, USA) with 
a Nikon Eclipse T.I confocal microscope (Nikon, Tokyo, Japan), equipped with a x40 Plan 
Apo lens (Nikon, Tokyo, Japan).  All images were captured with the same exposure and laser 
intensity at 40x magnification. Images were processed using Image J (NIH, MD, USA) and 
JASC Paint Shop Pro V 9.0 (JASC Software Inc., MN, USA). 
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Double immunostaining was used to localise the dermal/epidermal junction and ENFs in the 
same preparation. Two digital images were captured for each section, one corresponding to 
nuclear marker DAPI, and the other corresponding to nerves stained by pan-neuronal marker 
βIII-tubulin. DAPI staining was used to identify the epidermal/dermal junction due to a clear 
differentiation of cellular density.  
5.2.14 Nerve density analysis 
Quantification of nerve density of punch biopsy samples was performed using ImageJ (NIH, 
MD, USA). Biopsies were harvested as described previously (5.2.7) and sectioned at 50um. 
βIII-tubulin staining was performed as described in section 5.2.11. Blinded images of βIII-
tubulin immunoreactivity across all treatment groups were acquired using a Nikon Eclipse T.I 
confocal microscope (Nikon, Tokyo, Japan), equipped with a 40x Plan Apo (Nikon, Tokyo, 
Japan) objective using identical acquisition settings (1sec). Images were not taken near hair 
follicles.  Images of DAPI staining were acquired in parallel to βIII-tubulin 
immunoreactivity. All samples were evaluated blind. βIII-tubulin images were first 
background corrected using a 5-pixel rolling ball radius. In the DAPI image, a line was drawn 
7um above the basement membrane of the epidermis, and then the image was changed to the 
βIII-tubulin channel.  A plot profile of signal intensity along the line was acquired and 
transferred to an Excel spreadsheet.  A threshold point was evaluated based on examination 
of several images, and was set as a pixel intensity of 30. Any signal intensity above the 
threshold indicated presence of a traversing immunoreactive nerve fibre.  Given that width of 
immunoreactive nerve fibres were variable, positive threshold scores that occurred next to 
each other were measured as 1 immunopositive crossover (and thus one fibre) and were 
calculated per μm (immunoreactive crossovers/μm).  If nerves overlapped each other and as 
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such were visualised as one immunoreactive point, these were adjusted for manually. A 
minimum of 5 fields of each sample, corresponding to 4 sections at various locations within 
the biopsy, were processed for quantification.  Values were decoded by an independent 
evaluator and density of ENFs were compared between groups using the two-tailed Student’s 
t test in GraphPad Prism (Lauria et al., 2005). 
5.2.15  Induction of blisters 
Rats were anaesthetised and skin was prepared as outlined in chapter 4 section 4.2.3.  Blisters 
were produced by placing a 5mm suction cupule (JD Built Custom Scientific, TAS, AUS) on 
pre-prepared skin; the cupule was attached to a vacuum providing negative pressure of 
approximately 300 mmHg.  After 40 minutes, a partially fluid-filled blister formed.  This 
blister was injected via an indirect approach, inserting a 31G needle through adjacent skin 
and entering the blister void through the dermis underneath.   
5.2.16 Blister injection 
Blisters were raised as per section 5.2.15.  1mg/mL biotinylated-MTII was slowly injected 
into the void by inserting the needle in adjacent intact skin and delivering the needle tip into 
the blister.  Due to the skin being glaborous, hair follicles anchored the blister roof to the 
underlying dermis; however these anchor points were lifted and formed open pores as the 
blister was injected and filled, and therefore needed to be sealed with surgical glue during the 
injection process to prevent the solution leaking out.  
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Figure 5.4. Proposed method for blister induced focal denervation experiment 
 
A blister was raised on the skin’s surface using a gentle vacuum to separate the tissue along 
the papillary junction between the dermis and epidermis, severing nerves and causing a fluid 
filled void to form (Nanchahal and Riches, 1982). Nerve endings should initially retract into 
the dermis.  Growth cones are predicted to form at the nerve ends, and direct regenerative 
growth. By injecting a chemoattractant such as MTII into the blister void, it was hypothesised 
that regeneration would be directed towards the source of chemoattractant. Schematic shows 
approach required for injection, to prevent complete rupture of the delicate epidermal layer.  
Original figure. 
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Figure 5.5 An overview of experimental procedures for focal denervation via blister 
formation 
 
1 
• Anaesthetise rat, prepare skin 
• Raise blisters 
• Inject blister with agent 
• Allow rat to recover 
2 
• At appropriate timepoints (1,3,5 & 7 days), anaesthetise rat and 
excise an entire blister and surrounding area with a biopsy punch 
• Allow rat to recover 
• Stain tissue biopsies for ENFs using immunohistochemical 
techniques 
3 
• Image tissue, examine ENFs and evaluate regeneration 
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5.3 RESULTS 
5.3.1 Capsaicin-induced chemical denervation 
Capsaicin-induced denervation was used as a chemical model of denervation.  The majority 
of ENFs are TRPV1+ neurons, which are susceptible to capsaicin (Nolano et al., 1999). 
However, an anti-TRPV1 antibody was not an appropriate antibody for the evaluation of ENF 
regeneration in this model, as TRPV1 is present in keratinocytes as well as ENFs and 
appeared to deliver non-specific high background staining (Fig 5.6 A-B).  A pan neuronal 
marker was used in place of an anti-TRPV1 antibody.  In humans, PGP9.5 is the standard 
pan-neuronal ENF marker to be used for ENF quantification (Lauria et al., 2010), however, 
PGP9.5 did not robustly stain ENFs in rat tissue (Fig 5.6). However, in healthy and diabetic 
patients, PGP9.5 and βIII-tubulin are reported to co-localise in ENFs (Lauria et al., 2003, 
Lauria et al., 2004); therefore βIII-tubulin was used in place of PGP9.5 and resulted in 
distinct and reliable staining (Fig 5.6).  Anti βIII-tubulin was therefore used for the remainder 
of all in vivo experiments.   
As the kinetics of capsaicin induced denervation in rats were untested using 8% capsaicin 
cream approach, firstly, the effect of applying capsaicin for different times (15, 30 and 60 
minutes) was assessed.  Qualitatively, it was very clear that 1 hour caused marked 
denervation, with 15 and 30 minutes not having as robust a result (Fig 5.7; E-F compared to 
A-D). Therefore, 1 hour capsaicin application was used in further experiments.  
Weekly biopsies were harvested in order to assess the effect of MTII on ENF regeneration 
post capsaicin-induced denervation.  Although TRPV1+ neurons do not comprise all ENFs, 
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and capsaicin specifically causes retraction of TRPV1+ ENFs, a robust and significant 
denervation (62%, p<0.05) was still observed using a pan neuronal marker, 7 days after 
capsaicin treatment (48.4 ± 1.5 ENFs/mm in control tissue compared to 18.4±3.8 ENFs/mm 
in capsaicin treated tissue, Fig 5.8).   
Surprisingly, by 14 days, complete regeneration in saline-treated capsaicin tissue had 
occurred.  Saline-treated capsaicin treated skin had an ENF density of 42.1 ± 4.0 ENFs/mm, 
compared to saline treated control skin 49.6 ± 1.5 ENFs/mm (Fig 5.9). In contrast, in the 
presence of an intradermal injection of MTII, caused complete regeneration in just 7 days 
(Fig 5.8).  As this was a pilot study, with no previous data available to perform a power 
calculation, it was unknown whether this number of animals would be sufficient to generate 
statistical significance.  However, there was a significant difference between capsaicin 
denervated skin treated with saline vs MTII (p<0.02).  Capsaicin denervated skin treated with 
MTII had an average ENF density of 45.0 ± 4.9 ENFs/mm, compared to control skin treated 
with saline, which had a density  48.4 ± 1.5 ENFs/mm. These results demonstrate the potent 
effect of MTII in chemical induced denervation.  Qualitatively, there appeared to be a modest 
increase in branching of ENFs in response to MTII in control tissue, however this requires 
further validation. 
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Figure  5.6 βIII-Tubulin is a robust marker for ENFs. 
Representative images of punch biopsies taken from dorsal rat skin.  Dotted lines indicate 
demarcation of viable epidermis (E) and dermis (D).  In some cases, non-viable epidermis 
(stratum corneum) is visible above the epidermis, which is autofluorescent.  (A-B) Images 
demonstrate nonspecific staining by pan neuronal marker, anti-PGP9.5 antibody. (C-D) 
Images demonstrate staining by anti-TRPV1 antibody.  (E-F) Nerves are stained robustly 
with pan-neuronal marker βIII-tubulin. (G) Omission of primary antibody demonstrates 
specificity of the secondary antibody (H) Mouse IgG1 control indicates non-specific blinding 
attributed to mouse IgG1 in βIII-tubulin antibody.  Background staining is localised to the 
stratum corneum. 
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Figure  5.7 Denervation observed after 15, 30 and 60 minute applications of 8% capsaicin 
Representative images of punch biopsies taken 3 days after capsaicin application.  Dotted 
lines indicate demarcation of viable epidermis (E) and dermis (D).  In some cases, non-viable 
epidermis (stratum corneum) is visible above the epidermis.  Nerves are stained with pan-
neuronal marker βIII-tubulin (red). (A-B) Images of skin treated with capsaicin for 15 
minutes. (C-D) Images of skin treated with capsaicin for 30 minutes. (E-F) Images of skin 
treated with capsaicin for 60 minutes. Scale bar applies to all figures. 
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Figure  5.8 MTII rescues capsaicin induced denervation within 7 days 
Representative images of ENFs in punch biopsies taken 14 days after capsaicin application.  
Dotted lines indicate demarcation of viable epidermis (E) and dermis (D).  In some cases, 
autofluorescent non-viable epidermis is visible above the epidermis (stratum corneum).  
Nerves stained with pan-neuronal marker βIII-tubulin (red). (A) Image of control skin with 
saline injections, 7 days after control cream was applied. (B) Image of capsaicin denervated 
skin with saline injections, 7 days after capsaicin cream was applied.  (C) Image of control 
skin treated with MTII injections, 7 days after control cream was applied. (D) Image of 
capsaicin denervated skin with MTII injections, 7 days after capsaicin cream was applied.  
(E) Graph showing quantification of nerve density, demonstrated by nerve fibre 
immunoreactivity per mm of epidermis.*P<0.05, **P<0.02. Scale bar applies to all figures. 
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Figure  5.9 Capsaicin induced denervation regenerates over 14 days. 
Representative images of ENFs in punch biopsies taken 14 days after capsaicin application.  
Dotted lines indicate demarcation of viable epidermis (E) and dermis (D).  In some cases, 
autofluorescent non-viable epidermis is visible above the epidermis (stratum corneum).  
Nerves stained with pan-neuronal marker βIII-tubulin (red). (A) Image of control skin with 
saline injections, 14 days after control cream was applied. (B) Image of capsaicin denervated 
skin with saline injections, 14 days after capsaicin cream was applied.  (C) Image of control 
skin treated with MTII injections, 14 days after control cream was applied. (D) Image of 
capsaicin denervated skin with MTII injections, 14 days after capsaicin cream was applied.  
(E) Graph showing quantification of nerve density, demonstrated by nerve fibre 
immunoreactivity per mm of epidermis.*P<0.05, **P<0.02. Scale bar applies to all figures. 
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5.3.2 Diabetic neuropathy 
In order to evaluate function of MTII in a clinically relevant model of neuropathy, diabetic 
neuropathy was established in a cohort of rats.  Diabetes was established by supplementing 
rats with a high fat diet, and administering dual injections of STZ to specifically ablate 
insulin producing β-cells (Like et al., 1978).  Diabetic neuropathy with characteristic 
mechanical allodynia becomes established in these rats (Reed et al., 2000), however the 
progression of neuropathy over the timecourse of disease has not been thoroughly evaluated. 
The course of diabetes was monitored with weekly blood glucose tests. Nerve function was 
characterised by testing nociception of the hindlimb plantar surface with von Frey 
monofilaments, and allowed for the development of neuropathy to be detected. Neuropathy 
was confirmed by biopsy.  Examination of punch biopsies from the hindlimbs demonstrated 
that the model of neuropathy clearly exhibited the typical loss of ENFs and thinning of the 
epidermis (demonstrated qualitatively in Fig 5.10).  Loss of ENFs are associated with the 
development of mechanical allodynia, but are not indicative of the severity of disease (Lauria 
et al., 2010).  As such, von Frey monofilament testing of mechanical sensitivity was 
performed to evaluate the development and extent of mechanical allodynia (Weinstein, 
1993).  Typical nociceptive-like withdrawal of the hindlimb occurs when a pressure of 26 
grams is applied with von Frey monofilaments (Fig 5.11).  A drop in pressure required to 
elicit a withdrawal response indicates an increase in mechanical sensitivity and thus 
development in mechanical allodynia.   Characteristic development of mechanical allodynia 
was observed in diabetic rats, visualised by deviation of mechanical threshold in response to 
von Frey monofilaments compared to the control group by week 6 (Fig 5.12). Mechanical 
tolerance occurs when a stimulus is repeated, such that a reduction of the reaction or response 
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occurs over a period of time.  Rats developed tolerance to the repeated stimuli from von Frey 
monofilaments, such that a greater mass of monofilament was required to elicit a paw 
withdrawal response over time.  Unfortunately, rats developed tolerance to the von Frey 
testing protocol. In control rats this phenomenon was observed around 6 weeks.  In diabetic 
rats, tolerance was observed to progress much more gradually, and may have been offset by 
the development of mechanical allodynia (Fig 5.11).  Due to the development of tolerance to 
von Frey monofilaments over time, data from rats commencing treatment after week 14 (as a 
result of delayed onset of diabetes) was omitted from these graphs.  Furthermore, the 
remaining numbers in this dataset were too small to subject to statistical analysis 
appropriately.  The only conclusions that can be drawn from these von Frey measurements is 
that the use of Von Frey testing is not suited to longitudinal studies in rats. 
Table 5.1 Average blood glucose prior to, and at end of, treatment period. 
 
*Glucose measurement device has a threshold of 33.3, and as such SEM cannot be 
calculated.  
  
CTRL/SAL 
 
DB/SAL 
 
DB/MTII 
 
DB/EmB 
Average blood glucose at 
week 14, prior to treatment  
with MT, saline or EmtinB  
(mmol/L) 
 
8.4 
 
>21* 
 
>27* 
 
>26* 
Average blood glucose at 
week 18, at end of treatment 
with MT, saline or EmtinB 
(mmol/L) 
 
7.8 
 
>26* 
 
>33* 
 
>29* 
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Figure 5.10 Representative punch biopsies of hindlimb skin taken above the gastrocnemius 
in rats prior to treatment.  
Hindlimb biopsy from (A) control rat, and (B) diabetic rat (6 weeks after confirmation of 
diabetes). Hindlimb skin is highly elastic and retracts after biopsy increasing the apparent 
ENF density. Confocal microscope images show ENFs (dentoted by arrows) stained by anti-
βIII-tubulin (red). Qualitative analysis suggests that diabetic rats showed a decrease in skin 
ENF density indicating established neuropathy. Thinning of the epidermis is also noted in 
diabetic skin. 
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Figure 5.11 Characterisation of functional changes in sensation in diabetic neuropathy in 
non-diabetic and STZ/HFD diabetic rats 
Average mass of von Frey monofilament required to elicit a paw withdrawal response in rat 
hindpaws prior to treatment interventions (saline, EmtinB or MTII).  (A) Control non-diabetic 
rats began to develop tolerance to the repeated stimuli after 4 weeks of testing.  Grey shaded 
area indicates tolerance development. (B) Pooled diabetic rat data responses to von Frey 
fibres from all diabetic groups prior to introduction treatment. Data normalised for varied 
onset of diabetes.  The development of tolerance in diabetic rats develops gradually.  
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Figure 5.12 Mechanical thresholds before and after treatment with MTII, EmtinB and 
saline 
Average mass of von Frey monofilament required to elicit a paw withdrawal response in 
control rat hindpaws in control rats and diabetic rats. Grey shaded area indicates treatment 
period.  Divergence in mechanical sensitivities between control and diabetic groups begins 
from week 6.   
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5.3.3 Blister-induced focal denervation 
The use of blisters as a form of focal denervation is a novel concept, and as such, was 
established and assessed for reproducibility. Producing blisters on glaborous skin, particularly 
on skin with a very high density of hair follicles (such as is found on rats), was difficult.  Due 
to hair follicles forming anchor points, many blisters simply erupted when the blister filled 
with fluid, with the anchor points (Arrows, Figure 5.13) becoming dislodged, leaving a 
“pore.”  As a result, the blister instead was raised until only a nominal amount of fluid filled 
the void between the dermis and epidermis (approximately 40 minutes). However, blisters 
were not easily injectable as careful insertion of a needle collapsed the delicate epidermis, 
causing the injected fluid to leak out through the injection point.  It was not possible to seal 
the hole with surgical glue before much of the solution had leaked out, and as such it was not 
possible to deliver a consistent volume into the blister void.  Instead, blisters were injected 
using an indirect approach, injecting the surrounding intact tissue and delivering the needle 
into the bottom of the blister (see Fig 5.13).  When the void was then filled with solution, as 
the hair follicle anchors “lifted,” they could be sealed with surgical glue.  However, due to 
the strength and density of these anchor points, one could not inject enough fluid to fill the 
whole blister, and the volume injected was variable depending on each blister.  Furthermore, 
as this tissue was hairy, it was also highly vascularised.  Therefore even the relatively gentle 
suction resulted in petechiae formation, which in itself, adds an additional variable. Although 
this approach was able to get MTII into the skin in an ideal fashion, it required anaesthetising 
the rat for extended periods of time. Given that blisters were not consistently reproducible or 
consistently injectable, this precluded its consideration as a feasible model of denervation and 
was not investigated further.   
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Figure 5.13 Images of blister induced focal denervation model 
 
(A) Dorsum of rat with blister device applied (B) Image of typical blister raised after blister 
device has been applied for 40 minutes. Blister generally does not coalesce and hair follicles 
form anchor points (white arrows) (C) Image of injected blister sealed with surgical glue. 
Scale bar applies both to panel B & C (D) Histological section of blister stained with H&E. 
Hair follicles (HF) anchor the blisters (arrows) and form openings in the epidermis (*). (E) 
Histological section of injected blister stained with H&E, with injected MTII stained with 
DAB (black arrows). Scale bar applies to panel D & E. 
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5.4 DISCUSSION 
 
This chapter demonstrates that intradermal injection of MTII had a potent effect on 
promoting regeneration of nerves in response to capsaicin-induced denervation.  This chapter 
evaluated a number of experimental models in which to test the ability of MTII to support 
regeneration of epidermal nerve fibres.  
The capsaicin model of denervation proved an excellent model to assess for the regenerative 
effects of MTII, when delivered by intradermal injection.  Although capsaicin is an 
established means of chemical denervation of the skin, dosages and number of applications 
vary widely.  8% capsaicin patches are used clinically to treat conditions such as post-
herpetic neuralgia in humans, by causing the pain-triggering ENFs to retract deep into the 
dermis (Maihofner and Heskamp, 2013, Mou et al., 2013).  In addition, they only require a 
single, one hour application (compared to multiple lower-dose applications) and as such were 
well suited to an experimental paradigm in rats.  As 8% capsaicin patches had not been 
currently approved by the Australian TGA at the time of commencing these experiments and 
hence were unavailable locally, an 8% capsaicin cream was formulated instead and used in 
place of the patches.  A single one hour application of 8% capsaicin cream resulted in robust 
loss of ENFs.  
Capsaicin application resulted in a robust and predictable denervation and as such was a 
reliable model for testing MTII.  Regeneration of saline treated capsaicin tissue was complete 
within 14 days.  As the time course of ENF regeneration in response to 8% capsaicin in 
humans is 50-100 days (Polydefkis et al., 2004, Anand and Bley, 2011), the speed with which 
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regeneration was observed in rats was unexpected.  Furthermore, as this was a pilot study, 
with no previous data available to perform a power calculation, it was unknown whether this 
data would generate statistical significance.  MTII treatment of capsaicin-denervated skin 
promoted restoration of histological ENF density, resulting in regeneration of ENFs in just 7 
days, when compared to saline treatment.  Bolus injection of MTII into the dermis would 
likely result in blanket delivery of MTII to the tissue and not set up a microgradient whereby 
the concentration of MTII is highest in the epidermis.  Therefore, it is not possible to state 
whether the effects observed were due to a directed guidance of regenerating nerves back into 
the epidermis, or simply enhanced neurite outgrowth.  It is also not possible to state whether 
the enhanced nerve regeneration in response to MTII was an LRP-mediated response.  This 
question could be addressed with co-administration of pan-LRP inhibitor, RAP, with MTII.  
Regardless, the enhanced regeneration is a promising result which warrants further 
investigation. Furthermore, examination of shorter time points would also be intriguing, as it 
is possible that the observed effect of MTII occurred well within 7 days.  In humans, ENF 
density in the capsaicin model of denervation is quantitated using the accepted formula of 
Lauria and colleagues (2005).  However, this does not take into account changes in branching 
of ENFs within the epidermis. Qualitative examination of ENFs in punch biopsies would 
suggest an effect of MTII on promoting branching.  Furthermore, the observation that MTII 
injection into control tissue resulted in a non-significant trend towards an increase in ENF 
density (60.2 ± 8.2 ENFs/mm) compared to saline treated control tissue (48.4 ± 1.5 
ENFs/mm), would appear to support the notion of increased branching in response to  MTII. 
Excessive sprouting may be detrimental and results in aberrant sensation, such as allodynia 
(Zimmermann, 2001).  Excess regrowth of nerves and subsequent development of 
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neuropathic pain is a complication observed in previous clinical trials for neuropathy 
involving the use of neurotrophins or other growth factors (Apfel, 2002).  An assessment of 
the efficacy of lower concentrations and fewer injections of MTII would be pertinent, to 
ensure the maximal regeneration outcomes and least likelihood of excess sprouting. 
In the capsaicin model of denervation, the stimulus leading to ENF retraction is absent during 
the treatment period, however, in the case of diabetic neuropathy, the stimuli affecting ENFs 
persists as long as the diabetic condition remains.  It is important to consider that without 
correction or resolve of the stimuli that lead to ENF loss in diabetes, any restoration of ENF 
density in response to MTII treatment may not be prolonged.  Although STZ/HFD rats are an 
established model of type II diabetes, in the literature there is diversity in the dose of STZ, 
%fat in the high fat diet, age and breed of rats (Islam and Choi, 2007). As such, it was 
necessary to monitor the course of both diabetes and neuropathy by regular testing of blood 
glucose and mechanical sensibility, respectively.  The diabetic neuropathy model was 
established and exhibited a characteristic loss of ENFs and thinning of the epidermis. An 
unforeseen difficulty in functional evaluation arose from the finding that control rats 
developed tolerance to the repeated stimuli from von Frey monofilaments around 6 weeks, 
and because a similar effect was observed in the diabetic groups (albeit delayed), it was 
difficult to ascertain the onset of mechanical allodynia, which would have ordinarily marked 
the onset of the treatment intervention.  It became clear that von Frey testing is not suited to 
longitudinal studies evaluating mechanical sensitivity thresholds in rats.  The tolerance effect 
made interpretation of the mechanical threshold difficult and likely masked any therapeutic 
effects one may have observed in response to MTII or EmtinB. Future experiments should 
not use von Frey testing at such regular intervals, and treatments should be administered 
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earlier to overcome the likelihood of observing tolerance.  As a result of the issues 
surrounding the development of tolerance, and delayed onset of diabetes in some animals, 
only a few animals from each cohort who had treatment commenced at precisely the same 
time could be directly compared.  However, these numbers were too small to perform 
statistical analyses.  In the future, other measures of sensory modalities could be investigated, 
for example, testing of thermal nociception. In order to assess thermal sensory thresholds, the 
hindpaw withdrawal response can be measured, which is the time elapsed until the hindpaw 
is withdrawn after placing the plantar surface of the subject on a heated or cooled surface. 
This is a well-established behaviour measurement protocol used to measure changes in 
thermal sensation (Hargreaves et al., 1988).  Particularly in light of the observed pre-diabetic 
neuropathy symptoms in humans (Callaghan et al., 2012), an earlier therapeutic intervention 
in an animal model of diabetic neuropathy is warranted.  Due to time constraints, the 
histological evaluation of this work will form the basis of a future honours project and as 
such could not be included in this PhD.   
Epidermal blisters may provide a unique opportunity for a proof-of-concept study into the 
effect of MTII in guiding the growth of regenerating nerves in vivo. Theoretically, they allow 
for the controlled transdermal delivery of MTII to the site of severed, regenerating nerves, 
and establish a local gradient within the epidermis and underlying dermis.  Although not a 
therapeutically viable approach for delivering MTII in humans (producing many small 
blisters to treat an affected area of skin would not be suitable), blisters provide an opportunity 
to deliver a small volume of MTII which could diffuse into the surrounding tissue and 
produce a subtle gradient.  A gradient would allow for an investigation into whether MTII 
could direct the growth of regenerating nerve fibres in vivo.  Whilst this approach could be 
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used to create a concentration gradient of MTII, as visualised by immunohistochemistry, it 
was not consistently reproducible.  
Considerations remain for intradermal injection as a viable delivery method of MTII.  
Intradermal injections mechanically perforate skin, causing pain and localised trauma, 
potential inflammatory processes and infection, and results in the formation of scar tissue if 
injected in the same location repeatedly.  Scar tissue was particularly evident in 14-day 
samples and although these regions were avoided in analysis, this is potentially confounding 
as scar tissue would likely impede regeneration of ENFs.  Furthermore, in terms of potential 
clinical applicability, Hamilton (1995) reports that needle phobia is a condition affecting at 
least 10% of the population, and as such, an ongoing effort into finding a means by which to 
deliver MTII topically should be maintained.  Overall, the finding that MTII rapidly 
accelerated nerve regeneration in capsaicin-induced denervation supports the hypothesis, and 
indicates that MTII shows great promise as a therapeutic candidate in peripheral nerve 
damage. 
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CHAPTER 6   
CONCLUSIONS AND FUTURE DIRECTIONS 
 
The work within this thesis sheds new light on the function of LRP1 and LRP2 receptors as 
chemotactic receptors, and in conjunction with the existing body of knowledge, provides 
evidence of a putative role for LRPs as neurotrophic factor-like receptors – that is, to promote 
survival, neurite outgrowth, and chemotactic guidance of neurons (Purves, 1988, Oppenheim 
et al., 1991, Lindsay, 1996).   
To the best of our knowledge, there is no prior evidence of a mechanism by which LRP1 and 
LRP2 promote axon guidance.  Specifically outlined in this thesis is the discovery that LRP1 
and LRP2 are able to direct growth cone navigation.  Multiple LRP ligands (α2m, tPA, MTII 
and MTIII) were shown to direct axon guidance.  The signalling mechanisms investigated 
suggest that LRP-MT signalling is Ca
2+
 dependent, and can operate via classical and non-
classical mechanisms.   Based on evidence within this thesis, MT-LRP signalling likely 
requires crosstalk between multiple receptors, including the neurotrophin receptor TrkA. This 
is the first time crosstalk between LRP1 and LRP2 receptors have been proposed. 
Importantly, I also demonstrated the therapeutic potential of the MT-LRP signalling system 
which was shown to enhance regeneration of denervated skin in vivo. 
Consistent with the contrasting effects of MTII and MTIII, which were chemoattraction and 
chemorepulsion, respectively, this thesis reveals a disparity in their downstream signalling 
pathways.  For the first time, I provide evidence that MTIII requires LRP1 and LRP2 for its 
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signalling. As both MTII- and MTIII-LRP signalling pathways were Ca
2+
 dependent, further 
effort should be placed on acertaining which Ca
2+
 channels on the plasma membrane are 
required for the response, and also whether store-operated calcium entry processes are 
required to release Ca
2+ 
from internal stores.  It is known that it is not just the amount of Ca
2+ 
that enters the growth cone that is important for the turning response that eventuates, but the 
local source of Ca
2+ 
as well; so from a mechanistic point of view this question is pertinent, as 
understanding the underlying signalling mechanism would provide scope for the development 
of novel pharmacological agents.  Given the intimate association between Ca
2+
 and cyclic 
nucleotides in growth cone turning (Song et al., 1998), and the ability of Ca
2+
 signalling 
proteins to regulate cyclic nucleotide levels (Nishiyama et al., 2003), it would be logical to 
devote further investigation into the role of cyclic nucleotides in the mechanism of LRP-
mediated growth cone turning as this would most likely contribute to the mechanism of 
action.  Preliminary experiments have been performed by myself in this area, and support the 
notion that cyclic nucleotides are involved in LRP-MTII and LRP-MTIII signalling.  
Furthermore, based on the ability for LRP1 ligands, such as α2M, to induce Ca2+ influx 
through NMDA channels (Bacskai et al., 2000), it is important to ask whether α2M, tPA, 
MTII and MTIII function in a similar manner in growth cone turning. NMDA receptors are 
involved in the directed guidance of Xenopus spinal neurons (Zheng et al., 1996), but a 
similar role has not been investigated in mammalian cells. If so, this would be the first time 
NMDA receptors are described as receptors involved in growth cone motility in mammalian 
cells.   
Understanding the mechanisms by which MTs elicit this chemotactic response in neuronal 
growth cones has important implications for future therapeutic developments of MTs in 
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neuropathies and neuronal injury.  During development, neuronal growth cones use a range 
of guidance cues to navigate the embryonic environment, establishing the early framework of 
the neuronal circuitry.  While the major families of guidance cues such as netrins, ephrins and 
semaphorins are well established, it is likely that other context-dependent guidance cues 
exist.  For example, the extracellular environment associated with growth cones in the 
developing nervous system is likely to be very different to that encountered by regenerating 
neurons after a neuropathy or following physical injury in the mature brain.  This raises the 
question whether other receptor-ligand signalling complexes outside those established in 
neurodevelopment, such as the MT-LRP signalling system, might be exploited in neuronal 
regeneration.  Indeed, the finding that MTII enhanced regeneration in a model of chemical 
induced denervation strongly suggests that this may be the case. 
In addition to the current body of knowledge, the findings within this thesis implicate MTII 
as a therapeutic candidate in peripheral nerve axotomy and neuropathy.  Neuronal injuries, 
such as those sustained from cutaneous damage or in neuropathies, are not amenable to gross 
surgical intervention.  This thesis is the first to report the finding that MTII is able to promote 
regeneration in a model of chemical induced denervation of peripheral nerve fibres, and as 
such, offers a unique approach to remedy an otherwise untreatable nerve injury.  There are 
many potential indications for MTII as a therapeutic small molecule that warrant further 
investigation.  Sometimes the development of neuropathy is predictable, such as in 
neuropathies with an underlying genetic basis (for example, a slow progressive peripheral 
demyelinating neuropathy) or as a side effect of drugs such as chemotherapeutic agents.  As 
such, therapeutics, which may act as a prophylactic or slow disease progression, can be 
administered.  The development of neuropathy in response to some chemotherapeutic agents 
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is becoming an increasingly frequent problem, and is also a dose-limiting factor (Grisold et 
al., 2012). Future studies should address whether MTII has a protective effect in 
chemotherapeutic induced neuropathy. 
As a therapeutic, MTII requires an appropriate site-directed delivery approach.  In 
neuropathies affecting ENFs, regeneration would require regulated outgrowth towards the 
skin’s surface.  The promise of MTII as a multimodal therapeutic warrants further 
investigation into developing a carrier to allow MTII to be delivered into the skin topically to 
guide accurate axon regeneration.  There are several approaches to promote transdermal 
delivery which warrant further investigation. Those approaches include the use of ultrasound 
techniques, transiently heating the skin, and through the use of nanopatches.  In addition, 
combinations of penetration enhancement techniques may show synergistic effects (Karande 
et al., 2004).  Because iontophoresis provides a transport driving force, it may be especially 
useful when coupled with another method that increases skin permeability or penetration. For 
example, combining iontophoresis with microdermabrasion increases flux of 5-
aminolaevulinic acid by 15 times (Fang et al., 2004). 
A relatively recent development in the field of transdermal drug delivery is the invention of 
the Nanopatch
TM
. The Nanopatch is a specialised drug delivery system, which essentially is a 
refined version of the traditional injection, currently trialled for vaccine delivery (Prow et al., 
2010).  The nanopatch is constructed with an array of super-fine tapering microneedles that 
when applied to the skin is painless; it delivers the molecule more accurately and evenly to 
the area of interest, and may facilitate the use of even lower doses (Fernando et al., 2010).  
Nanopatches also have the advantage of less scar tissue formation – intradermal injections 
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cause micro-trauma of the skin, with repeated injections in the same locale resulting in scar 
tissue formation. 
 
Schematic representation of the distribution of drug from needle delivery versus the 
nanopatch. (Fernando et al., 2010) 
Ultrasound is an additional approach used to enhance delivery of drugs into the skin.  The 
most effective form of ultrasound for drug delivery is cavitational ultrasound, which 
specifically uses low frequencies, facilitating the formation of cavitational bubbles in the 
applied solution. As the bubbles collapse at the skin surface, the shearing force that results 
disrupts the stratum corneum and delivers microjets of liquid into the epidermis. In addition, 
it may also increase fluidity of the lipid bilayer (Prausnitz and Langer, 2008). It has 
successfully been used experimentally to deliver large molecules into the skin, and is 
currently used to accelerate the delivery of topical anaesthetic lidocaine in an FDA-approved 
system (SonoPrep
®
). The aforementioned avenues are worth considering for future 
developments of an MTII topical delivery system. 
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Diabetic neuropathy is the single most prevalent form of neuropathy worldwide (Callaghan et 
al., 2012).  Although there are a number of types of diabetic neuropathy, the most common is 
diabetic peripheral neuropathy which exhibits a characteristic loss of epidermal nerve fibres, 
resulting in a number of poorly tolerated symptoms (Dyck et al., 2011). Although a study was 
commenced into the ability of MTII to promote regeneration in a model of diabetic 
neuropathy, due to time constraints, the outcome in terms of ENF regeneration was not 
evaluated within this thesis.  However, in an experimental model of chemical induced 
denervation I showed MTII could enhance regeneration, and it is possible that a similar effect 
may be observed in diabetic neuropathy.  A caveat to address is that due to varied etiology of 
diabetes, the underlying pathophysiology may mean that a loss of ENFs are resultant from 
neuronal death, not just retraction of the outermost ENF, and as such, regeneration may be an 
unrealistic expectation. MTII may, however, facilitate a pro-survival interaction with existing 
neurons. 
The ability of MTII and MTIII to guide neuronal growth, in addition to their established 
repertoire of action, is intriguing; these findings suggest a similarity with cytokines and 
growth factors. Though MTs are constitutively expressed, they are upregulated in a number 
of host defence mechanisms and downregulated or upregulated in several disease states 
(Antonelli et al., 2012).   Comparing and contrasting the effects of MTII with the function of 
neurotrophic factors (which are a subset of growth factors specific to neurons) indicates 
surprising overlaps in function and as such warrants review. 
The function of neurotrophic factors in neurons is to promote survival, differentiation, 
maintenance and chemotactic guidance to neurons (Buchman and Davies, 1993).  Different 
subsets of sensory neurons in the PNS require trophic support and pro-survival signals from 
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different neurotrophic factors (Buchman and Davies, 1993).  For example, the family of 
neurotrophic factors include the nerve growth factor (NGF), which provides the trophic 
signals for small unmyelinated nociceptive neurons, brain derived neurotrophic factor 
(BDNF), which provides the trophic signals for mechanoreceptive (tension and pressure 
relaying) neurons, and neurotrophic factor-3 (NT-3), which provides the trophic signals for 
large proprioceptive (touch relaying) neurons (Baudet et al., 2000, Kirstein and Farinas, 
2002). The requirement of specific chemotactic factors by neurons can change during 
development; for example, a subset of non-peptidergic sensory neurons switches from NGF 
to GDNF dependency postnatally (Molliver and Snider, 1997).  Different neurotrophic 
factors show overlapping, yet distinct patterns of activities and a lack of specificity for 
neuronal types (Lindsay, 1996). Different neurotrophic factors share receptors and their 
subunits, indicating redundancy and pleiotropism in chemotactic function (Davies, 1994). 
Not all neurotrophic factors have roles in directing growth in development.  NGF is a 
chemoattractant of growth cones of sensory neurons (Levi-Montalcini, 1979), although little 
use is made of this property in establishing initial target contact (Vogel and Davies, 1991). 
Similarly, the work described in this thesis demonstrates that MTII is also a chemoattractant 
of sensory neuron growth cones, but given that MTI/II knockout mice do not appear to have 
major faults in sensory neuron pathfinding in development, the importance of its chemotactic 
function in development shares intriguing similarity with NGF. 
During development, neurons endocytose growth factors or neurotrophins secreted from their 
target tissue by receptor mediated processes, which are transported in a retrograde fashion to 
the cell body to induce the expression of genes that are involved in survival (Kirstein and 
Farinas, 2002).  As long as this connection is maintained, this signalling is continuously 
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stimulating survival (Eade and Allan, 2009). Therefore, neurotrophic factors are important for 
survival and maintenance of neurons (Purves, 1988, Oppenheim et al., 1991). Similarly, 
many studies corroborate the fact that MTI/II have important roles in promoting neuronal 
survival, especially in response to stressors or toxicants (West et al., 2008).  MTII is 
endocytosed via LRP receptors (Ambjorn et al., 2008), and in addition, our lab has visualised 
retrograde transport of MTII down axons to the cell body (West et al., Unpublished data). 
MTs are able to translocate to the nucleus, where they are able to indirectly influence gene 
transcription by delivery of vital zinc to zinc-finger transcription factors within the nucleus 
(Cherian and Apostolova, 2000).  
Some growth factors are transported in an anterograde fashion: one example is bFGF.  bFGF 
is synthesized and released by retinal cells in vivo (Hageman et al., 1991) and exogenous 
bFGF is transported anterogradely in retinal ganglion cell axons toward the superior 
colliculus (Ferguson and Johnson, 1991), which depends on afferent input for survival of its 
neurons. Similarly, it is well established that MTI/II and MTIII have endogenous 
neuroprotective functions in the retina, safeguarding neurons from degenerative processes 
(Ito et al., 2013b). Our laboratory has previously shown that intravitreal injection of MTII 
after an optic crush injury promotes neuronal regeneration (Chung et al., 2008), and given 
that MT is endocytosed it is possible that MTII is transported to the cell body to deliver zinc, 
in addition to the LRP-mediated transcriptional changes which result in growth promoting 
and anti-apoptotic effects (Chung et al., 2008). 
Not only do some neurons (particularly sensory neurons) produce neurotrophic factors, but 
they may also express their corresponding receptors and act in an autocrine fashion (Acheson 
and Lindsay, 1996). For example, some DRG neurons synthesise BDNF, and express its 
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cognate receptor, TrkB (Klein et al., 1990, Klein et al., 1991).   This facilitates a self-
sustaining cycle of growth and maintenance prior to forming a connection with its target cell. 
Although it is not clear whether MT performs in this specific manner, it is able to act in an 
autocrine fashion: MTs can promote self-upregulation, particularly in response to metal 
toxicity (Alvarez et al., 2012).  
In vivo, neurotrophic factors also behave in a paracrine fashion. Cerebellar granule cells 
depend on Purkinje cells for survival (Herrup and Sunter, 1987). Secretion of aFGF , BDNF, 
and NT-3 are likely candidates behind this pro-survival interaction (Hatten et al., 1988, 
Maisonpierre et al., 1990, Lamballe et al., 1991, Cheng et al., 2001).  It has been 
demonstrated that MTII can be secreted by astrocytes, and elicit pro-survival effects on 
surrounding neurons, thereby also demonstrating paracrine function (Chung et al., 2008).  It 
is clear that there is convincing evidence that MTII behaves in a similar manner to many 
neurotrophic factors; in some cases, exhibiting more characteristics of neurotrophic factors 
than some archetypal neurotrophic factors themselves. 
This thesis describes new roles for LRP1 and LRP2 in axon pathfinding, particularly in the 
context of the developing, injured and diseased nervous system, new functions for LRP 
ligands, α2M, tPA, MTII and MTIII, and provides compelling evidence that MTII is able to 
promote regeneration of nerve fibres in chemical induced denervation.  This body of work 
provides the basis for many additional studies into LRP receptor/ligand biology and 
therapeutic application, and challenges the way we currently view LRP1 and LRP2 receptors. 
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APPENDIX 1 
7.1 SOLUTION PROTOCOLS 
7.1.1 DMEM-F12: 1L 
Combine 15.6g Dulbecco’s Modified Eagle’s Medium F-12 medium powder, 16mL 7.5% 
sodium bicarbonate solution, 800mL dH20 until powder is just dissolved. Adjust pH to 7.2 
with NaOH. Make up to 1L. Filter sterilise into autoclaved schott bottle. Store at 4°C. 
 
7.1.2 Sensory neuron media (SNM): 50mL 
Combine 46mL DMEM-F12 (1:1), 500µL Stock solution penicillin G (10,000U/mL) and 
streptomycin (10,000µg/mL), 25µL Nerve Growth Factor, 2.5mL Fetal calf serum and 500µL 
N2 neural medium supplement. Keep stored in 37°C and 5% CO2 supplemented incubator, 
with lid partially unscrewed. Prepare fresh as required. 
 
7.1.3 Phosphate Buffered Saline (PBS): 1L 
Combine 8g NaCl, 1.44g Na2HPO4, 0.2g KCl, 0.24g KH2PO4, 800mL dH20. Adjust pH to 7.4. 
Make up to 1L with dH2O. Autoclave. Can be stored at room temperature.  For PBS-T add 
0.1% Tween after solution has been pH adjusted. 
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7.1.4 TBS 1:1: 1L 
Dissolve 3g TRIS, 0.2g KCl and 8g NaCl in 800mL dH20. pH adjusted to 8.0. Make up to 
1L.   For TBS-T add 0.1% Tween after solution has been pH adjusted. 
 
7.1.5 Hank’s Balanced Salt Solution, Ca+2 free media: 30mL 
Add 0.285g Hank’s Balanced Salt Solution (HBSS), Ca+2 and Mg+2 free media powder and 
140µL 7.5% Sodium bicarbonate solution to dH20, and mix until dissolved. pH adjusted to 
7.2 with HCl. Make up to 30mL. Filter sterilise.  Add 300µL Stock solution penicillin G 
(10,000U/mL) and streptomycin (10,000µg/mL), 15µL Nerve Growth Factor, 300µL N2 
neural medium supplement.  Keep stored in 37°C and 5% CO2 supplemented incubator, with 
lid partially unscrewed. Prepare fresh as required. 
 
7.1.6 0.4% Triton X: 100mL 
Combine 99.6mL PBS and 400µL Triton X-114 stock solution.  Store at room temperature. 
 
7.1.7 4% Paraformaldehyde (PFA): 500mL 
Combine 500mL PBS with 20g paraformaldehyde (PFA) in a fume hood.  Stir on a heated 
stirrer until the temperature reaches 60C.  Ensure temperature is monitored as the flashpoint 
for PFA is 90°C.  Adjust pH to 8 with 5M NaOH and allow PFA to dissolve.  Allow to cool 
then adjust pH to 7.2 with HCl. Store at -20°C or at 4°C if to be used within a week. 
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7.1.8 Zamboni’s Fixative : 5L 
Combine 460ml 0.2M Na2HPO4+ 1540ml 0.2M NaH2PO4. Adjust pH to 7.2-7.4.  Add 2L 2% 
paraformaldehyde and 705ml saturated picric acid (about 5g per 400ml water).  Stable at 4C 
for 1 year 
 
7.1.9 Nuclear Fast Red solution: 100mL 
Combine 0.1 g Nuclear Fast Red with 100 ml 5% Aluminum-sulfate solution 
(Al2(SO4)3·18H20 aluminium sulfate octadecahydrate).  Boil for 5 min. Add grain of thymol 
as preservative. 
 
7.1.10 Poly-L-ornithine 1mg/mL solution: To make 5ml  
Combine  500µl 10mg/ml stock Poly-L-ornithine solution with 4500µl 50mM TRIS, pH 7.4.  
use immediately.  
 
7.1.11 50mM TRIS: To make 10mL 
Combine 500µL 1M TRIS stock, pH 7.4, 9500µL MilliQ H2O. Store at room temperature. 
 
7.1.12 50ug/mL Laminin: To make 1mL  
Combine 50µL 100µg/ml Laminin stock solution with 950µL 150mM NaCl/50mM TRIS 
solution. Use immediately. 
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7.1.13 150mM NaCl/50mM TRIS: To make 10mL  
Combine 500µL 1M TRIS pH 7.4, 300µl 5M NaCl, 9.2mL Milli-Q H2O. Store at room 
temperature. 
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